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In mammals, the transcription factor, Osterix (Osx) controls osteoblast 
differentiation. Its role in non-mammalian bone formation, however, remains 
elusive. In the first project, osx knock-out medaka mutants were generated and 
characterized. Severe bone defects in mutants were examined and found to be 
caused by a block of osteoblast maturation. Low numbers of osteoclasts were 
observed in osx knock-out mutants, suggesting that differentiated osteoblasts 
are necessary for efficient osteoclast formation. Additionally, phenotypes 
caused by osx deficiency were also observed in heterozygous larvae. In general, 
this study showed a crucial role for osx in teleost skeletogenesis, and revealed 
conserved and non-conserved features of osx function during vertebrate bone 
formation.  
Osteoblasts interact with osteoclasts to achieve skeletal homeostasis. Excess 
osteoclast activity leads to bone disorders such as osteoporosis. To better 
characterize drugs for disease treatment, novel in vivo models are required. 
Earlier work from our laboratory has shown that ectopic expression of receptor 
activator of nuclear factor κB ligand (RANKL), a key factor for 
osteoclastogenesis, resulted in osteoporosis-like lesions in medaka. In the 
second project, I treated transgenic medaka larvae with osteoporotic defects 
with bisphosphonates, compounds commonly used in human therapy. Live 
imaging in transgenic medaka reporter lines demonstrated the anti-resorptive 
activity of these compounds in vivo and allowed the visualization of bone cell 
interaction at various stages during bone resorption and repair. This study 
established medaka as a model for drug screening of bone modulating 
compounds and allows an in vivo analysis of osteoblast-osteoclast interactions. 
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1.1 An overview on skeletal development in mammals 
As an essential organ developed during vertebrate evolution, the bony skeleton 
serves as a strong architecture to provide mobility, support and protection. Bone 
development in vertebrates occurs either by chondral or intramembranous 
ossification. Chondral ossification requires a cartilage frame that is later 
replaced by mineralized bone. In contrast, intramembranous ossification does 
not involve a cartilage scaffold. Instead, mesenchymal cells differentiate 
directly into osteoblasts and secrete osteoid to form bone. An example of 
intramembranous ossification is the formation of the craniofacial skeleton such 
as the cranial vault. Intramembranous bone in the skull forms by controlled 
recruitment of new bone cells at the sutural edges of the bone fronts in response 
to signals arising from the expanding neurocranium. Growth of the cranial vault 
can thus be precisely coordinated with an increase in size of the neurocranium 
(reviewed by Opperman, 2000). On the other hand, the appendicular skeleton, 
such as long bones, develop by endochondral ossification. Mesenchymal stem 
cells (MSCs)-derived chondrocytes contribute to the formation of a cartilage 
growth plate. Closure of the cartilage growth plate indicates the cessation of 
bone extension or elongation and reflects the end of puberty (reviewed by 
Karsenty et al., 2009).  
Although many species have unique genetically determined skeletal features to 
help them adapt to their living habits and functions, the general composition of 
bone tends to remain similar (Huang et al., 2003). Bone contains calcium- and 
phosphate-rich crystals, known as hydroxyapatite, which bind to a protein-rich 
matrix called the osteoid, mainly assembled of type I collagen fibrils. Formation 
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of collagen protein chains and fibres increases bone strength (Seeman et al., 
2006), while abnormalities in type I collagen (col1a1 and col1a2) can result in 
a genetic bone disease called osteogenesis imperfecta (OI). Patients with OI 
suffer from skeletal deformities and fragile bones with high risk of fractures 
(Forlino et al., 2011).  
The shape and strength of mammalian bone is mainly determined by an outer 
dense layer called cortical bone (compact bone), which makes up 75% of the 
skeletal mass. The cortical bone layer provides sites for attachment of tendons 
and muscles to allow body movements. In order to support the body frame 
without excessive weight, bones are hollow inside and consist of connections 
of plates and rods called trabecule (cancellous bone). Trabecular bone is 
abundant especially in the spine and at the ends of long bones to help maintain 
bone strength (Hayes and Bouxsein, 1991). Also, with a structure similar to a 
fine network, trabeculae provide a large bone surface, which allows general 
mineral exchange as well as bone modeling and remodeling. Bone modeling 
usually happens before adolescence, allowing the establishment of ultimate 
bone size and shape by resorbing bone matrix and forming new bone at different 
sites (Seeman, 2003). By the time of early twenties in human, bone reaches the 
peak mass and remodeling becomes the dominant process. With the removal of 
either parts of trabecule or the inner layer of cortical bone followed by the 
deposition of new bone at the same site, bone remodeling is not a re-shaping 
action but is vital for maintaining bone strength and health (reviewed by Raisz, 
1999). While micro-damages and deformed areas can be removed during bone 
remodeling, old accumulated bone which has lost resilience can also be replaced 
to prevent brittle bone (Burr et al., 1985). With active bone remodeling and 
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continuous stress accumulating from body weight and movements, trabecular 
bone is the common place of bone fractures (Kontulainen et al., 2002). A 
common method to evaluate bone quality is through the analysis of bone 
strength with a parameter known as bone mineral density (BMD). BMD can be 
measured using bone volume, density and microstructures of trabecular bone. 
Low BMD indicates weakness in the skeleton which links to high risks of bone 
fracture (Chesnut and Rosen, 2001).  
 
1.2 Osteogenesis in mammals 
Throughout life, bone undergoes continuous structural reorganisation, which is 
dependent on the coordinated activity of osteoblasts and osteoclasts. These two 
cell types form a bone multicellular unit (BMU) to remodel both cortical and 
trabecular bone (reviewed by Eriksen, 2010). 
 
1.2.1 Osteoblasts 
Mesenchyme-derived osteoblasts can be observed in orderly layers on the bone 
surface (see Fig. 1). In addition to producing osteoid to form bone matrix, the 
close connections between osteoblasts and the bone surface also contribute to 
bone strength (reviewed by Eriksen, 2010). Cytokines such as bone 
morphogenetic proteins (BMPs), transforming growth factor-β (TGF-β) and 
insulin growth factor (IGF) can stimulate the recruitment of osteoblast 
precursors to regulate bone formation (Sims and Martin, 2014). For example, 
BMPs regulate the early phase of osteoblast differentiation and play potent roles 
in their later differentiation (Centrella et al., 1995; Maeda et al., 2004). In 
addition, the differentiation of osteoblasts is carefully modulated by the activity 
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of mainly three transcription factors, namely Sex determining region Y-box 9 
(Sox9), Runt-related transcription factor 2 (Runx2) and Osterix (Osx) and 
(reviewed by Long, 2012).  
Sex determining region Y-box 9 (Sox9) 
Sox9 is highly expressed in mesenchymal cells, which give rise to osteoblasts, 
chondrocytes and adipocytes (reviewed by Harada and Rodan, 2003; Akiyama 
et al., 2005). Sox9 modulates osteoblast differentiation by interacting with 
Runx2 and Osx (Bi et al., 1999; Franceschi and Xiao, 2003; Glass and Karsenty, 
2006). Down-regulation of Sox9 in mesenchymal cells stimulates the up-
regulation of Runx2 and the formation of osteo-chondroprogenitor cells. 
Subsequent up-regulation of Osx and further down-regulation of Sox9 will 
direct cells into the osteoblast lineage, while the absence of Osx and continual 
expression of Runx2 and Sox9 will direct cells into the chondrogenic lineage 
(Kaback et al., 2008).  
Runt-related transcription factor 2 (Runx2) 
Runx2 is an early osteoblast marker and regulates the differentiation of 
mesenchymal cells towards the osteoblast lineage (Komori et la., 1997; Choi et 
al., 2001). Runx2 triggers osteoblastogenesis via the BMP-SMAD signalling 
pathway, which activates the expression of Osx (Lee et al., 2000; Matsubara et 
al., 2008). In mice, homozygous knock-out of Runx2 results in the absence of 
endochondral and intramembranous bone formation (Komori et al., 1997), 
while heterozygous Cbfa1/Runx2 mutants exhibited defects in 
intramembranous ossification and skeletal abnormalities, such as hypoplasia of 
the clavicle and delayed bone formation, which are similar to those in the human 




While Runx2 is required for the development of mesenchymal cells into 
osteoblast precursors, its downstream regulator, Osx, is essential for subsequent 
osteoblast differentiation. Osx is an osteoblast-specific transcription factor and 
its increase in expression is consistent with the onset and progression of 
osteoblast differentiation at embryonic stages in mice (Nakashima et al. 2002; 
Hilton et al., 2005; Baek et al. 2010; Zhou et al. 2010; Oh et al., 2012). Without 
Osx, osteoblast differentiation is arrested. In Osx mutant mice, late osteoblast 
markers, such as osteocalcin (Osc), alkaline phosphatase (AP) and type I 
collagen (Col1) are undetectable, while Runx2 expression is not affected 
(Nakashima et al., 2002; Murshed et al., 2005). Severe bone defects caused by 
complete absence of osteoblasts, concomitant with ectopic cartilage formation 
were reported in Osx null mice, suggesting that Osx is implicated in skeletal cell 
fate decisions (Nakashima et al. 2002; Koga et al. 2005). In postnatal life, Osx 
continues to be expressed in osteoblasts and plays an essential role in 
maintaining bone homeostasis. Inactivation of Osx in adult mice leads to the 
arrest of new bone formation and affects calcification of the cartilage matrix 
(Zhou et al., 2010). On the other hand, overexpression of Osx inhibits osteoblast 
differentiation and bone formation, showing as osteopenia in adult mice 
(Yoshida et al., 2012). Importantly, a single base pair deletion (1052delA) in 
the OSX gene of a human patient with osteogenesis imperfecta has also been 
reported. The reduced activity of OSX could alter expression of  its bone-
specific target gene, collagen type1, which leads to a phenotype including 
fractures and bone deformities, seen in osteogenesis imperfecta patients 




Bone-forming osteoblasts interact with bone-resorbing osteoclasts and the 
balance between these two cell types is required for the maintenance of a healthy 
bone environment (see Fig. 1). Hematopoietically derived osteoclasts are 
polarized, multinucleated giant cells with unique morphology. Their irregular 
cellular surface and the ruffled border allow them to attach onto the bone matrix 
and develop regions known as resorption lacunae for intensive bone resorption 
(Henriksen et al., 2007). By secreting hydrochloric acid and proteases, such as 
cathepsin K and tartrate resistant acid phosphatase (TRAcP) across the ruffled 
border to the bone surface, osteoclasts are capable of breaking down the organic 
and inorganic components of bone (Baron et al., 1985; reviewed by Boyle et al., 
2003 and Teti, 2013). Osteoclasts differentiate from myeloid precursors under 
the influence of macrophage colony stimulating factor (MCSF) and receptor 
activator of NF-κB ligand (RANKL) (Khosla 2001; reviewed by Boyle et al., 
2003). RANKL is secreted by osteoblasts and binds to its receptor (RANK) on 
osteoclast progenitors to stimulate osteoclast proliferation, differentiation and 
activity. Osteoprotegerin (OPG), a decoy receptor for RANKL, is produced by 
cells of the osteoblast lineage. It can bind to RANKL to inhibit 
osteoclastogenesis. The RANK/RANKL/OPG pathway is mainly controlled by 
the osteoblast lineage and is critical in initiating, stimulating or slowing down 
bone resorption (Lacey et al., 2012). Recent in vitro and in vivo studies 
identified several coupling factors (clastokines) that are derived from 
osteoclasts and modulate osteoblast formation, such as collagen triple repeat 
containing 1 (Cthrc1), sphingosine-1-phosphate (S1P) and complement factor 
3a (C3a) (reviewed by Charles and Aliprantis, 2014). While increased Cthcr1 
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expression could be found in osteoclasts after the initiation of bone resorption 
(Takeshita et al., 2013), deficiency of Cthcr1 resulted in decreased number of 
osteoblasts and bone formation rates (BFRs) both in vivo and in vitro (Kimura 
et al., 2008). Osteoblast-specific deletion of Cthcr1 did not lead to a bone 
phenotype. However, loss of bone mass was detected with deletion of this gene 
in osteoclasts (Kimura et al., 2008; Takeshita et al., 2013). This indicates that 
Cthcr1 is produced by osteoclasts as a bone anabolic molecule to stimulate 
recruitment of osteoblasts and bone repair. Similarly, C3a can also stimulate 
osteoblast differentiation. An antagonist of C3a accelerates bone resorption and 
causes further bone damage (Matsuoka et al., 2014). For the clastokine S1P, 
both in vitro and in vivo animal studies showed its capability to promote 
osteoblast differentiation (Ryu et al., 2006; Pederson et al., 2008; Lotinun et al., 
2013). While ablation of S1P receptor 1 (S1pr1) resulted in reduced bone mass, 
deletion of S1P receptor 2 (S1pr2) mildly increased bone mass. This indicates 
that despite of its effects on osteoblasts, S1P also affects osteoclasts (Ishii et al., 
2009; Ishii et al., 2010). These clastokines show that in addition to bone 
resorption, osteoclasts can also stimulate bone formation and increase bone 
strength. Thus, inhibiting osteoclast resorption instead of entirely ablating them 
should be emphasized when treating diseases with increased bone turnover rate, 
such as glucocorticoid-induced osteoporosis (GIOP) (Thudium et al., 2014). 
 
1.2.3 Osteocytes 
While bone remodeling is mediated mainly by osteoblasts and osteoclasts, the 
initiation of osteoclast-induced bone resorption in mammals involves signals 
sent from another bone cell type, the osteocyte (Henriksen et al., 2009; 
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Bonewald, 2011). Defined as descendants of osteoblasts, osteocytes are the 
most abundant cell type in the bone of most vertebrates (Bianco, 2008). Buried 
inside the bone matrix, osteocytes connect to each other and reach out towards 
osteoblasts found on the bone surface in the form of an extensive network (see 
in Fig. 1) (Bonewald, 2011). Regions of micro-damage contain apoptotic 
osteocytes, while quiescent sites do not (Schaffler and Majeska, 2005). This 
indicates that these dying osteocytes are likely to define the location and extent 
of resorption needed (Parfitt, 2002). Mechanical forces or injuries to bone are 
detected by the buried osteocytes, which send signals to stimulate either bone 
resorption or formation. For example, in the presence of micro-damages, 
osteocytes can undergo apoptosis to release RANKL, stimulating osteoclast 
differentiation and formation and thus initiating bone remodeling (Schaffler and 
Majeska, 2005; Bonewald, 2011). Recent studies showed that two osteocyte-
derived proteins, sclerostin and DKK-1 are both involved in the regulation of 
bone remodeling. As specific inhibitors of the Wnt/β-catenin pathway, the 
decreased expression of sclerostin and DKK-1 is associated with increased bone 
formation (Baron and Kneissel, 2013). Active osteocytes also produce 
inhibitors of osteoclastogenesis, such as TGF-β and OPG, as well as insulin-like 
growth factor-1 (IGF-1), which is involved in responding to mechanical force 
and regulating bone turnover (Lean et al., 1996; Schafer et al., 2011; Matilda et 
al., 2013). Furthermore, osteocytes are believed to play a role in mediating the 
effects of parathyroid hormone (PTH) on bone remodeling (Bellido et al., 2013; 




Figure 1: Osteoclastogenesis, osteoblastogenesis and bone remodeling in 
mammals. Osteoclasts are hematopoietic stem cell (HSC)-derived 
multinucleated bone-resorptive cells. Osteoblasts are mesenchymal stem cell 
(MSC)-derived bone-forming cells. A subset of osteoblasts can become 
osteocytes, which are responsible for sending signals to initiate bone 
remodeling. Together, these cells control bone homeostasis. 
 
1.3 Hormones and bone homeostasis in human 
In addition to providing mechanical support and protection, the skeleton serves 
as a store of calcium and phosphate. Bone remodeling plays a role in the 
maintenance of calcium levels in blood, which is important for the supply of 
minerals to tissues such as nerves and muscles (Riggs et al., 2002). As bone is 
important for structural support, the maintenance of good bone health is critical. 
A series of specialized hormones, including parathyroid hormone (PTH) and 
sex steroids such as estrogen are involved to maintain a dynamic bone turnover 
and to properly regulate the function of bone as a reservoir of minerals (Mundy 
and Guise, 1999).  
 
1.3.1 Parathyroid hormone (PTH)  
PTH is the principal peptide regulator of calcium homeostasis and bone 
remodeling. Secreted by the parathyroid glands, it is highly sensitive to small 
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changes in calcium concentration in the blood. Even a slight decrease in levels 
of calcium can stimulate an increased secretion of PTH. Apart from stimulating 
the increase in intestinal absorption of calcium to provide minerals for bone 
formation, PTH can also alter the transfer of calcium from bone to blood 
(reviewed by Rubin et al., 2002). Clinical administrations of PTH have been 
shown to have both catabolic and anabolic effects on bone, depending on the 
amount and duration (reviewed by Poole and Reeve, 2005). Intermittent 
injections of small amounts of PTH help to speed up bone formation by 
increasing osteoblast numbers and delaying osteoblast apoptosis (reviewed by 
Jilka, 2007; Mosekilde, 2008). One hypothesis for the anabolic effect of PTH 
suggests its ability to extend the survival of hematopoitic stem cells (HSCs), 
which stimulates bone formation (Calvi et al., 2003; Weber et al., 2006). On the 
other hand, a continuous high-dose of PTH is predominantly catabolic. Binding 
to its receptor PTHrP on osteoblasts, PTH can stimulate the expression of 
RANKL, which accelerates osteoclastogenesis and leads to increased bone 
resorption (reviewed by Swarthout et al., 2002).  
 
1.3.2 Estrogen  
Apart from calcium-regulating hormones, sex hormones, such as estrogen are 
also essential in modulating the growth and strength of the bony skeleton 
(Falahati-Nini et al., 2000). Estrogen production begins with the onset of 
puberty in humans and is responsible for the stimulation of bone growth. At the 
end of puberty, a high concentration of estrogen initiates the closure of cartilage 
plates at the end of long bones to stop further increase in length (Manolagas et 
al., 2013). Estrogen also contributes to skeletal homeostasis during adulthood, 
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by directly stimulating osteoclast apoptosis. Osteoclast-specific deletion of 
estrogen receptor (ER) resulted in an increased lifespan of osteoclasts and 
decreased trabecular bone mass (Nakamura et al., 2007; Martin-Millan et al., 
2010). In addition to direct effects on osteoclasts, estrogen can also suppress 
RANKL signaling by stimulating expression of OPG, the decoy receptor of 
RANKL (Hofbauer et al., 1999; Khosla et al., 2001). Thus, estrogen can 
indirectly inhibit RANKL-induced osteoclastogenesis (Shevde et al., 2000; 
Srivastava et al., 2001; Robinson et al., 2009). The dramatic decrease in 
estrogen during menopause in women is associated with increased expression 
of RANKL, which leads to more active osteoclasts and enhanced bone 
resorption (Nakamura et al., 2007; Martin-Millan et al., 2010). Furthermore, 
estrogen has displayed the propensity to inhibit bone remodeling, probably via 
osteocytes (Tomkinson et al., 1998; Imai et al., 2011), as well as increase 
osteoblast lifespan and activity by decreasing oxidative stress (Kousteni et al., 
2001). In postmenopausal women, decreased levels of estrogen are associated 
with a high bone remodeling rate, indicating a larger population of both 
osteoclasts and osteoblasts (Manolagas, 2000; Riggs et al., 1998). Even with 
elevated number of osteoblasts, the rate of bone formation is not sufficient to 
re-build the bone matrix removed by osteoclasts, resulting in postmenopausal 
osteoporosis (Han et al., 1997). 
 
1.4 Osteoporosis 
Bone is a highly dynamic tissue that undergoes continuous turn-over to retain 
its stability and rigidity. Bone homeostasis is achieved through coordination of 
the number and activities of different bone cell types (Harada and Rodan, 2003). 
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Interactions between osteoclasts and osteoblasts occur during all phases of bone 
modeling and remodeling. Increased bone resorption by osteoclasts stimulates 
an increase of bone formation by osteoblasts and vice versa (Charles and 
Aliprantis, 2014). Disequilibrium in the activity and number of bone cells can 
result in diseases like osteoporosis. Characterized by high bone turnover, low 
bone mass and deterioration of the microarchitectural bone structure, 
osteoporosis is a chronic, progressive disease (Mauck and Clarke, 2006; 
Seeman and Delmas, 2006). Patients with osteoporosis suffer from a high risk 
of fracture, which significantly affects their quality of life. The World Health 
Organization (WHO) considers osteoporosis to be second only to 
cardiovascular disease as a critical health problem (Kanis et al., 2013). It is 
estimated that nowadays over 200 million people worldwide have osteoporosis. 
In the United States alone, more than 10 million people suffer from osteoporosis 
and 33.6 million have low bone density in the hip with high risk of fragility 
fractures. Without immediate actions, it is estimated that 50% of all Americans 
will have low BMD and osteoporosis by 2020 (US Department of Health and 
Human Services, 2004).  
 
1.4.1 Age-related primary osteoporosis 
Osteoporosis can be divided into many types. Age-related osteoporosis is by far 
the most common form of primary osteoporosis. It occurs two to three times 
more frequently in postmenopausal women than men due to estrogen deficiency. 
Weakness of cortical and trabecular bone results in impaired self-repair 
capability, leading to higher risk of hip, vertebral and wrist fractures (Kasturi et 
al., 2009). For aging men, low levels of testosterone appear to be a major factor 
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in age-related osteoporosis. An increased level of sex hormone binding globulin 
in elder humans can cause deficiency in biologically active sex steroids, by 
preventing both testosterone and estrogen usage in the body (Cawthon et al., 
2016; Zha et al., 2015). In the elderly osteoporotic population, a decrease in 
MSC numbers and their ability to differentiate towards the osteoblast lineage 
leads to a continuous decline in osteoblast numbers, which further decreases 
bone formation (Scaffidi and Misteli, 2008; Kasper et al., 2009; Almeida and 
O’Brien, 2013). 
 
1.4.2 Glucocorticoid-induced secondary osteoporosis 
Cortisol is a hormone that is critical in the regulation of stress and injury 
response. Synthetic cortisols, called glucocorticoids (GCs), are widely used as 
the most effective treatment for human inflammatory conditions, including 
arthritis, asthma, and chronic lung disease. A serious adverse clinical effect of 
long-term glucocorticoid steroid treatment is glucocorticoid-induced 
osteoporosis (GIOP). GIOP is by far the most common form of secondary 
osteoporosis produced by drug treatment (reviewed by Weinstein, 2011). While 
50% of patients taking glucocorticoids for longer than six months can develop 
osteoporosis (Adinoff and Hollister, 1983; reviewed by Mazziotti et al., 2006), 
30% of this population could suffer from a fracture with a 5-year treatment 
(Reid, 1997). GCs can stimulate a transient anti-apoptotic effect on mature 
osteoclasts to extend their lifespan and increase osteoclast number, which could 
result in excessive bone resorption (O’Brien et al., 2004; Swanson et al., 2006). 
An ealier in vitro study indicated that GCs can trigger osteoclastogenesis by 
increasing RANKL expression with decreased levels of OPG (Sivagurunathan 
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et al., 2005). Chronic GC treatment (longer than 4 weeks), on the other hand, 
suppresses both osteoblastogenesis and osteoclastogenesis, which causes 
inadequate bone formation and turnover (Weinstein et al., 2004; Weinstein, 
2011). GCs affect osteoblast differentiation and activation, as well as stimulate 
osteocyte apoptosis (Liu et al., 2004; O’Brien et al., 2004; Ohnaka et al., 2005; 
Wang et al., 2005; Ito et al., 2007). Lack of osteocytes can lead to micro-damage 
accumulation and bone fragility, resulting in a higher risk of fractures 
(Weinstein et al., 1998). 
 
1.5 Current therapies for osteoporosis 
A number of different osteoporosis therapies are currently being developed. 
These therapies aim to increase bone mass with the use of either antiresorptive 
or bone-anabolic drugs.  
 
1.5.1 Antiresorptive therapy: Bisphosphonates (BPs) 
Bisphosphonates (BPs) are currently the most commonly used antiresorptive 
agents for human osteoporosis therapy to inhibit excessive bone resorption 
(Rogers et al., 2011). Bisphosphonates (BP) are pyrophosphate analogs that 
contain a carbon with variable side chains instead of the oxygen bridge in 
pyrophosphate (see Fig. 2A,B) (Fleisch, 1987; Russell and Rogers, 1999). 
Depending on the different side chains, BPs can be classified into non-nitrogen-
containing bisphosphonates (non-N-BPs) and nitrogen-containing 
bisphosphonates (N-BPs) (Rogers et al., 2000). An example of a non-N-BP is 
etidronate, and one of a N-BP is alendronate. As BPs have a special chemical 
structure similar to pyrophosphate, they are capable of chelating Ca2+ on the 
15	
	
bone surface. Preferentially binding on sites with high turnover rates, BPs can 
significantly affect bone metabolism and lead to a general reduction in bone 
remodeling (Jobke et al., 2014). When osteoclasts are in their resorptive phase, 
a highly acidic micro-environment is created to facilitate the release of BPs into 
the resorption lacunae. This leads to high local concentrations of BPs that are 
then internalized by endocytic vacuoles into osteoclasts (Tabane and Vorobiof, 
2011). Released BPs will then be internalized by endocytic vacuoles into 
osteoclasts (De Sarro et al., 2012). 
Etidronate 
Etidronate represents the first-generation of non-N-BPs that forms non-
hydrolyzable cytotoxic ATP analogs (AppCp) after internalization by 
osteoclasts. This leads to the inhibition of mitochondrial ADP/ATP translocase, 
blocking of energy metabolism, impairment of osteoclast function, and 
eventually a trigger of the caspase-mediated apoptosis pathway (see Fig. 2C) 
(Benford et al., 2001; Lehenkari et al., 2002; Dominguez et al., 2011; Ebetino 
et al., 2011; Peruzzi et al., 2012).  
Alendronate 
Alendronate is a member of the second generation of BPs and belongs to the N-
BP family. After uptake by osteoclasts, alendronate works by interfering with 
the function of farnesyl pyrophosphate synthase (FPPS), a key branch-point 
enzyme in the mevalonate pathway. This inhibits the mevalonate pathway and 
cholesterol biosynthesis (see Fig. 2C) (Kavanagh et al., 2006; Rondeau et al., 
2006). Moreover, it can also prevent prenylation of small GTPases (Luckman 
et al., 1998). This disrupts the cytoskeleton and affects the ruffled border of 
osteoclasts, resulting in a loss of their resorptive function (Rogers et al., 2000; 
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Ebetino et al., 2011; Rogers et al., 2011; Jobke et al., 2014). Apart from 
inhibiting over-resorption caused by osteoclasts, N-BPs at a lower concentration 
also have an anabolic effect on bone. They can prevent osteoblast and osteocyte 
apoptosis and maintain their viability both in vitro and in vivo (Plotkin et al., 
1999; Plotkin et al., 2008). They can even stimulate osteogenic differentiation 
of MSCs and osteoblast proliferation (von Knoch et al., 2005; Duque and Rivas, 




Figure 2: Chemical structure of pyrophosphate and bisphosphonates (BPs) 
and mechanisms of BPs. A, B. Chemical structure of pyrophosphate (A) and 
BPs (B). C. Antiresorptive mechanisms of non-N-BPs (etidronate) and N-BPs 
(alendronate). While Etidronate works as a non-hydrolyzable cytotoxic ATP 
analog to inhibit the energy metabolism in osteoclasts, Alendronate affects the 
function of FPPS to inhibit mevalonate pathway and cholesterol biosynthesis, 
which disrupts the formation of the ruffled border of osteoclasts. 
 
1.5.2 Anabolic therapy: intermittent parathyroid hormone (iPTH) 
iPTH is one of the few presently used anabolic therapies for osteoporosis. 
Intermittent administration of low doses of PTH stimulate Wnt signaling by 
down-regulating sclerostin, leading to enhanced osteoblast activity and bone 
formation (Sawakami et al., 2006; Jilka et al., 2010; Bellido et al., 2013). Two 
PTH peptides have been used for osteoporosis therapy. A once-daily 
administration of systemic recombinant teriparatide [hPTH (1-34)] can increase 
BMD and improve bone microarchitecture and stiffness in premenopausal and 
postmenopausal women (Aspenberg et al., 2010; Cohen et al., 2013). Recently, 
it has been shown that intermittent teriparatide injections have anabolic effects 
on osteogenesis in the murine model (Ogura et al., 2016). A once-daily injection 
of another PTH peptide, PTH 1-84, for 8 weeks can accelerate healing of 
osteoporotic fractures in postmenopausal women (Peichl et al., 2011). Studies 
showed that the combined therapy strategy of PTH, followed by BPs can 
maintain or even increase bone gain achieved (Black et al., 2003; Keaveny et 
al., 2008; reviewed by Compston, 2012). With reports showing PTH-mediated 
HSC stimulation (Calvi et al., 2003; Weber et al., 2005), pre-clinical studies are 




1.6 Teleosts as models for osteogenesis research 
1.6.1 Bone biology of teleosts 
Small teleost fish, such as zebrafish (Danio rerio) and medaka (Oryzias latipes) 
have emerged as popular animal models for bone research over the last few 
decades (Schilling and Kimmel, 1994; Van Eeden et al., 1996; Wagner et al., 
2003; Renn et al., 2006; Apschner et al., 2011; Mackay et al., 2013; To et al., 
2015). The bony skeleton shows high conservation across teleost and 
mammalian species with respect to many of the genetic regulators as well as the 
control of some major signalling pathways (Apschner et al., 2011). Similar to 
mammals, the craniofacial skeleton of teleosts is formed via intramembranous 
and chondral ossification (see Fig. 3) (Schilling and Kimmel, 1994; Fleming et 
al., 2004; Witten and Huysseune, 2009). Chondral ossification can be 
perichondral, which involves a persisting cartilage rod inside a bone tube, or 
endochondral bone formation, which involves replacement of the cartilage with 
spongiosa (Witten et al., 2002; Witten et al., 2010). A distinct feature of teleost 
bone formation is the intramembranous ossification of the vertebral column, 
which begins with mineralization of the notochordal sheath in a segmental 
pattern and does not involve a cartilaginous scaffold like in mammals (Arratia 
et al., 2001; Grotmol et al., 2003; Inohaya et al., 2007; de Azevedo et al., 2012). 
The dermal skeletal elements in teleosts, including teeth, scales and fin rays, 
have an unlimited regeneration potential, which is another significant difference 
as compared to endoskeletal structures in mammals (Witten and Huysseune, 
2009). With osteocytes buried inside the bone matrix, cellular bone is 
commonly seen in mammals and some teleosts including adult zebrafish 
(Ekanayake and Hall, 1988). However, the majority of bony fishes, including 
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medaka, possess acellular bones. Interestingly, the lack of osteocytes does not 
affect the adaptation of bone to mechanical load (Witten and Huysseune, 2009; 
Witten and Hall, 2015). Osteoblasts in teleosts are responsible for bone 
formation. Osteoblast-osteoclast coupling is essential for controlling bone 
homeostasis in teleosts. However, osteoclasts in zebrafish and medaka larvae 
are usually small mononucleated cells that can resorb bone without forming 
typical resorption lacunae (Witten and Huysseune, 2009). Similar to mammals, 
the balance between bone formation and resorption in teleosts is carefully 
regulated by hormones. For example, zebrafish exhibit similar calcitonin 
secretions as compared to mammals (Elsalini et al., 2003; Alt et al., 2006). 
However, the roles of calcitonin as well as other important hormones such as 
parathyroid hormone related protein (PTHrP) in calcium homeostasis are still 
unclear (Fuentes et al., 2006; Canario et al., 2006; Guerreiro et al., 2002; 
Mukherjee et al., 2004).  
 
Figure 3: Schematic representation of bone and cartilage elements in the 
cranial skeleton of wildtype medaka larvae at 15-20 dpf. Intramembranous 
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bone elements in wildtype medaka larvae are shown in red, including 
branchiostegal rays (bs), parasphenoid (ps), operculum (op) and cleithrum (cl). 
Parts of mineralized perichondral bone elements are shown in yellow, including 
basihyal (bh), palatoquadrate (pq) and ceratohyal (ch). Cartilage elements are 
shown in blue, including Meckel’s cartilage (m), non-mineralized bh, pq, ch1-
5 and hyosmplectic (hs). Other types of bone elements are shown in orange, 
including teeth, otolith (ot), pharyngeal teeth (pt), occipital arches (oa), basilar 
plate (bp) and notochord (nc). 
 
1.6.2 Fish mutants for human bone disorders 
Although long restricted to the field of developmental biology, zebrafish and 
medaka have recently been extensively used as models for human pathogenesis. 
Recent studies revealed that zebrafish has orthologs of at least 70% of human 
protein coding genes, including disease-related genes (Howe et al., 2013), 
suggesting great potential of teleosts as models for human pathologies. 
Genome-wide large-scale mutagenesis screenings in zebrafish and medaka have 
been carried out to identify genetic mutants with distinct phenotypes (Haffter et 
al., 1996; Furutani-Seiki et al., 2004). Both zebrafish and medaka mutants have 
been reported for skeletal dysplasia studies (reviewed by Wittbrodt et al., 2002; 
reviewed by Laizé et al., 2014; Mackay et al., 2015). While the phenotype-
driven screening is an unbiased approach for analysis of gene function, gene 
knock-out provides a complementary method for further definition and 
confirmation. Mutants, successfully established by zinc finger nucleases (ZFNs) 
and transcription activator-like effector nucleases (TALENs) showed the 
simplicity of genome manipulation in both medaka and zebrafish (reviewed by 
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Ota and Kawahara, 2014; reviewed by Ma and Liu, 2015). The newly developed 
genome editing tool, Type II Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) – CRISPR-associated (Cas) system has been shown to work 
in zebrafish and medaka embryos. This system utilizes short RNA-guided 
endonucleases to cleave and degrade target sequences with high efficiency 
(Jinek et al., 2012; Hwang et al., 2013; Ansai and Kinoshita, 2014).  
 
1.6.3 The role of osx during teleost skeletogenesis in mutants and 
morphants 
A key regulatory role for Osx in mammalian bone formation is well established, 
and many downstream targets and interacting factors have been identified 
(reviewed in Long 2012; Hojo et al., 2016). However, it remains unknown 
whether the function of osx in bone formation is conserved in non-mammalian 
vertebrates. Two recent reports described the generation of osx mutants in 
members of the cyprinid family, the common carp and zebrafish. Both showed 
deformed skull, spines and vertebral centra. However, these osx mutants are 
viable until sexual maturation and exhibit bone defects only at later stages of 
life (Zhong et al., 2016; Kague et al. 2016), which suggested rather a delay in 
osteoblast maturation than a critical function of osx in early osteogenesis. In 
mice, on the other hand, a knock-out of Osx efficiently interrupts osteoblast 
differentiation and bone formation, leading to embryonic lethality (Nakashima 
et al., 2002). Therefore, bone formation during carp and zebrafish 
embryogenesis and larval development was not blocked as in mice raising 
doubts of a highly conserved role of osx during vertebrate osteogenesis. Medaka 
is a teleost fish with intramembranous and perichondral formation of bone. 
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Similar to the murine situation, the respective osx orthologs in medaka and 
zebrafish are expressed in premature and mature osteoblasts (Spoorendonk et 
al. 2008; Renn and Winkler 2009; DeLaurier et al. 2010). Our lab recently 
reported that a Morpholino-mediated knock-down of osx in medaka resulted in 
reduced mineralization of bone elements in the cranium and vertebral column 
suggesting an important role for osx also in medaka bone formation (Renn and 
Winkler 2014). However, due to the limited stability of Morpholino oligomers, 
these bone defects were evident only during early stages but recovered during 
later embryonic development.  
 
1.6.4 Transgenic fish for in vivo imaging 
As a consequence of the complicated regulation systems, endogenous bone 
homeostasis and responses to drug treatments cannot be fully recapitulated in 
vitro. Thus, there is a clear need for reliable in vivo animal models. Compared 
to cell-culture settings, in vivo models can provide valuable insights into the 
multicellular networks within the bone environment. Despite the mouse model 
having an advantage as a mammalian system, technical limitations exist for 
conducting live analysis (reviewed by Komori, 2015). Small teleost fish, on the 
other hand, serve as attractive alternatives for in vivo imaging. The transparency 
of small fish larvae allows the use of fluorescent fusion proteins to label bone 
cells and dyes to bind to calcified skeletal matrix (Du et al., 2001; Fleming et 
al., 2004). This facilitates the observation of cellular behaviours and disease 
changes in the living animal. Advances in technology, including I-SceI 
meganuclease-mediated transgenesis and Tol2 transgenesis, strongly increase 
the efficiency of germline integration for the generation of transgenic fish 
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(reviewed by Hammond and Moro, 2012). Over the past years, large numbers 
of transgenic fish lines have been established for bone research (Spoorendonk 
et al., 2008; Renn and Winkler, 2009, reviewed by Hammond and Moro, 2012; 
reviewed by Long, 2012). Our lab previously reported transgenic medaka lines 
that express fluorescent reporters in bone cells under control of various 
osteoblast- and osteoclast-specific promoters. These include premature 
osteoblasts (osterix, osx; Renn and Winkler, 2009; collagen type 10a1, col10a1; 
Renn et al., 2013), mature osteoblasts (osteocalcin, osc; Renn and Winkler, 
2009) and osteoclasts (cathepsin K, ctsk; To et al., 2012).  These unique 
transgenic lines allow in vivo visualization of osteoclast formation and 
osteoblast-osteoclast interaction during bone degeneration and repair by live 
imaging. 
 
1.6.5 Teleosts as osteoporosis models and for high-throughput chemical 
screening 
Mammalian models have been intensively used for studying osteoporosis. 
Overiectomized mammals, such as rats, monkeys and sheep are classic models 
for postmenopausal osteoporosis, mimicking human osteopenic conditions due 
to estrogen depletion (reviewed by Komori, 2015). However, all these models 
share similar drawbacks, such as slow bone development and their embryos 
being covered by opaque skin and tissue, which limits image acquisition 
(reviewed by Jee and Yao, 2001). A recent discovery shows that similar to 
postmenopausal women, decreased estrogen levels can also be observed in 
aging female medaka, resulting in osteoporotic phenotypes (Shanthanagouda et 
al., 2014). This finding suggests that medaka could serve as a potential animal 
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model for osteoporosis study, without the need of ovariectomy. Our lab 
previously generated a transgenic line that expresses the osteoclast-inducing 
factor RANKL under control of a heat-inducible promoter (To et al., 2012). 
Induction of RANKL in this system results in ectopic formation of activated 
osteoclasts. This leads to increased bone resorption and a severe osteoporosis-
like phenotype, with drastically reduced mineralization in the vertebral bodies 
(To et al., 2012). Due to rapid development, large clutch number and minute 
size, the medaka osteoporotic larvae open the possibility of teleost larvae as an 
easy to handle animal model for the in vivo analysis of osteoporosis and large-
scale screening of drugs. Zebrafish and medaka have been used for chemical 
screens and drug discoveries for decades (reviewed by MacRae and Randall, 
2015). Fish larvae are tolerant to DMSO and able to absorb compounds from 
aquatic environments either through their skin or gastrointestinal tract (Barrett 
et al., 2006; Ablain and Zon, 2013). With the advantage of visualization of 
osteoclasts and osteoblasts in transgenic fish larvae (Chatani et al., 2011; To et 
al., 2012), observations can be conducted in vivo to directly evaluate the effects 
of compounds on bone cells and the mineralized skeleton.  
 
1.7 Aims of the project 
Osterix/sp7 (osx) encodes a zinc finger transcription factor expressed in 
premature and mature osteoblasts of vertebrates. Osx null mice showed severe 
bone defects caused by disrupted osteoblast differentiation, and a homozygous 
frame shift mutation in OSX results in osteogenesis imperfecta (OI) in human. 
A key regulatory role for Osx in mammalian bone formation is well established. 
However, whether a similarly important role of osx is conserved in non-
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mammalian vertebrates remains unknown. Therefore, the first aim of this 
project was to study the function of a constitutive osx deficiency during 
skeletogenesis in medaka. The strategy was to generate stable medaka mutant 
lines carrying mutations in two transcript isoforms of the osx gene using 
CRISPR/Cas9. Long-term bone and cartilage effects were to be analyzed in 
mutants with an osx deficiency. By crossing mutants with different medaka 
transgenic reporter lines, bone cell behaviours, including osteoblast 
differentiation and osteoblast-osteoclast coupling were characterized through in 
vivo imaging.  
Skeletal homeostasis depends on an intimate coupling between osteoblasts and 
osteoclasts. Excess osteoclast activity leads to reduced bone mineral density, a 
hallmark of diseases such as osteoporosis. Processes that regulate osteoclast 
activity are therefore targeted in current osteoporosis therapies. To identify and 
characterize drugs for treatment of bone diseases, suitable in vivo models are 
needed to complement cell culture assays. The second aim of my project was to 
establish medaka transgenic lines as robust models for drug screening of bone 
modulating compounds. To achieve this, the previously established medaka 
osteoporosis model was used for analysis of the antiresorptive and/or bone-
anabolic effects of etidronate and alendronate, two bisphosphonates commonly 
used in human osteoporosis therapy. Using live imaging, osteoclast activity in 
response to the drug treatment was analyzed. Studies of bone integrity and 
osteoblast distribution were also included for better understanding of drug 
mechanisms in this unique teleost model.  
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2. MATERIALS & METHODS 
2.1 Maintenance of transgenic fish 
2.1.1 Fish husbandry 
Wild-type, as well as ctsk:nlGFP, RANKL:HSE:CFP, osx:mCherry, 
col10a1:nuGFP and osc:eGFP single or compound transgenic medaka fish were 
kept at 26°C under a controlled light cycle (14 hours light, 10 hours dark) to 
induce spawning. Embryos were kept in 0.3x Danieau’s solution (fish medium) 
(19.3 mM NaCl, 0.23 mM KCl, 0.13 mM MgSO4, 0.2 mM Ca(NO3)2 and 1.7 
mM HEPES, pH 7.0) at 30°C in Petri dishes and medium was changed daily to 
ensure normal development of the embryos. One month old fish were raised in 
a fish system with recirculating water flow. The medaka fish reached sexual 
maturation within three months. All experiments were performed in accordance 
with approved IACUC protocols of the National University of Singapore 
(BR019-10, BR15-0119, 014/11, R14-293). 
2.1.2 Transgenic embryo screening 
All medaka transgenic reporter lines used were established by Dr. To and Dr. 
Renn (former postdocs in the Winkler Lab). As described previously (To et al., 
2012), nlGFP expression was observed in heads and tails of ctsk:nlGFP embryos, 
starting from 5 days post fertilization (dpf). RANKL:HSE:CFP transgenic 
offspring were heat-shocked at 39°C for 20 mins at 2 dpf for screening of 
positive embryos via ubiquitous CFP expression indicating successful RANKL 
induction (To et al., 2012). Transgenic mCherry or nuGFP expression was 
observed in the cleithrum and parasphenoid of osx:mCherry or col10a1:nuGFP 
embryos, starting from 5 dpf (Renn and Winkler., 2009; Renn et al., 2013). The 
expression of osc:eGFP appears later around the hatching stage at 8-10 dpf 
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(Renn and Winkler., 2009). Embryos from compound transgenic lines including 
RANKL:HSE:CFP/ctsk:nlGFP, osx:mCherry/col10a1:nuGFP, 
osx:mCherry/osc:eGFP, osx:mCherry/ctsk:nlGFP and 
osx:mCherry/RANKL:HSE:CFP/ctsk:nlGFP were screened according to the 
expression patterns of the individual single transgenic line. Embryos were 
staged according to Iwamatsu (Iwamatsu, 2004).  
 
2.2 Generation of medaka osx mutant lines 
2.2.1 osx guide RNA design and synthesis 
osx guide RNAs (gRNAs): osx_tv1 crispr1 and osx_tv1 crispr2, were designed 
by Dr. Graf (former PhD student in the Winkler Lab) according to (Hwang et 
al. 2013). Two 20 bp oligo pairs targeting the medaka osx locus 
(ENSORLT00000006574) either at 190 nt downstream of the translation start 
site (osx_tv1 crispr1: primers: osxcrispr1_for and osxcrispr1_rev) or at 211 nt 
(osx_tv1 crispr2: primers: osxcrispr2_for and osxcrispr2_rev) were mixed in 
equimolar ratio and annealed. The annealed oligos had 5’ and 3’ overhangs that 
allowed ligation into the BsaI site of the gRNA encoding plasmid DR274 
(Addgene; #42250). The annealed oligos were phosphorylated prior to ligation 
and the BsaI (New England Biolabs) linearized plasmid was dephosphorylated. 
The ligated, gRNA containing vectors were linearized with DraI (Thermo 
Fisher Scientific).  
osx_tv1&2 crispr gRNA target sites were identified using the CCTop-
CRISPR/Cas9 target online predictor tool (Stemmer and Thumberger, 2015). 
The identified 20 bp sequences (osx_tv1&2 crispr) were used to design gBlocks 
that were ordered from Integrated DNA Technologies (IDT). The 
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commercialized gBlock DNA contains primer binding sites (RNAamp for and 
RNAamp rev) for amplification and also a T7 promoter for in vitro transcription. 
Lyophilized double-stranded oligos obtained from IDT were dissolved in 20 µl 
TE buffer to make a final concentration of 10 ng/µl. PCR amplification was 
performed using the Takara PrimerStar MAX proof reading enzyme on a PCR 
thermal cycler, and components were as follows: gBlock 10 ng/µl (1 µl), 2x 
PrimerStar enzyme Mix (Takara) (25 µl), RNAamp Forward/ Reverse  primer 
(1 µl), ddH2O (add up to 50 µl). The PCR program was as follows: 98°C 10 s, 
55°C 5 s, 72°C 5 s, 25 cycles. PCR products were gel extracted and purified 
with Wizard® SV Gel and a PCR Clean-Up System kit (Promega) according to 
the manufacturer's instructions.  
The Ambion MEGA shortscript T7 kit (Life Technologies) was used for in vitro 
transcription to generate gRNA according to the manufacturer's instructions. 
osx_tv1 crispr1 and osx_tv1 crispr2 gRNAs were diluted to 100 ng/µl as the 
working concentration. osx_tv1&2 crispr gRNA was diluted to 356 ng/µl as the 
working concentration.  
Table 1. List of target site sequences of guide RNAs (gRNAs)  
S/N Name Sequence (5' - 3') 
1 osx_tv1 crispr1 GGGCGGACGACAGACGCCAG 
2 osx_tv1 crispr2 GGCCTGGCGGACTCCTACAC 
3 osx_tv1&2 crispr CCCCGGCATAACTTCTGCCC 
 
2.2.2 Cas9 mRNA synthesis 
To generate Cas9 mRNA, the plasmid MLM3613 (Addgene; #42251) was 
linearized with PmeI (New England Biolabs) and used as template for in vitro 
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transcription using the T7 mMessage mMachine kit (Life Technologies). Prior 
to injection, the Cas9 mRNA was polyadenylated with the Poly (A) Tailing Kit 
(Thermo Fisher Scientific), and purified by phenol-chloroform extraction using 
the RNeasy Mini Kit (QIAGEN). Cas9 mRNA was diluted to a working 
concentration of 300 ng/µl.  
 
2.2.3 Microinjection 
Agarose injection plates were made by placing a mould with ridges facing down 
into a Petri dish with molten agarose. Purified gRNAs were well mixed before 
loading into glass capillaries (Harvard Apparatus) with sharp tips pulled with a 
needle puller (Narishige, Japan). osx_tv1 crispr1 and osx_tv1 crispr2 gRNAs 
(100 ng/µl each) were mixed with Cas9 mRNA (300 ng/µl). osx_tv1&2 crispr 
gRNA (356 ng/µl) was mixed with Cas9 mRNA (300 ng/µl). Microinjection 
was performed with a Femtojet Microinjector (Eppendorf). The mixed solutions 
were injected into the cytoplasm of one-cell staged medaka embryos. 
 
2.2.4 Genomic DNA extraction 
9-15 dpf larvae or adult fish were anaesthetized with 0.01% or 0.005% ethyl 3-
aminobenzoate methanesulfonate (Tricaine; Sigma), respectively. Larvae or 
clipped caudal fin fragments were lysed individually in 50 µl of 50 mM NaOH 
and incubated at 95°C for 15 mins. Samples were neutralized with 5 µl of 1 M 
Tris-HCl (pH 8.0). Embryos after in situ hybridization or bone/cartilage staining 
were fixed and washed with 1x PBST for 3x 5 times before genomic DNA 
isolation. Larvae were lysed individually with DNA lysis buffer (10 mM Tris 
HCl pH 8.2, 50 mM KCl, 0.3% NP 40, 0.3% Tween) and Proteinase K (Sigma) 
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in a ratio as 49:1 and incubated at 55°C for 60 mins and 90°C for 10 mins. 
Samples were centrifuged and the supernatant containing genomic DNA was 
used for analysis. 
 
2.2.5 Detection of mutations by restriction fragment length polymorphism 
(RFLP) analysis 
Genomic DNA from F0 larvae or clipped caudal fin fragments was used as DNA 
template for PCR amplification, components were as follows: DNA template (1 
µl), 5x Buffer (5 µl), dNTP (1 µl), MgCl2 (2 µl), Forward primer (1 µl), Reverse 
primer (1 µl), GoTaq Polymerase (0.2 µl), ddH2O (add up to 25 µl). The PCR 
program was as follows: 95°C 3 mins, 95°C 30 s, 58 - 62°C 20 s (temperature 
depending on annealing temperature of primers), 72°C 50 s, 35 cycles from step 
2 to step 4, 72°C 10 mins, 4°C hold.  
For genotyping mutations caused by osx_tv1 crispr1 and osx_tv1 cripsr2 using 
restriction fragment length polymorphism (RFLP), a 430 bp fragment was 
amplified (primers: osx_tv1 for and osx_tv1 rev). 1 µg (10-15 µl) of the PCR 
product was digested at 37˚C overnight using 1 µl of HaeIII (New England 
Biolabs), together with 5 µl Cutsmart Buffer, ddH2O (add up to the 50 µl).  
For genotyping mutations caused by osx_tv1&2 crispr using RFLP, a 336 bp 
fragment was amplified (primers: osx_tv1&2 for and osx_tv1&2 rev). 1 µg (10-
15 µl) of the PCR product was digested at 37˚C overnight using 2 µl of HpaII 
(Thermo Fisher Scientific), together with 2 µl (10x) Tango Buffer, ddH2O (add 
up to the 30 µl).  
2% agarose gels were prepared freshly by dissolving agarose powder into 1x 
TAE buffer with 6% SYBR® safe DNA gel stain solution. Electrophoresis was 
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performed at 85-90V constant voltage with a gel electrophoresis chamber and 
PowerPacTM basic power supply unit (BioRad). Gels were imaged with a 
GeneSnap software using a G:BOX gel documentation system (SynGene). 
Mutants showed undigested fragments with larger sizes because restriction sites 
(HaeIII or HapII) were mutated.  
 
2.2.6 Sequencing of DNA 
DNA in undigested larger fragments was gel extracted with a Wizard® SV Gel 
and PCR Clean-Up System kit (Promega) according to the manufacturer's 
instructions. Sequencing reactions were performed using the BigDye® 
Terminator v3.1 cycle sequencing kit on a PCR thermal cycle. For a Sequencing 
PCR, components were as follows: BigDye ready reaction premix (1 µl), 5x 
BigDye sequencing buffer (1 µl), DNA template (1 µl), Forward/ Reverse 
primer (1 µl) (primer: osx_tv1 for/ osx_tv1 rev; osx_tv1&2 for/ osx_tv1&2 rev), 
ddH2O (add up to 10 µl). The PCR program was as follow: 96°C 2 mins, 96°C 
15 s, 58 - 62°C 20 s, 62°C 4 mins, 30 cycles from step 2 to step 4, 4°C hold. For 
precipitation of PCR products, 10 µl samples were transferred to 1.5 ml 
Eppendorf tubes and mixed together with 10 µl ddH2O, 2 µl 3M NaOAc and 50 
µl 100% EtOH. Samples were centrifuged at 14000 rpm for 45 mins at 4 °C in 
a centrifuge. The supernatants were removed carefully and 1 ml 70% EtOH was 
added. Samples were centrifuged again at 14000 rpm for 30 mins at 4 °C. 
Supernatants were removed and samples were dried at 42 °C in a heat block. 
Precipitated PCR products were kept at -20 °C before sending for sequencing at 
the DNA Sequencing Laboratory (DSL) in NUS Department of Biological 
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Sciences (DBS) on an Applied Biosystems 3130x1 Genetic Analyser (ABI). 
Sequencing results were analyzed using BioEdit software. 
 
2.2.7 Generation of homozygous osx mutants   
F0 adult potential mutant founders were genotyped by fin clipping, RFLP and 
sequencing. F0 founders were incrossed to obtain a larger population of F1 fish 
carrying different mutant alleles. Adult genotyped F1 fish were outcrossed with 
wildtype fish to obtain heterozygous F2 fish. One or two different mutated 
alleles were detected in F2 heterozygous fish. Incrossing F2 heterozygous adult 
fish with the same mutant allele yielded F3 homozygous mutant embryos. 
Homozygous carriers in F3 were analyzed for phenotype.  
 
2.3 Total RNA extraction and first strand cDNA synthesis 
RNA extraction and clean-up with appropriate controls was done from larvae 
using the RNeasy Mini Kit (QIAGEN 74104) according to the manufacturer's 
instructions. All RNA samples were subjected to DNase I digestion for 60 mins 
to remove genomic DNA. RNA was stored at -80°C prior to use. 1 µg total RNA 
was reverse transcribed using the RevertAid First Strand cDNA Synthesis Kit 
(Life Technologies K1621) according to the manufacturer's instructions. 
Control samples without addition of Reverse Transcriptase (-RT) were 
generated for each batch of RNA following the same setup. cDNA was kept at 





2.4.1 Semi-quantitative Reverse Transcription (RT)-PCR  
For semi-quantitative RT-PCR the GoTaq® Flexi DNA Polymerase kit, 
components and PCR program were used as described in section 2.2.5. The 
following primers were used (forward, reverse): β-actin; osx; osc; TNF-α; 
osx_tv1RT; osx_tv1&2RT; DMY. 1% Agarose gels were prepared freshly by 
dissolving agarose powder into 1x TAE buffer with 5% SYBR® safe DNA gel 
stain solution. Electrophoresis and gel image acquisition was done as described 
in section 2.2.5. Relative gene expression levels were deduced by quantifying 
gel band intensities using ImageJ in three biological replicates. The 
housekeeping gene β-actin was used for normalization to ensure the consistency 
of loading amount and accuracy. 
Table 2. List of used RT-PCR primers 
S/N Name Sequence (5' - 3') 
1 osxcrispr1_for TAGGGCGGACGACAGACGCCAG 
2 osxcrispr1_rev GCGGACGACAGACGCCAGGTTT 
3 osxcrispr2_for TAGGCCTGGCGGACTCCTACAC 
4 osxcrispr2_rev CCTGGCGGACTCCTACACGTTT 
5 RNAamp for CATTATGGTGAAAGTTGGAAC 
6 RNAamp rev GTGGCACCGAGTCGGTGCTTTT 
7 osx_tv1 for ACACTCGCTATGGCTCCAGT 
8 osx_tv1 rev ATGACACACCCTTACGGCTC 
9 osx_tv1&2 for GGATCCGTCTCTTCTCGTGT 
10 osx_tv1&2 rev TCACATCTCCTCCAACCCTC 
11 β-actin for TTCAACAGCCCTGCCATGTA 
12 β-actin rev GCAGCTCATAGCTCTTCTCCAGGGAG 
13 osx for ACACTCGCTATGGCTCCAGT 
14 osx rev ATGACACACCCTTACGGCTC 
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15 osc for GAACCCGAGGTTATTGTGGA 
16 osc rev GAACTGAACGTTGCCTGTGA 
17 TNF-α for GGAAGATACTTGTGGTCCTGGTCT 
18 TNF-α rev GCTTCTCAAAATCAGTGGGAGG 
19 osx_tv1&2RT for TCTCCCCTCAGCTTCCTTAG 




22 DMY for GGCCGGGTCCCCGGGTGCCCA 
23 DMY rev CCATGTGAGTTCACCCGAAA 
 
2.4.2 Quantitative Real-time PCR (qPCR) 
cDNA of osx mutants and WT control were used for qPCR. β-actin was used 
for normalization. The following primers were used: β-actin 
(GCCAACAGGGAGAAGATGAC, CATCACCAGAGTCCATGACG); osx 
(CAGATAAGACCGGCAGCAC, TCCTCCAGCTGTGGTGAAG). 
Comparisons of the gene expression levels in osx mutants relative to WT 
controls were performed using the Prism7000 software.  
 
2.5 Fish skeleton staining 
2.5.1 Live staining of mineralized bone matrix  
For live bone matrix staining, medaka larvae were incubated in filtered 0.1% 
alizarin-3-methyliminodiacetic acid (Alizarin Complexone, ALC; Sigma 
A3882) or 0.01% calcein (Sigma C0875) in fish medium at 30°C for 2-2.5 hours 
(for larvae at 9-17 dpf). After incubation, larvae were rinsed in fish medium for 
30 mins to 1 hour before being mounted for imaging. ALC or calcein stained 




2.5.2 Whole mount cartilage and bone staining 
Larvae were fixed in 4% paraformaldehyde (PFA)/ PBST in 2 ml Eppendorf 
tubes for 2 - 4 hours at room temperature (r.t.) and washed with 1x PBST 3x 5 
mins on a rotator at r.t. Samples were washed with 50% EtOH for 10 mins 
before being incubated in staining solution [EtOH (70%), MgCl2 (9.52%), 
Alcian Blue (0.04%), Alizarin Red (0.028-0.056%, for 10-20 dpf larvae), 40 µl 
ddH2O] in the dark (covered with aluminium foil) overnight on a rotator. The 
next day, stained larvae were washed with ddH2O by manually inverting the 
tubes. Samples were incubated in bleaching solution (50 µl H2O2 (30%), 500 µl 
KOH (2%), and 450 µl ddH2O) for 20 mins at r.t. on the table top. After 
bleaching, samples were incubated in washing solution I (400 µl glycerol (50%), 
125 µl KOH (2%), 475 µl ddH2O) for 1-3 hours, before being transferred into 
washing solution II (600 µl glycerol (100%), 125 µl KOH (2%), 475 µl ddH2O) 
for 1 - 2 days until the background staining in the muscles was removed. Micro-
dissection of cartilage was performed for morphometric analysis by following 
the protocol in DeLaurier et al. 2010. 
For fixed bone and cartilage staining in adult medaka fish, samples were fixed 
in 4% PFA for 2-3 days at 4 °C. All scales, muscles and intestines were removed 
by manual dissection before the addition of Proteinase K (30 µg/ml) for 6 hours 
at r.t. Samples were re-fixed in 4% PFA at 4 °C overnight. The adult fish were 
washed with PBST 3x 10 mins on a rotator at r.t. Samples were washed with 
50% EtOH for 20 mins. Samples were then incubated in staining solution [11 
ml EtOH (100%), 1 ml MgCl2 (0.5 M), 1 ml Alcian Blue (0.5%), 0.5 ml Alizarin 
Red (2.8%), 0.5 ml ddH2O] for 4 hours at r.t. on a rotator in the dark. The 
bleaching step was extended to 1 hour. Extra washing steps were employed 
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dependant on the persistence of the background staining. All samples were kept 
in 100% glycerol at r.t. for storage.  
 
2.6 Whole mount RNA in situ hybridization 
All RNA probes were synthesized by Dr. Renn. Note that the osx probe detects 
both osx_tv1 and osx_tv2. For whole mount RNA in situ hybridization, embryos 
were fixed in 4% paraformaldehyde (PFA)/ PBST for at least 4 hours at r.t. or 
at 4 °C overnight. Embryos were washed with 1x PBST for 3x 5 mins. Embryos 
were dechorionated and deyolked before dehydration using a 100% MeOH 
wash for 5 mins. Samples were kept in fresh 100% MeOH at -20 °C for long 
term storage. Embryos were rehydrated in a descending series of 75%, 50% and 
25% MeOH/ PBST each for 5 mins at r.t. Samples were washed with 1x PBST 
for 5x 5 mins before Proteinase K treatment with diluted stock of Proteinase K 
(Fermentas) in PBST. 4-6 dpf medaka embryos were incubated in 2 µl 
Proteinase K/5 ml PBST with a final concentration of 30 µg/ml for 40-60 mins. 
Enzymatic digestion reactions were stopped by two consecutive washes with 1x 
Glycine/PBST (0.027M). Samples were re-fixed with 4% PFA/PBST for 2-3 
hours at r.t. and washed with 1x PBST for 5x 5mins on a rotator. 
Prehybridization was done by incubating embryos in Hybmix [50% Formamide, 
5x SSC, 150 µg/ml Heparin, 5 mg/ml torula RNA, 0.1% Tween, ddH2O (add up 
to 50 ml)] without RNA probe for 3 hours at 70 °C in a water bath. RNA probe 
working solutions were prepared at a 1:50 or 1:100 fold dilution and denatured 
at 80 °C for 10 mins and chilled on ice before being added to samples for 
overnight incubation at 70 °C in a water bath. The next day, samples were 
washed with SSCT buffer I (50% formamide/2x SSC Tween) for 2x 30 mins, 
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SSCT buffer II (2x SSC Tween) for 30 mins and SSCT buffer III (0.2x SSC 
Tween) 2x 30 mins at 70 °C in a water bath, followed by three 10 mins washes 
with 1x PBST at r.t. The embryos were blocked with 5% sheep serum/ PBST 
for 3 hours at r.t. on a rotator, before incubating them in anti-DIG-alkaline 
phosphatase (AP) or anti-FLU-AP (Roche) diluted 1:2000 at 4 °C overnight. 
The next day, samples were subjected to five 1x PBST washes for 40 mins, and 
one wash at 4 °C overnight. Samples were then incubated in pre-staining buffer 
(1 ml of 5 M NaCl, 5 ml of 0.5 M MgCl2, 5 ml of 1 M Tris HCl pH  9.5, 250 µl 
of 20% Tween 20, ddH2O add up to 50 ml) 2x 5 mins. Samples were stained 
with NBT staining solution (200 µl of 5 M NaCl, 1 ml of 1 M Tris HCl pH  9.5, 
50 µl of 20% Tween 20, 200 µl of NBT, ddH2O add up to 10 ml) at r.t. in the 
dark until colour development was completed. The time needed varied 
depending on the RNA probes used. 1x PBST was used to stop the staining 
reaction by washing samples  3x 5 mins and one extra wash at 4 °C overnight. 
 
2.7 Bisphosphonate treatment of medaka larvae  
2.7.1 Preparation of Bisphosphonate solutions 
Etidronate (Sigma P5248) and alendronate (Sigma A4978) powders were 
dissolved in fish medium to make stock solutions with a concentration of 50 
µg/ml (etidronate) and 100 µg/ml (alendronate). Different working solution 
were prepared with concentrations of 5, 7.5, 10, 12.5 and 15 µg/ml (etidronate) 
and 25, 37.5, 50, 62.5 and 75 µg/ml (alendronate). 
 
2.7.2 Bisphosphonate treatment of larvae 
RANKL:HSE:CFP transgenic medaka larvae at 9 dpf were subjected to heat-
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shock at 39°C for 1.5 or 2 hours to induce RANKL expression. After a recovery 
period of 1 hour at 30°C, larvae were screened for CFP expression indicating 
successful RANKL induction. Larvae showing expression of both CFP and 
ctsk:nlGFP were transferred to six-well plates (six larvae per well) for 
subsequent BP treatment. Different concentrations of etidronate and 
alendronate working solutions were added to the larvae at different time points, 
as specified in Chapter IV. Control larvae were kept in fish medium after heat-
shock (+RANKL non-BP-treated control, +Heat-shock -RANKL non-BP-
treated control) or received no heat-shock (-RANKL non BP-treated control; -
RANKL BP-treated control). All media were changed daily. 
 
2.7.3 Statistical analysis of Bisphosphonate treatment  
The number of larvae with phenotypes was recorded. Results are presented as 
percentages with mean ± SD (Standard Deviation) as determined using 
Microsoft Excel 2010. Two-tailed Student’s t-test was used for comparison of 
groups individually and determination of significance. The level of significance 
was set as follows: * 0.01 < p < 0.05 and ** p < 0.01. 
 
2.8 Imaging and image analysis 
2.8.1 Imaging of live samples  
For live fluorescence imaging, larvae were anesthetized with 0.01% ethyl 3-
aminobenzoate methanesulfonate (tricaine; Sigma A5040) and pictures were 
taken using a Nikon SMZ1000 stereomicroscope equipped with NIS-Elements 
BR 3.0 software (Nikon, Japan). For live confocal imaging, larvae were 
anesthetized with 0.005% tricaine and embedded in 1.5% low-melting-point 
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agarose in a glass-bottom-Petri dish. Confocal pictures were taken with a Zeiss 
LSM 510 Meta using 405, 488 and 543 nm laser lines for DAPI, GFP and 
mCherry analysis, respectively.  
 
2.8.2 Imaging of fixed samples 
Whole-mount fixed larvae and samples after micro-dissection were mounted in 
100% glycerol for photography with a Nikon SMZ1000 stereomicroscope and 
a Nikon Eclipse 90i upright microscope equipped with NIS-Elements BR 3.0 
software (Nikon).  
 
2.8.3 Image processing 
Imaging data were processed using Zeiss LSM Image Browser Version 
4.2.0.121, ImageJ 1.4.3.67 and Adobe Photoshop CS6 13.0.0.0 software.  
 
2.9 Histological analysis and electron microscopy  
Samples for histological analysis were sectioned and imaged by Dr. Paul 
Eckhard Witten and Dr. Ann Huysseune (University of Ghent, Belgium). For 
plastic sections and transmission electron microscopy (TEM), larvae were first 
pre-fixed in 10% formalin or fixed in a mixture of 1.5% glutaraldehyde and 1.5% 
PFA in 0.1 M cacodylate buffer for 24 hrs. After this they were subjected to 
decalcification in 10% EDTA dissolved in the glutaraldehyde 
paraformaldehyde fixative for a minimum of 48 hrs. Samples werer then sent to 
the collabortors in Belgium for further processing. Specimens were postfixed 
with osmium tetroxide [2.5 ml Na2HAsO4 x 12 H2O (0.2 M, pH 7.4), 0.3 ml 
glutaraldehyde, 0.5 ml PFA (15%), 0.01 ml CaCl2 (0.5%) and 1.69 ml ddH2O] 
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and embedded in Epon epoxy resin. Semithin sections (1 µm) were stained with 
toluidine blue for 1 min (0.2% toluidine blue, 2% Na2CO3), rinsed with water, 
air-dried, mounted with DPX (Fluka, Switzerland) and analyzed with a Zeiss 
Axio Immager–Z compound microscope equipped with a Zeiss Axiocam 
(www.zeiss.com). Ultrathin sections (0.02µm) were cut on a Reichert-OM 13 
ultramicrotome, mounted on coated copper grids and contrasted with uranyl 
acetate and lead citrate. Sections were observed with a Jeol JEM 1010 
transmission electron microscope (www.jeolusa.com) operating at 60 kV. 




















3. RESULTS  
3.1 Analysis of osx function in medaka using CRISPR/Cas9 mutants 
Medaka has been used as a popular animal model for bone research. A key 
regulatory role of Osx in mammalian bone formation is well established, 
however, its role in teleost skeletal development remains elusive. Our lab had 
previously shown that a transient morpholino (MO)-mediated knock-down of 
osx in medaka resulted in reduced mineralization of bone elements, suggesting 
an important role for osx also in medaka bone formation (Renn and Winkler, 
2014). The study also reported that the medaka osx mRNA has two spliced 
isoforms (osx_tv1 and osx_tv2). osx_tv1 is the predominantly expressed isoform 
during medaka embryogenesis, while osx_tv2 only showed upregulation when 
osx_tv1 was knocked down (Renn and Winkler, 2014). However, due to the 
limited stability of morpholino oligos, bone defects could only be observed 
during early stages. Therefore, my first project aimed to generate stable osx 
mutant lines using CRISPR/Cas9, knocking out the predominantly expressed 
osx_tv1 as well as both osx_tv1 and osx_tv2 to better understand the 
mechanisms of osx regulated bone formation. For this, in vivo analysis of 
osteoblast differentiation and osteoblast-osteoclast coupling in the medaka fish 
was conducted.  
 
3.1.1 Two splice isoforms of osx mRNA in medaka  
Our lab had previously reported two spliced forms of osx mRNA in medaka: 
osx_tv1 and osx_tv2. Osx_tv2 has an alternative splice donor, leading to the 
formation of an mRNA that is 342 nucleotides shorter than osx_tv1. The 
alternatively spliced region is indicated in grey in Fig. 4 (also see in Renn and 
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Winkler, 2014). With intact zinc-finger domains close to the C-terminal, osx-
_tv2 could play a compensatory role when osx_tv1 is deficient. Mutations in 
osx_tv1 mutants, caused by osx_tv1 crispr1 and osx_tv1 cripsr2 (Fig. 4 red and 
blue bar, respectively) are within the alternatively spliced region. Thus, the 
function of osx_tv2 is likely not affected as zinc-finger domains located 
downstream are expected to be intact (Fig. 4A purple bars). On the other hand, 
mutations in osx_tv1&2 mutants, caused by osx_tv1&2 crispr (Fig. 4 orange 
bar), are predicted to result in a disruption of both osx isoforms and a general 
knock-out of osx.  
 
Figure 4: Schematic diagram showing CRISPR/Cas9 target sites in two osx 
isoforms in medaka. The target sites for osx_tv1 crispr1 (red bar) and osx_tv1 
crispr2 (blue bar) target sites are located in the alternatively spliced region (grey 
bar). The position of the osx_tv1&2 crispr (orange bar) target site is in the 
common region of both osx_tv1 and osx_tv2. Zinc-finger domains are indicated 
in purple bars. Numbers indicate nucleotides position according to the first ATG.  
 
3.1.2 Generation of F0 founders carrying CRISPR/Cas9-induced osx_tv1 
mutations  
To induce mutations in the first transcript isoform of medaka osx (osx_tv1), two 
guide RNAs (gRNAs), osx_tv1 crispr1 (100 ng/µl) and osx_tv1 cripsr2 (100 
ng/µl), targeting the second exon of osx from 190-209 nucleotides (Fig. 4A red 
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sequence) and 211-230 nucleotides (Fig. 5A blue sequence), respectively, were 
co-injected with 300 ng/µl of Cas9 mRNA into one-cell stage osx:mCherry 
transgenic medaka embryos (Renn and Winkler 2009) (Fig. 5B). Severe defects 
with respect to numbers and distribution of osx positive osteoblasts were 
observed in the vertebral bodies of injected larvae (Fig. 5C), suggesting 
osteoblast differentiation defects in this transient CRISPR/Cas9 assay. Only 23 
out of 138 (7.24%) injected embryos developed into adulthood. 13 of them were 
severely deformed (data not shown) and not viable, while only 10 out of 23 did 
not show obvious skeletal or other malformations. To identify potential mutant 
carriers, genomic DNA obtained from clipped fins of F0 fish were used as 
template and a 430 bp PCR product was amplified and digested with the 
restriction enzyme HaeIII (underlined in Fig. 5A). In wildtype, a 241 bp 
fragment, a 136 bp fragment and a 45 bp fragment (not shown on the gel) were 
observed. Mutants were detected by restriction fragment length polymorphism 
(RFLP) because mutations disrupted the HaeIII binding site and resulted in a 
larger fragment (around 294 bp), which varies slightly according to the mutated 
sequences (Fig. 5D asterisks). 5 out of 10 F0 adult fish without severe 
malformation were genotyped as mutant (Fig. 5D). After outcrossing with 
wildtype fish, different types of insertion-deletion (indel) mutations were 




Figure 5: Defects in osteoblast distribution in osx_tv1 CRISPR/Cas9 
injected larvae at 15 dpf. A. The position of osx_tv1 crispr1 (red) and osx_tv1 
crispr2 (blue) target sites in exon 2 of osx. A HaeIII restriction site used for 
genotyping is underlined. PAM sequence: “TGG” is just after the osx_tv1 
crispr2 gRNA. B. Normal distribution of osx:mCherry cells in non-injected 
control larvae at 15 dpf (see B’ for higher magnification). C. Severe defects, 
including reduced numbers of osx positive osteoblasts around arches (yellow 
arrows) and deformed notochord in injected larvae (see C’ for higher 
magnification). na: neural arch, ha: haemal arch, n: notochord. Scale bars: 500 
µm. D. Genotyping by RFLP analysis in CRISPR/Cas9 injected F0 adult fish. 
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After HaeIII digestion, mutations at the target site result in larger fragments 
(asterisks), along with the predicted 241 bp, 136 bp and 45 bp (not shown) 
fragments. E. Indel mutations (purple) in seven different alleles in heterozygous 
F2 adult fish.  
 
3.1.3 Homozygous mutants carrying different mutant alleles show identical 
phenotypes 
Homozygous osx_tv1 mutant F3 embryos were obtained by incrossing F2 
heterozygous adult fish with the same mutant allele and were used for 
phenotypic analysis. Two alleles (osxdel138a, 25 bp deletion; osxdel137a, 28 bp 
deletion) were analyzed. Both alleles result in frameshifts, leading to premature 
stop codons at positions of 138 and 137, respectively, upstream of the three 
zinc-finger DNA-binding domains (Fig. 6A). Homozygous carriers for both 
alleles were obtained and showed identical phenotypes, such as lack of 
intramembranous ossification in cranial structures, reduced number of otoliths 
and absence of neural arches, as well as reduced number of osteoblasts (Fig. 




Figure 6: Identical bone phenotypes in osx_tv1 homozygous mutants with 
different alleles. A. Alignment of wildtype osx sequence with that of osxdel138a 
and osxdel137a. Bone mineralization defects in 15 dpf mutants (E,F and H,I), 
compared with 10 dpf wildtype larvae (B,C) as revealed by Alizarin Red 
staining, including reduced number of otoliths (arrows in B,E,H), non-
mineralized cleithrum (C, F, I black arrows) and caudal fin rays (C, F, I red 
arrows) and lack of neural arches in the trunk (C, F, I green arrows). Alcain 
Blue staining shows no distinct difference in osx mutants and wildtype controls. 
Decreased number of osx:mCherry-positive cells in cranial structures and can 
hardly be observed in vertebral columns of mutants as shown in lateral view 
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(G,J). Note that younger wildtype larvae were used as controls to exclude that 
the defects in mutants are due to a developmental delay.  
 
3.1.4 Knocking-out osx_tv1 strongly disrupts intramembranous bone 
formation but has almost no effect on perichondral ossification  
Alizarin red staining was performed to compare bone formation in wildtype and 
osx_tv1 mutants. This revealed reduction or absence of intramembranous bones 
in the cranial structures in mutants (Figs. 6,7), i.e. smaller operculum (Fig. 7A,G 
arrows), missing parasphenoid (Fig. 7B,H), significantly shorter or absent 
branchiostegal rays (Fig. 7C,I, also see in Fig. 6E,H). Ultrastructural analysis 
revealed reduced bone matrix formation in branchiostegal rays and the 
cleithrum (Fig. 8). The osx_tv1 mutants also showed a reduced number of 
otoliths (Fig. 6H arrow) and thinner and shorter cleithra (Fig. 7F,L red arrow). 
In osx_tv1 mutants, no bone matrix and no Alizarin red staining was detected in 
the arches (Fig. 6I green arrow), which confirmed by high contrast imaging 
(data not shown). In addition, the caudal fin rays of osx_tv1 mutants were not 
mineralized (Fig. 6I red arrow). As compared to intramembranous bone, defects 






Figure 7: Mineralization of intramembranous bone is strongly disrupted in 
osx_tv1 mutants, while perichondral bone mineralization is less affected. 
Alizarin Red staining for bone, in wildtype control larvae (A-F) and osx_tv1 
mutants (G-L), ventral views. Smaller operculum (op) in mutants (G, arrows). 
Magnifications show the strong defects in intramembranous bone structures 
including: reduced parasphenoid (p) (H), shortened and deformed 
branchiostegal rays (bs) (I) as well as thinner cleithrum (cl) (L, red arrow). Less 
affected perichondral bone including: palatoquadrate (pq) (J), ceratohyal (ch) 





Figure 8: Ultrastructural details of branchiostegal rays (A-D) and 
cleithrum (E-H) in wildtype (A-B and E-F) and osx_tv1 mutants (C-D and 
G-H) at 15 dpf. A. Cross section of a wildtype branchiostegal ray at low 
magnification. Note well developed bone matrix, likely with a mineralized 
centrum (asterisk) and a peripheral layer of osteoid (arrowheads), surrounded 
by flattened osteoblasts (white arrows). Inset: Semithin cross section through 
two branchiostegal rays (black arrows), indicating the region shown in the TEM 
picture. B. Higher magnification of osteoblasts (boxed area in A) surrounding 
the bone matrix. Rough endoplasmatic reticulum cisternae and orientation of 
collagen fibrils in the osteoid (arrowhead) constitute evidence of their secretory 
activity. C. Cross section of a branchiostegal ray in a mutant at low 
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magnification. Note plump osteoblast-like cells (white arrows) surrounding a 
small amount of woven bone matrix (asterisk). Inset: Semithin cross section 
through two branchiostegal rays (black arrows), indicating the region shown in 
the TEM picture. D. Higher magnification of osteoblast-like cells (boxed area 
in C) surrounding the sparse bone matrix (asterisk). Compare with the secretory 
osteoblasts shown in B. E. Sagittal semithin section through the cleithrum 
(arrow) of a wildtype medaka. The light centre indicates mineralization of the 
matrix (minerals were removed during sample preparation). F. Abundant bone 
matrix with preferential fibril organisation in the cleithrum of a wildtype 
medaka. G. Sagittal semithin section through the cleithrum (arrow) of an osx 
mutant medaka. The bone is clearly less developed and possibly less 
mineralized than in WT. H. Sparse and loosely organized bone matrix in the 
cleithrum of mutant medaka. Scale bars in insets A-C, E, G: 25 µm; in A and C: 
2 µm, in D: 1 µm and in B, F and H: 0.5 µm. Images were provided by P.E. 
Witten and A. Huysseune (University of Ghent). 
 
Tooth formation appeared to be normal in numbers and patterning in osx_tv1 
mutants, although tooth sizes were generally smaller and lacked sharp tips (Fig. 
9B) compared to wildtype siblings (Fig. 9A). Detailed observations revealed 
that the smaller tooth size in mutants was due to less dentin deposited and to the 
absence of attachment bone normally connecting the tooth to the underlying 





Figure 9: Teeth at the dentary in osx_tv1 mutants. Tooth formation in 
wildtype siblings (A and C) and mutants (B and D). A. Alizarin Red stained 
teeth with sharp tips and in regular arrangement in wildtype larvae. Note that 
teeth formed earlier in the center are bigger in size. B. Symmetrically formed 
teeth in osx_tv1 mutants. The teeth in mutants appear slightly reduced in size. 
Note that increased tooth number in mutant is due to different age (15 dpf) when 
compared to control (13 dpf). Note the arrangement of tooth is irregular, 
pointing in different directions, indicated by the arrows. Tooth in osx_tv1 
mutant with less dentin deposited (D arrow). Attachment bone in wildtype (C 
arrowhead) fails to form in mutants. Mc = Meckel’s cartilage. Scale bars in A 
and B: 20 µm, in C and D: 25 µm. Images were provided by P.E. Witten and A. 
Huysseune (University of Ghent). 
 
Likely because of severe bone defects, less than 1% of osx mutants (n > 100 
mutants analyzed) survived beyond one, and none beyond two months. Mutant 
one month old fish lacked scales and showed a complete absence of mineralized 
arches, as well as ribs and lacked bony fin rays of all paired and unpaired fins 
(Fig. 10), similar as the Osx null mice. However, unlike in the mouse model 
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(Oh, et al., 2012), the formation of cartilage appeared normal in medaka osx 
mutants (Fig. 11).  
 
Figure 10: Mineralization defects in juvenile osx_tv1 mutants. Alizarin Red 
and Alcian Blue staining in 1.5-month old wildtype fish (A) and osx_tv1 mutant 
(B). Note lack of mineralized scales and reduced cranial skeleton in osx_tv1 
mutants. Also note a complete absence of arches and fin rays. Scale bars: 1 mm. 
 
 
Figure 11: Normal cartilage formation in osx mutants. Alizarin Blue stained 
wildtype (A-B) and mutant (C-D) larvae. Scale bars in A and C: 100 µm, in B 






3.1.5 Differentiation and maturation of osteoblasts is inhibited in osx_tv1 
mutants  
For in vivo analysis of premature osteoblasts, observations were performed in 
osx:mCherry/col10a1:nuGFP double transgenic medaka larvae. In control fish, 
a high percentage of overlapping expression of osx:mCherry and 
col10a1:nuGFP in cells around the branchiostegal rays (Fig. 12D,E,G) indicates 
the presence of premature osteoblasts. Successive live staining with alizarin 
complexone (ALC) and calcein four days later allows previously existing 
mineralized (stained with ALC, red) matrix to be distinguished from de novo 
mineralized matrix (stained with calcein, green) (Fig. 12A-C”). Confocal 
images showed early mCherry-expressing osteoblasts forming at the position of 
newly formed branchiostegal rays, cleitrum, neural and haemal arches and 
caudal fin rays (Fig. 12A-C”), which were initially nuGFP negative (Fig. 12F-
F’). This suggests that col10a1:nuGFP positive cells are slightly more 
differentiated premature osteoblasts than osx:mCherry-expressing cells. 
col10a1 is also expressed in chondrocytes (Renn et al., 2013), allowing the 




Figure 12: Visualization of newly mineralized bone matrix and premature 
osteoblasts in wildtype larvae. (A-C”) Lateral view of cranial bone structure 
showing de novo mineralization evident by calcein labeling at the tip of the 
cleithrum (arrowhead in A”), neural arches (B”) and caudal fin rays (C”). 
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osx:mCherry-expressing cells are present at the tips of branchiostegal rays (D), 
cleithrum (E) and caudal fin rays (G) as well as neural arches (F-F’) (yellow 
arrowheads). col10a1:nuGFP-expressing cells (white arrowhead) forming 12 
hours later at the same neural arches (F’) indicating that col10a1-expressing 
cells are slightly more differentiated premature osteoblasts compared to osx-
expressing cells. Scale bars: 50 µm. 
 
Live imaging of osx:mCherry and col10a1:nuGFP labeled cells in the cranium 
of  wildtype larvae  revealed almost overlapping expressing patterns of 
osx:mCherry and col10a1:nuGFP labeled cells in intramembranous bone 
structures (Fig. 13A-A3 cells in yellow). On the other hand, in osx_tv1 mutants, 
there was an almost complete absence of col10a1-positive pre-osteoblasts in 
intramembranous bones such as the branchiostegal rays (Fig. 13B1), operculum 
(Fig. 13B2 yellow arrow) and cleithrum (Fig. 13B3 yellow arrows). 
Interestingly, the number of osx:mCherry-positive cells was also greatly 
reduced, e.g. in the branchoistegal rays (Fig. 13B1) and operculum (Fig. 13B2). 
Also, although the number of osx:mCherry-positive cells was reduced in these 
bones, some cell persisted, which opened the possibility that a limited number 
of pre-osteoblasts can form. These cells exhibit osx promoter activity but are 
unable to switch on other pre-osteoblast markers such as col10a1 suggesting 




Figure 13: Knocking-out of osx_tv1 blocks differentiation of premature 
osteoblasts in intramembranous bones. Single channel and merged confocal 
images are shown, ventral view of the head at 15 dpf. Boxed areas in A and B 
are shown as confocal images in higher magnification in A1-A3 and B1-B3, 
respectively. Decreased numbers of osx:mCherry/col10a1:nuGFP-positive 
osteoblasts in the branchoistegal rays (A1,B1), operculum (A2,B2) and 




Osteocalcin (osc) is a marker for fully differentiated mature osteoblasts 
(Huitema et al. 2012). To test whether osteoblast maturation is inhibited by 
knocking-out osx_tv1, the distribution of osc:eGFP-positive mature osteoblasts 
was analyzed in osx_tv1 mutants (Fig. 14A,B). osc:eGFP-positive cells were 
completely absent, e.g. in the operculum (Fig. 14A1”,B1”) and branchiostegal 
rays (Fig. 14A2”,B2”). Other than pigment cells showing auto-fluorescence 
(Fig. 14B1’ yellow fluoresence), no fluorescence from the osc:eGFP transgene 
was detected. Over-exposure with 24-fold increased laser power revealed that 
only few cells with very low osc:eGFP expression were remaining in the 
cleithrum of these samples (Fig. 15C-C’ yellow arrow), validating that 
osteoblast maturation was generally blocked in osx mutants. RT-PCR analysis 
confirmed the dramatic decrease of osc expression in osx mutants (Fig. 15D). 
This shows that osx is required for differentiation of most osteoblasts in medaka, 
with the exception of a few osteoblast cells, e.g. in the cleithrum region (Fig. 





Figure 14: Formation of mature osteoblast is blocked in medaka osx_tv1 
mutants. Wildtype controls (A-A2”) and osx mutants (B-B2”) in a 
osx:mCherry/osc:eGFP transgenic background. Ventral views of the head are 
shown. Decreased numbers of osx:mCherry-positive cells and absence of 
osc:eGFP-positive osteoblasts in the operculum (B1-B1”) and branchoistegal 







Figure 15: Distribution of osx:mCherry/osc:eGFP-positive osteoblasts in 
wildtype control larvae (A-A’) and osx_tv1 mutants (B-B’) at 15 dpf in cranial 
structures. Using a 24 times higher laser power than in Fig. 8 reveals the 
presence of single osc positive cells with very low eGFP expression around 
cleithrum (C-C’, arrow). Scale bars: 50 µm. D. Down-regulated osx and osc 
expression in osx mutants as analysed by RT-PCR (top). β-actin loading control 
was used for normalization. No DNA band was detected in RNA samples 
without addition of Reverse Transcriptase (-RT), indicating absence of genome 
DNA contamination (bottom). E. Osx expression in mutant relative to WT as 
analysed by quantitative RT-PCR (qPCR) in biological triplicates. ** P<0.01.	
 
Perichondral osteoblast differentiation was also affected in osx_tv1 mutants. 
col10a1:nuGFP/osx:mCherry double positive perichondral osteoblasts were 
absent from the palatoquadrate (Fig. 16B’,F’ arrow). Interestingly, a few of 
these perichondral cells remained in the mutant ceratohyoid and expressed 
col10a1:nuGFP (Fig. 16G’ arrow). The fact that some of these undifferentiated 
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cells persist in the perichondrium of the analyzed osx mutants (Fig. 16G-G”), 
hints to a possible compensation by additional molecular pathways, such as the 
alternative contribution of osx_tv2. Chondrocytes positive for col10a1:nuGFP 
appeared to form normally, for example in the palatoquadrate (Fig. 16B’,F’), 
consistent with the observation that cartilage matrix formation is normal in 




Figure 16: Reduced numbers of perichondral osteoblasts in medaka 
osx_tv1 mutants. Analysis of osx:mCherry/col10a1:nuGFP-positive 
perichondral osteoblasts (arrows in B’ and C’) and col10a1:nuGFP-positive 
chondrocytes in wildtype control larvae. Boxed areas in A are shown as 
confocal images in higher magnification in B (palatoquadrate), C (ceratohyal) 
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and D (ceratobranchials 5). In osx_tv1 mutants (E), col10a1:nuGFP-expressing 
perichondral osteoblasts are almost absent in the palatoquadrate (arrow in F) 
and only residual cells were seen in the ceratohyal (arrow in G). Note that strong 
mCherry expression in the palatoquadrate might be due to mCherry aggregation 
of non-functional cells. Expression in teeth and cartilage of the 5th 
ceratobranchials is similar to wildtype (arrows in H-H”). Scale bars: 50 µm. 
 
3.1.6 Osx is not required for notochordal sheath mineralization 
Besides ossification defects in the cranium, deficiencies in the developing 
vertebral column were also observed. Osteoblasts secrete extracellular bone 
matrix to build up the perichordal bone layer, forming around the mineralized 
notochodral sheath in vertebral centra in the medaka fish (Inohaya et al., 2007). 
Whether the notochord itself or cells outside the notochord are responsible for 
notochordal sheath mineralization remains an unresolved question.  
Mineralized arches were absent in osx_tv1 mutants but interestingly, the 
notochordal sheath-based vertebral centra anlagen of osx_tv1 mutants appeared 
normally mineralized (Fig. 17A,F, also see Fig.6). In order to understand how 
osteoblast formation is affected in the vertebrae of osx_tv1 mutants, live 
imaging of medaka bone transgenic reporter lines was performed. The number 
of osx:mCherry- as well as osc:GFP-positive cells were strongly reduced in both 
neural and haemal arches as well as in the centra (Fig. 17B,D,G,I). In contrast, 
the number of col10a1:nuGFP-positive cells was normal in the vertebral centra 
of osx_tv1 mutants (Fig. 17C,E,H,J). This supports the idea that 
col10a1:nuGFP-positive but osx:mCherry-negative cells regulate 
mineralization of notochordal sheath in medaka as suggested earlier (Renn et 
al., 2013). Transmission electron microscopy (TEM) imaging performed by our 
collaborators (Dr. Witten and Dr. Huysseune) revealed normal notochordal 
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sheath formation but almost complete absence of perichordal bone in osx_tv1 
mutants (Fig. 17K,L, black arrow), supporting the idea that osx-positive 
osteoblasts are neither required for notochordal sheath mineralization nor for 
cartilage formation but that their role is restricted to bone formation (Fleming 
et al. 2015). An immature osteoblast reduced endoplasmic reticulum was 
identified outside the mineralized bone layer (Fig. 17L, red arrow). The 
interrupted osteoblast differentiation in osx mutants could be the reason causing 
the absence of perichordal bone and affecting arch formation. On the other hand, 
the unaffected notochordal sheath (Fig. 17J) might indicate another mechanism 
for mineralization of this structure, which is different from that of outer 
perichordal bone layer. 
 
Figure 17: Normal mineralization of the notochordal sheath, but absence 
of perichordal bone in the centra of medaka osx_tv1 mutants. A-D. 
Confocal imaging in wildtype control larvae showing mineralization of neural 
arches (na) and centra (c) (A) and normal distributed fluorescently labeled 
osteoblasts (B-D). E. Lateral view of wildtype col10a1:nuGFP transgenic 
medaka larva. F-I. Confocal imaging of vertebral bodies in osx_tv1 mutants. 
Centra lacked mineralized neural arches (F) and showed the absence of 
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osx:mCherry (G), col10a1:nuGFP (H) and osc:eGFP (I) cells in the neural 
arches (dashed line yellow box in G and I), compared with osx:mCherry- and 
osc:eGFP-expressing osteoblasts, indicated in yellow box in B and D. 
col10a1:nuGFP positive cells were abundant in centra of mutant larvae (H). 
Scale bars: 50 µm. J. Lateral view of col10a1:nuGFP expression in osx_tv1 
mutant larva showed absence of col10a1-positive osteoblasts in the arches. K-
L. TEM images showing normal notochordal sheath (ns) but almost complete 
absence of perichordal bone (pb). Scale bars: 1000 nm. Images K and L were 
provided by P.E. Witten and A. Huysseune (University of Ghent). 
 
3.1.7 Medaka osx_tv1 mutants show reduced transcription of osteoblast 
progenitor markers  
As osteoblast differentiation was blocked in osx_tv1 mutants, it was next tested 
whether osteoblast progenitor cells accumulate. RNA whole-mount in situ 
hybridization was performed on embryos at 4 and 6 dpf to exclude any 
developmental delay in osx_tv1 mutants. This revealed that transcription of 
runx2, a general marker for osteoblast and chondrocyte progenitor formation 
(Flores et al. 2004; Li et al. 2009), was strongly reduced at both 4 and 6 dpf (Fig. 
18A-D).  
On the other hand, transcription of the chondrocyte marker col2a was normal 
as expected (Fig. 18E-F). Comparable with my findings using the osx:mCherry 
reporter line, transcription of osx was slightly reduced especially in the 
parasphenoid and operculum (Fig. 18G,H). It remains to be shown whether this 
reduction is due to nonsense-mediated decay of the mutant mRNA. col10a1 (Fig. 
18I,J) and osc (Fig. 18K,L) transcripts were almost completely absent in osx_tv1 
mutants. Together, these data show that not only differentiation of osx-positive 
cells into mature osc-expressing osteoblasts is blocked in medaka osx mutants, 




Figure 18: Pre-osteoblast markers are down-regulated in medaka osx_tv1 
mutants as shown by RNA in situ hybridization. A-D. Reduced transcription 
of runx2 in mutants at 4 and 6 dpf (B and D). E-F. Normal transcription of col2. 
G-H. Slightly reduced transcription of osx in osx_tv1 mutants. I-L. Almost 
complete absence of col10a1(J) and osc (L) transcripts in mutants. p: 
parasphenoid, op: operculum, bs: branchiostegal rays, pt: pharyngeal tooth, cl: 
cleithrum. Scale bars: 50 µm. 
 
3.1.8 Formation of osteoclasts is affected in medaka osx_tv1 mutants 
Osteoblast-osteoclast coupling is essential for bone homeostasis. To analyze 
whether osteoclast behaviour is affected in osx_tv1 mutants, 
ctsk:nlGFP/osx:mCherry expression was analyzed. The ctsk:nlGFP transgenic 
reporter line allows visualization of cathepsin k (ctsk)-expressing osteoclasts 
(To et al., 2012). At 25 dpf, endogenous osteoclasts were observed at the base 
of the vertebral arches in controls (Fig. 19A), while the formation of 
endogenous osteoclasts seemed to be interrupted in the mutant (Fig. 19B). 
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Because osx mutants generally develop slower than their wildtype sibilings, a 
developmental delay could have caused the absence of endogenous osteoclasts.  
 
Figure 19: The formation of endogenous osteoclast might be affected in 
osx_tv1 mutants. (A) Note nlGFP-expressing osteoclasts form around arches 
in wildtype control larvae at 25 dpf (arrows). (B) Absence of ctsk:nlGFP cells 
in the vertebral columns in osx mutants. 
 
Therefore, triple transgenic osx:mCherry/RANKL:HSE:CFP/ctsk:nlGFP larvae 
were used to analyze the effect of an osx deficiency on transgenically induced 
osteoclasts at an earlier stage by live imaging. Ectopic osteoclast formation was 
triggered by heat-shock inducible expression of RANKL at 9 dpf for 2 hours 
similar to what was described in To et al. 2012. In control larvae nlGFP-
expressing cells were ectopically found around the neural arches and vertebral 
centra (Fig. 20B-B’). On the other hand, the induction of osteoclasts in the 
majority of osx_tv1 mutants (n=10/12) was not as obvious, showing only few 
nlGFP-positive cells 12 hours after RANKL overexpression at 9.5 dpf (Fig. 
20C-D’). Two days after RANKL induction, a dramatic increase in the number 
of ectopic osteoclasts was observed forming from anterior to posterior in 
wildtype larvae (Fig. 20E), covering the neural arches and the entire vertebral 
centra (Fig. 20F-F’). In contrast, in osx_tv1 mutants, the induction of osteoclasts 
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was consistently affected, shown in lower numbers (Fig. 20 compare E with G). 
The ctsk:nlGFP-expressing cells in osx_tv1 mutants show weak GFP expression 
and are only detected when using higher laser power (Fig. 20H-H’). Three days 
after RANKL induction (12 dpf), large numbers of ectopic osteoclasts are 
evident in control larvae (Fig. 20I-J’). Numbers of osteoclasts remained low in 
mutants of the same age (Fig. 20K). Continous observation using the same 
mutant larva showed decreased number of osteoclasts in the same vertebral 
columns were observed (Fig. 20L-L’). This shows that differentiated osteoblasts 
are necessary for the efficient formation of osteoclasts after transgenic RANKL 
induction.  
 
Figure 20: Osteoclast induction and maintenance are deficient in osx_tv1 
mutants. A-D. Osteoclast formation starts at 9.5 dpf upon RANKL induction 
at 9 dpf. Less ctsk:nlGFP osteoclasts form in mutants (C-D’) as compared to 
controls (A-B’) at 9.5 dpf. E-H. Ectopic RANKL stimulates formation of 
ectopic osteoclasts at 11 dpf. Overviews show inefficient induction of 
osteoclasts in osx_tv1 mutants (G), compared to controls (E) at 11 dpf. Note 
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increased number of osteoclasts in both controls (F) and mutants (H) with 
confocal images, compared to 9.5 dpf. However, the ctsk:nlGFP-expressing 
cells in the mutant have low levels of GFP expression and were detected only 
with a higher laser power (H-H’). I-L. Maintenance of osteoclasts at 12 dpf. 
Overviews show a significantly larger number of RANKL-induced osteoclasts 
in controls (I) than in osx_tv1 mutants (K). Confocal images show similar 
number of nlGFP-expressing osteoclasts in wildtype at 11-12 dpf. Same larva 
was used for continuous observation. Note slight decrease in the number of 
osteoclasts in osx_tv1 mutants at 12 dpf as compared to 11 dpf. Scale bars: 50 
µm. 
 
In control larvae, large lesions in the notochordal sheath were observed as a 
consequence of ectopic osteoclasts and consequently increased resorption of 
mineralized matrix (Fig. 21B arrows, also see in To. et al., 2012). In contrast,  
similar lesions were almost absent in osx_tv1 mutants (Fig. 21C), indicating that 
osx mediated osteoblast formation is required for the differentiation and 
maturation of osteoclasts. Hence, additional factors other than osteoblast-




Figure 21: Absence of osteoporotic lesions in osx_tv1 mutants with ectopic 
RANKL expression. A. Intact vertebral column with completely mineralized 
neural arches, haemal arches and vertebral centra in 
osx:mCherry/RANKL:HSE:CFP/ctsk:nlGFP control larvae without RANKL 
induction. B. Loss of mineralized arches and large lesions in vertebral centra 
(arrows) in osx:mCherry/RANKL:HSE:CFP/ctsk:nlGFP control larvae three 
days after RANKL induction; see also (To et al. 2012). C. Lesions due to bone 
resorption are less obvious upon RANKL-induction in the centra of osx_tv1 
mutants. Note that loss of mineralized arches in osx mutants is due to absent 
osteoblasts, but lesions in centra are caused by RANKL-induced ectopic 
osteoclasts. 
 
3.1.9 Heterozygous phenotypes in osx_tv1 mutant larvae and adult female 
fish 
After hatching, heterozygous osx_tv1 mutant larvae had mild defects in 
osteoblast distribution, showing an irregular positioning of osx:mCherry-
positive osteoblasts (Fig. 22B). As previously described, all homozygous larvae 
show severe defects and are not viable (Fig. 22C). Heterozygous female fish 
developed a kyphosis-like spinal curvature phenotype after five months (Fig. 
23B), as compared to wildtype adult fish with normal straight vertebra (Fig. 
23A).  This shows that two alleles of non-mutated osx are needed for proper 




Figure 22: Heterozygous osx_tv1 mutant larvae at 12 dpf exhibit mild 
defects in osteoblast distribution. A. Normal distribution of osx:mCherry-
positive osteoblasts in neural arches of wildtype control larvae. B. Reduced 
number of osteoblasts in shortened neural arches with irregular length (arrows) 
in heterozygous osx mutants. C. Loss of osx-expressing cells in arches of 
homozygous osx mutants (also see in Fig. 3F,I). Boxed regions in A, B and C 





Figure 23: A kyphosis-like spinal curvature phenotype in a heterozygous 
osx+/- female carrier at 6 months of age. Scale bars: 3 mm. 
 
Different from zebrafish but similar to humans, medaka has an XX-XY sex 
determining system (Aida, 1921). Therefore, to test whether there are any 
gender effects responsible for the observed lethality in osx mutant carriers, the 
presence of DMY, the medaka Y chromosome-specific sex-determining gene 
(Matsuda et al., 2002), was used to detect the sex of larvae and adult fish (Fig. 
24). Theoretically, 50% of embryos obtained from wildtype parents should be 
DMY+. The slight decrease of DMY+ embryos detected in our wildtype strain 
(38.9%) could be due to a temperature-induced female to male sex reversal that 





et al., 2007) (Fig. 24A red column). When heterozygous osx mutant females 
were crossed to wildtype DMY+ male fish, there was no significant change in 
the percentage of DMY+ embryos obtained when compared to wildtype (Fig. 
24B green column). Strikingly, however, when two heterozygous osx carriers 
were crossed, no DMY+ embryos were identified in the offspring (Fig. 24A 
purple column). This opened the possibility that the parental heterozygous 
males were DMY-. To test this hypothesis, male and female heterozygous osx 
carriers were phenotypically identified according to the shape and size of their 
dorsal and anal fins (Iwamatsu, 2004) and analyzed by PCR for the presence of 
DMY. Female fish were used as controls to confirm the specificity of the DMY 
PCR conditions (Fig. 24B red and green column). The percentage of DMY+ 
wildtype adult male fish in our colony was found to be 84.4% (data collected 
by FYP student, Mohamed Haniffa B Hasan M) (Fig. 24B blue column). 
Interestingly, however, all tested osx+/- male carriers were negative for DMY 
(Fig. 24A purple column). This strongly suggests that the osx+/- male fish, 
identified according to their external phenotypes, had earlier undergo a sex 
reversal, which explains the 0% of DMY+ embryos obtained when crossing a 
pair of heterozygous parents. The fact that DMY+/osx+/- larvae were only 
detected at larval stages (as progenier from wildtype males, Fig. 24A green 
column), but no heterozygous adult fish carrying a Y chromosome were 
identified (Fig. 24B green column), suggests gradually developing bone defects 
happening only in male heterozygous larvae. This could highly likely lead to 
lethality before sexual maturation and all male heterozygous adult carriers are 




Figure 24: Knocking-out osx causes lethality in heterozygous male carriers. 
A. Percentage of DMY+ embryos obtained from crossing adult fish with 
different genotypes. The ‘+/+ x +/+’ percentages reflect the expected values 
according to Mendel’s laws (blue columns). B. The percentage of DMY+ adult 
fish in male wildtype is 84.4%, with 15.6% sex-reversed DMY- females (blue 
column). Female wildtype and heterozygous fish were used as controls for the 
specificity of DMY gene (red and purple columns). The percentage of DMY+ 
adult fish in male heterozygous is 0.0% (purple column), indicating that all 
males are sex-reversed DMY- female heterozygous fish. This is consistent with 
the finding that 0.0% of DMY+ embryos were obtained when heterozygous fish 
were crossed (A, purple column).  
 
3.1.10 Analysis of the bone phenotype in a medaka mutant with disrupted 
osx_tv1&2 
A forward primer and a reverse primer binding to the alternatively spliced 
region were used to test for mRNA expression of osx_tv1. The same forward 
primer and a different reverse primer binding to the common region of both 
osx_tv1 and osx_tv2 were used to test for transcription of both isoforms (Fig. 
25A). Slightly upregulated osx_tv1 expression was observed (Fig. 25B). Note 
that the size of the osx_tv1 band was slightly smaller in mutant (-/-) compare to 
wildtype control (+/+) due to the 28 bp deletion.  
As previously reported in Renn and Winkler, 2014, a second transcript variant 
osx_tv2 is upregulated after morpholino (MO) knock-down and could play a 
compensatory role. A similar upregulation of osx_tv2 was also observed in 
74	
	
homozygous osx_tv1 mutants (Fig. 25B asterisk). Since osx_tv2 is expressed in 
osx_tv1 mutants, mutant lines with deficiencies in both osx isoforms were 
established to test for a potential compensating role of osx_tv2 and further 
understand the mechanism of osx during skeletogenesis. 
 
Figure 25: Schematic diagram showing two osx transcript isoforms and the 
upregulation of osx_tv2 upon knocking-out osx_tv1. A. A schematic cartoon 
of two splice isoforms of osx mRNA. A common forward primer: osx_tv1&2RT 
for (green) and a reverse primer: osx_tv1RT rev (red) were used to test for 
mRNA expression of only osx_tv1. osx_tv1&2RT for (green) forward primer 
and the reverse primer osx_tv1&2RT rev (blue) were used to test for 
transcription of both osx_tv1 and osx_tv2 (osx_tv1&2) isoform. B. Upregulation 
of osx_tv2 in osx_tv1 mutants (asterisk). (+/+) indicates wildtype cDNA and (-
/-) indicates osx_tv1 homozygous cDNA. β-actin loading control was used for 
normalization. Note that expression of osx_tv2 is below detection limit in 
wildtype embryos (+/+). 
 
An osx_tv1&2 Crispr gRNA was designed and synthesized, targeting the second 
exon of osx from 477-497 nucleotides (Fig. 25A orange bar). Deletions or 
insertions around the osx_tv1&2 Crispr target region are expected to affect the 
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triplet nature of gene expression by codon, which can cause fram shift mutations, 
leading to premature stop codons upstream of the zinc-finger domains in both 
osx_tv1 and osx_tv2 isoforms, leading to a non-functional osx protein. 
Osx_tv1&2 crispr (356 ng/µl) was co-injected with 300 ng/µl of Cas9 mRNA 
into col10a1:nuGFP transgenic medaka embryos (Renn et al., 2013) at the one-
cell stage (Fig. 26B). To identify potential mutants, a 366 bp PCR product was 
amplified and digested with HpaII (colored in blue in Fig. 26A). In wildtype, 
two smaller fragments (246 bp and 116 bp) could be detected. Mosaic mutants 
with mutations disrupting the HpaII binding site resulted in larger fragments 
(around 366 bp), which vary according to the mutated sequences (Fig. 26D 
asterisks), as well as two smaller wildtype fragments (246 bp and 116 bp). 
Severe defects were observed already in the injected F0 larvae (Fig. 26C). These 
defects include a lack of col10a1-expressing osteoblasts at the branchiostegal 
rays (red arrow), cleithrum (yellow arrow), neural arches (white arrow) and 
caudal fin rays (blue arrow). These defects observed in F0 mosaic mutants 
suggest a stronger effect on osteoblasts with the disruption of both osx_tv1 and 
osx_tv2 isoforms than with osx_tv1 alone. F0 founders were incrossed to obtain 
large populations of F1 fish carring mutations. As expected, different types of 
indel mutations were detected in heterozygous F2 adult fish. A mutated allele 
(osxdel161a, 4 bp deletion), with a frameshift and premature stop codon at amino 
acid position 161, upstream of the three zinc-finger DNA-binding domains, was 




Figure 26: Defects in osteoblast distribution in osx_tv1&2 Crispr injected 
larvae. A. The position of osx_tv1&2 (green) target site. PAM sequence: “CCA” 
is just before the gRNA. Indel mutations (black) in four different alleles in F0. 
Note that the osxdel161a mutation was detected in both F0 mosaic mutants and F2 
stable mutants, and was used for further phenotype analysis. B. Normal 
distribution of col10a1:nuGFP-positive cells in a 9 dpf wildtype control larva. 
C. Severe defects, including loss of col10a1-positive osteoblasts at the 
branchiostegal rays (red arrow), cleithrum (yellow arrow), surrounding the 
neural arches (white arrows) and caudal fin rays (blue arrow) in the injected 
larvae. D. Genotyping by RFLP analysis in Crispr injected F0 larvae. After 
HpaII digestion, mosaic mutations at the target site result in larger undigested 






Knocking-out both osx_tv1 and osx_tv2 isoforms caused more severe defects 
than osx_tv1 in bone formation (Fig. 27). These defects were analyzed in detail 
with the help of FYP student, Mohamed Haniffa B Hasan M. osx_tv1&2 
mutants lost all intramembranous bones, including the operculum (A,C arrows), 
parasphenoid (A1,C1), branchoistegal rays (A2,C2) and cleithrum (A5,C5 black 
arrow). The majority of the analyzed mutants (10 out of 15) showed absence of 
mineralized perichondral bones such as the palatoquadrate (A3,C3), ceratohyal 
(A4,C4) and the 5th ceratobranchial (A5,C5, white arrow). The rest of the 
analyzed mutants showed strongly reduced mineralized perichondral bone as 
compared to osx_tv1 mutants. osx_tv1&2 mutants also lacked mineralization in 
the caudal fin (E,F arrow) and in all vertebral arches (E-E’,F-F’ arrows). Similar 
to the osx_tv1 mutant, there is no obvious cartilage defect after knocking-out 
both osx isoforms (B,D), indicating that osx is not involved in the regulation of 
chondrocyte differentiation. Importantly, with more severe bone defects, 
osx_tv1&2 mutants were already weak after hatching at around 9 dpf. They had 
difficulties in swimming and were not viable. 
At the cellular level, osx mutants showed interrupted osteoblast differentiation 
(Fig. 28). Almost all premature osteoblasts co-expressing osx:mCherry and 
col10a1:nuGFP were absent in osx_tv1&2 mutants, in both intramembrounous 
bone (A1-A2,B1-B2 arrow) and perichondral bone (A3-A4,B3-B4 arrow). In 
the vertebral column, formation of osteoblasts in neural arches was completely 
blocked (C-C’,D-D’ arrows). On the other hand, col10a1:nuGFP cells were 
abundant at the normally mineralized centra providing further support for the 
hypothesis that col10a1-expressing cells may be responsible for mineralization 
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of the notochordal sheath. This also suggests an osx-independent mechanism 
for the initial stages of vertebral centra formation. 
 
Figure 27: Mineralization of both intramembranous and perichondral 
bone is strongly disrupted in medaka osx_tv1&2 mutants. Alizarin Red 
stained bone matrix of 13 dpf wildtype control larvae (A-A5) and osx_tv1&2 
mutants (C-C5), ventral views. Absence of operculum in mutants (C, arrows). 
Magnifications show the absence of intramembranous bone structures including: 
parasphenoid (C1), branchiostegal rays (C2) and cleithrum (C5, black arrow), 
as well as perichondral bone structures inclusing: palatoquadrate (C3), 
ceratohyal (C4) and the 5th ceratobranchial (C5, white arrows). Alizarin Blue 
stained cartilage showed no obvious defects in wildtype (B) and mutant (D) 
larvae. Lateral view of alizarin Red stained bone matrix showed non-
mineralized caudal fin rays (F, arrow) and absence of neural arches (F’ arrows) 




Figure 28: Knocking-out osx_tv1&2 blocks differentiation of premature 
osteoblasts in intramembranous and perichondral bones as well as neural 
arches. Merged fluorescence images showed ventral view of the head at 15 dpf 
wildtype (A-A4) and osx_tv1&2 mutants (B-B4). Confocal images in higher 
magnification showed absence of osx:mCherry/col10a1:nuGFP-positive 
osteoblasts in the branchoistegal rays (B1) and dramatically reduced number of 
premature osteoclasts in the operculum (B2) in osx_tv1&2 mutants. 
col10a1:nuGFP-expressing perichondral osteoblasts are absent both in the 
palatoquadrate (arrow in B3) and ceratohyal (arrow in B4). Merged 
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fluorescence images showed lateral view of wildtype (C) and mutant (D) 
transgenic medaka larva. Confocal imaging of vertebral bodies in osx_tv1&2 
mutants showed lack of osx:mCherry/col10a1:nuGFP in the neural arches. 
col10a1:nuGFP positive cells were abundant in centra of mutant larvae (D). 
Scale bars: 50 µm. 
 
RNA whole-mount in situ hybridization revealed that transcription of runx2 and 
col10a1 was strongly reduced in osx_tv1&2 mutants at 6 dpf (Fig. 29A-B,E-F), 
similar as in osx_tv1 mutants (see Fig. 18A-D,I-J). Interestingly, transcription 
of osx was also reduced (Fig. 29C-D), much stronger when compared to the 
situation in osx_tv1 mutants (see Fig. 18G-H). RT-PCR analysis confirmed a 
more than 40% decrease of osx expression in osx_tv1&2 mutants (Fig. 29G 
asterisk, H). osx_tv2 expression was undetectable in osx_tv1&2 mutants (Fig. 
29G dashed line square). Overall, these findings suggest a novel role of osx_tv2 
to stimulate and maintain the expression level of osx_tv1, which is interrupted 
in osx_tv1&2 mutants.  
 
Figure 29: Down-regulation of pre-osteoblast markers in osx_tv1&2 
mutants as analyzed by RNA in situ hybridization and RT-PCR. A-F. 
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Reduced transcription of runx2 (A-B), osx (C-D) and col10a1 (E-F) in 
osx_tv1&2 mutants at 6 dpf. p: parasphenoid, op: operculum, bs: branchiostegal 
rays, pt: pharyngeal tooth, cl: cleithrum. G. An osx_tv1&2RT for forward 
primer and an osx_tv1&2RT rev reverse primer were used to test for osx mRNA 
expression by RT-PCR. Strongly reduced osx_tv1 band was observed (asterisk). 
The lower osx_tv2 band was not detectable (boxed area). No β-actin DNA band 
was detected in RNA samples without addition of Reverse Transcriptase (-RT), 
indicating absence of genomic DNA contamination. H. Fold regulation values 
compared between wildtype (+/+) larvae showing a more than 40% decreased 
of osx expression in mutants (-/-). β-actin loading control was used for 
normalization. 
 
Heterozygous osx_tv1&2 mutant larvae showed strong defects in osteoblast 
distribution (47.1%, n=17). osx:mCherry-positive osteoblasts formed in a 
random pattern in the mutants (Fig. 30C,D), compared with the regular pattern 
observed in wildtype controls (Fig. 30A,B). This confirms that both alleles of 
fully-functional osx are required for proper osteoblast differentiation in medaka. 
To test whether there was a gender-specific effect on osteoblast distribution, 
imaged heterozygous larvae were genotyped to identify the presence of DMY 
gene. Strikingly, among osx_tv1&2 heterozygous mutant carriers, DMY+ 
embryos (i.e. males) showed strong defects, where as DMY- embryos (i.e. 
females) showed only mild or normal osx:mCherry distribution. Heterozygous 
larvae with strong defects on osteoblast distribution were weak after hatching 
and had difficulties in swimming. Together, these observations suggest that 
males are stronger affected by an osx deficiency than females, resulting in 




Figure 30: Heterozygous osx_tv1&2 mutant larvae at 12 dpf exhibit strong 
defects in osteoblast distribution. A-B. Normal distribution of osx:mCherry-
positive osteoblasts in the vertebral column including the neural arches in 
wildtype control larva (arrow in B). C-D. Disrupted distribution pattern of 
osteoblasts in heterozygous osx_tv1&2 mutants. osx:mCherry positive 
osteoblasts were observed in a random distribution pattern instead of forming 
strictly along the neural arches and around vertebral centra (arrows in D). Boxed 
regions in A and C are magnified in B and D. 
 
In conclusion, my studies showed that knocking-out osx in medaka strongly 
interrupted osteoblast differentiation and maturation, resulting in bone 
formation and mineralization defects. This confirmed a critical role of osx for 
bone formation also in non-mammalian vertebrates. A potential non-conserved 
feature of osx function towards osteoblast progenitor maintenance was also 
observed. Furthermore, osteoblast-osteoclast coupling in homozygous mutants 
as well as heterozygous phenotypes were analyzed with deficient osx expression. 
Together, my findings provide new insights into the mechanism of osx-





3.2 Live imaging of osteoblast-osteoclast coupling in bisphosphonate 
treated medaka fish 
To better characterize drugs used for osteoporosis treatment, suitable in vivo 
models are needed. Small teleost fish are widely used to analyze cellular 
behaviour during bone formation, degeneration and repair. Our lab had 
previously shown that inducible expression of receptor activator of nuclear 
factor kappa-B ligand (RANKL) in transgenic medaka fish results in ectopic 
osteoclast formation, which leads to a severe osteoporosis-like phenotype. 
Therefore, my second project aimed to establish this medaka transgenic line as 
an animal model for the in vivo analysis of drug mechanisms and bone cell 
behaviour, which could complement in vitro studies and offer a novel system 
for testing drug action in the skeletal system.  
 
3.2.1 Etidronate and alendronate inhibit osteoclast activity in medaka and 
prevent mineralization loss after RANKL induction 
Bisphosphonates (BPs) are commonly used antiresorptive agents for human 
osteoporosis therapy to inhibit excessive bone resorption (Rogers et al., 2011). 
Etidronate and alendronate, two compounds representing non-N-BP and N-BP, 
respectively, have previously been shown to maintain skeleton mineralization 
in a zebrafish model for glucocorticoid-induced osteoporosis but their effect on 
bone cells remained unknown (Barrett et al., 2006; Fleming et al., 2005). Similar 
BP concentrations were used in this study to determine the effect of BPs on 
osteoclast formation and activity in bone transgenic medaka reporter lines.  
To test how BP treatment affects osteoclast activity in vivo, 
RANKL:HSE:CFP/ctsk:nlGFP double transgenic medaka larvae were analyzed. 
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Larvae were heat-shocked at 9 dpf for 1.5 hours to induce ectopic osteoclast 
formation, as described previously (To et al., 2012). The heat-shock slightly 
delayed larval development, as evident by the extent of mineralization in the 
caudal fin rays. Importantly, however, this delay was identical in non-BP treated 
and BP treated larvae (Fig. 31).  
 
Figure 31: Effect of heat shock on larval development. (A-C) ALC staining 
of mineralized matrix in larvae at 10 dpf without heat shock and BP treatment 
(A), after heat shock, without both RANKL induction and BP treatment (B), 
and after heat shock, without RANKL induction but with Etidronate treatment 
(C). Note slightly delayed development as evident by reduced number of 
mineralized caudal fin rays (yellow box) in heat shock-treated larvae (B,C). 
Importantly, the developmental stage is similar in non-BP treated and BP treated 




Wildtype control larvae or transgenic larvae without RANKL induction develop 
a mineralized vertebral column at 11 dpf, with mineralized dorsal neural arches 
and vertebral centra (Fig. 32A-C”). No ctsk:nlGFP-expressing osteoclasts are 
visible in the trunk region in control larvae at this stage (Fig. 32A,C). After heat-
shock-induced RANKL expression, excessive numbers of ectopic ctsk:nlGFP-
expressing osteoclasts were found covering vertebral bodies and neural arches 
(Fig. 32D-F”). Accumulation of these tartrate-resistant acid phosphatase (TRAP) 
and CathepsinK positive osteoclasts (see To et al., 2012) results in enhanced 
resorption of mineralized matrix, which consequently leads to the absence of 
alizarin complexone (ALC)-stained neural arches and large non-mineralized 
cavities in the notochordal sheath and vertebral centra in 82.2% of the analyzed 
larvae (n = 52) (arrowheads in Fig. 32F).  
 
Figure 32: Osteoclast formation and vertebral body mineralization after 
RANKL induction. (A,B) Absence of ctsk:nlGFP-expressing osteoclasts in 
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vertebral bodies in ctsk:nlGFP larvae at 11 dpf (A), and intact mineralization (B) 
without RANKL induction. (C-C’’) Confocal stack of area boxed in (A,B), 
showing ALC-stained intact vertebral bodies (C), GFP autofluorescence of 
pigment cells (C’) and an overlay with GFP (C’’). (D,E) Ectopic osteoclast 
formation at 11 dpf, after RANKL induction at 9 dpf in 
RANKL:HSE:CFP/ctsk:nlGFP larvae (D), and ALC-stained mineralization (E). 
(F-F’’) Confocal stack of area boxed in (D-E), showing absence of mineralized 
neural arches and cavities in vertebral centra (arrowheads in F), where active 
osteoclasts cover the vertebral bodies (overlay in F’’). Scale bars, 50 µm. 
 
Dose response studies were conductied by treating RANKL-expressing larvae 
with BPs at different concentrations. A concentration of 10 µg/ml for etidronate 
and 50 µg/ml for alendronate was most efficient to affect osteoclast activity in 
medaka. Next, transgenic larvae were treated with etidronate and alendronate. 
BP treatment started on the same day as the heat-shock (9 dpf) and continued 
for two days. In 56.3% of BP-treated larvae the osteoclast distribution appeared 
reduced, especially in axial skeleton regions (Fig. 33). This effect on osteoclast 
formation was even more pronounced when BP treatment was started 1-4 days 
before RANKL induction (Fig. 34). This raises the possibility that BPs cause a 




Figure 33: Effect of etidronate treatment on osteoclast induction. (A-A”’) 
(A-A”’) Ectopic osteoclast formation in larvae after RANKL induction without 
etidronate treatment. ctsk:nlGFP-positive osteoclasts can be seen in anterior 
regions of the vertebral column one day after RANKL induction at 10 dpf 
(arrowhead; A’). Increased osteoclast numbers can be observed in the same 
larvae at 11 and 12 dpf (A’-A”). (B-B”’) Delayed formation of ectopic 
osteoclasts after RANKL induction and etidronate treatment. No ctsk:nlGFP-
positive osteoclasts are detectable at 10 dpf (B) but appear in the same larvae 
one day later at 11 dpf (arrowhead; B”). At 12 dpf, the extent of RANKL-
induced osteoclast in the etidronate-treated larva (B”’) is similar to non-treated 





Figure 34: Early BP treatment affects subsequent osteoclastogenesis. (A) 
Formation of ectopic osteoclasts in RANKL:HSE:CFP/ctsk:nlGFP larvae at 11 
dpf, two days after RANKL induction at 9 dpf. (B-C) Pre-treatment of larvae 
with Etidronate (B) or Alendronate (C) from 5-6 dpf results in reduced numbers 
of ectopic osteoclasts at 11 dpf after RANKL was induced at 9 dpf. The same 
phenotype is observed at 11 dpf when BPs were added from 6-7 dpf or 7-8 dpf, 
i.e. one or two days before RANKL induction at 9 dpf (data not shown). Scale 
bar, 1mm. 
 
Larvae with an equal extent of ectopic osteoclast formation were then analyzed 
after BP treatment for mineralization of the neural arches and vertebral centra 
(Fig. 35B,C,E,F) and compared with RANKL-induced larvae without BP 
treatment (Fig. 32E,F). The number of larvae with mineralization defects 
significantly decreased after treatment with etidronate (60.0%, n = 57; Fig. 
35C,J) and alendronate (51.5%, n = 49; Fig. 35F,J). These rescued larvae 
showed almost completely intact neural arches and centra in the presence of 
ectopic osteoclasts (Fig. 35C-C”,F-F”). Notably, the remaining larvae showed 
mineralization defects that were qualitatively less severe than those observed in 
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non BP-treated +RANKL larvae (Fig. 36). Also, the general morphology of 
osteoclasts appeared to change after BP treatment. When compared with cells 
without BP treatment (Fig. 35G), cells after BP treatment often appeared less 
extended and more compacted (Fig. 35H,I). In histological sections of RANKL 
control larvae, the basis of neural arches was surrounded by active osteoblasts, 
with no indication of resorption (Fig. 35K). In the +RANKL non-BP-treated 
group, larvae with severe vertebral defects showed areas where neural arches 
were resorbed and fenestrated by what appeared to be multinucleated 
osteoclasts (Fig. 35L, white arrowheads), leading to the absence of neural arches 
in ALC-stained specimens (Fig. 32F). In BP treated animals, by contrast, intact 
arches were seen histologically (Fig. 35M), confirming the observations shown 
with ALC staining in Fig. 35C,F. Etidronate also prevented mineralization 
defects in arches when RANKL was induced at a much later time point (15 dpf; 
Fig. 37). These findings strongly suggest that treatment with etidronate and 
alendronate efficiently interferes with osteoclast function after induction by 




Figure 35: Treatment with etidronate or alendronate blocks osteoclast 
function and bone resorption. (A-C”) Expression of ctsk:nlGFP in ectopic 
osteoclasts after addition of etidronate at the same day as RANKL induction. 
(C-C”) Confocal imaging shows vertebral bodies with almost intact neural 
arches (arrowheads in C), in the presence of abundant ctsk:nlGFP-positive 
osteoclasts (C’). (D-F’’) Expression of ctsk:nlGFP in osteoclasts after addition 
of alendronate on the same day as RANKL induction. (F-F”) Confocal imaging 
shows intact vertebral bodies with neural arches (arrowheads in F), in the 
presence of ectopic osteoclasts (F’). (G) Confocal image of ctsk:nlGFP-
expressing osteoclasts after RANKL induction without BP treatment (taken 
from the same larvae as in Fig. 31F’, boxed area). (H,I) Confocal image of 
RANKL-induced osteoclasts after editronate or alendronate treatment, 
respectively (taken from the same larvae shown in C’ and F’, boxed areas). (J) 
Statistical analysis of larvae with intact neural arches at 11 dpf, without RANKL 
induction (blue), after RANKL induction (red), after RANKL induction with 
etidronate (green; *0.01<P<0.05) or alendronate (purple; **P<0.01) treatment. 
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(K-M) Transverse plastic sections (2 µm) through the notochord (no), spinal 
cord (sc) and the basis of the anteriormost neural arches at the same cross 
sectional level, in –RANKL control larvae (K) and in larvae after RANKL 
induction without (L) or with (M) BP treatment. The base of the neural arches 
is labeled with a black arrowhead, osteoblasts are marked by black arrows and 
osteoclasts by white arrowheads. The basis of the bony arches is outlined by a 
dotted line. The sections in K, M are slightly oblique so that the neural arches 
of only one side can be seen. Scale bars, 50 µm in C,F; 30 µm in K,L,M. Images 
K-M were provided by P.E. Witten and A. Huysseune (University of Ghent). 
 
Figure 36: Mineralization defects in arches of BP-treated larvae are less 
severe than in non-BP treated larvae. (A) More than 80% of non BP-treated 
RANKL-expressing larvae exhibit a complete absence of mineralized neural 
arches (arrowheads) and cavities in the vertebral centra. (B-C) Significantly 
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more BP-treated larvae show completely mineralized arches (see statistics in 
Fig. 35). The remaining BP-treated larvae show less severe defects than non 
BP-treated larvae in (A), with partial mineralization (arrowheads) after 
Etidronate (B) or Alendronate treatment (C). Scale bars, 50 µm. 
 
Figure 37: Etidronate treatment blocks osteoclast function and bone 
resorption after late RANKL induction. (A-B) Ectopic osteoclast formation 
at 17 dpf, two days after RANKL induction at 15 dpf in 
RANKL:HSE:CFP/ctsk:nlGFP larvae (A), and ALC stained mineralization (B). 
(C-C’’) Confocal stack of area boxed in (A-B), showing absence of mineralized 
neural arches and cavities in vertebral centra (arrowheads; C’), where active 
osteoclasts cover the vertebral bodies (overlay in C”). (D-E) Expression of 
ctsk:nlGFP in ectopic osteoclasts after addition of Etidronate at the same day as 
RANKL induction at 15 dpf. (F-F”) Confocal imaging shows vertebral bodies 
with almost intact neural arches (arrowheads; F’), in the presence of abundant 






3.2.2 Bisphosphonates induce morphological changes in medaka osteoclasts 
When RANKL expression is triggered by heat-shock at 9 dpf, the induced 
ctsk:nlGFP-expressing osteoclasts usually persist for several days (Fig. 38A), 
but most of the cells have disappeared at 15 dpf (To et al., 2012; and Fig. 38A’). 
By contrast, a considerable fraction of etidronate-treated and alendronate-
treated embryos continued to show ctsk:nlGFP positive osteoclasts (n = 7/95, 
7.4% for etidronate and n = 15/118, 12.7% for alendronate; Fig. 38C,D). These 
cells aggregated into large clusters and appeared to fuse into giant cells (Fig. 
38B’-E; DAPI stain in Fig. 38E’,E”). Light and transmission electron 
microscopic observations confirmed the occurrence of cell aggregates and the 
possible presence of multinucleated cells within these aggregates (Fig. 38F,G). 
Similar cell behaviour, i.e. aggregation and possible fusion, was not observed 
in RANKL:HSE:CFP/ctsk:EGFP double transgenic medaka larvae without BP 
treatment (Fig. 38A’). This suggests that BPs can extend the lifetime of 
osteoclasts in medaka and possibly promote cell fusion. Interestingly, “giant-
osteoclasts” with extensively increased cell size and excess nuclei have been 
described	in human osteoporosis patients after long-term BP treatment (Jobke 
et al., 2014). Thus, BPs can trigger effects in medaka that are similar to those 




Figure 38: BPs induce morphological changes in osteoclasts. (A,A’) 
ctsk:nlGFP expression in one RANKL:HSE:CFP/ctsk:nlGFP larva at 11 and 15 
dpf, 2 and 6 days after RANKL induction, respectively. Note the reduction in 
the number of nlGFP-positive cells at 15 dpf. (B-B’) ctsk:nlGFP expression in 
one larva at 11 and 15 dpf, after RANKL induction and etidronate treatment. 
Note aggregation of nlGFP-positive cells (arrowhead). (C) ctsk:nlGFP 
expression in larvae at 15 dpf, after etidronate treatment. (C’) Confocal stack of 
area boxed in C showing accumulation of small osteoclasts (left and middle; 
arrows) and giant ctsk:nlGFP-expressing cell (right). (D) Larva with extensive 
aggregates of ctsk:nlGFP-expressing cells after alendronate treatment. (E-E”) 
ctsk:nlGFP-expressing cell aggregates stained with DAPI. (F) Ventral lesion 
(white arrowheads) in the notochord (no) after RANKL induction and BP 
treatment at 15 dpf (2 µm parasagittal plastic section). The notochordal sheath 
(ns) is disrupted, and notochordal cells are bulging out. They are delimited by a 
thin layer of matrix (black arrowheads). Outside, multiple nuclei are visible. (G) 
A higher magnification of this region in transmission electron microscopy 
shows that at least some nuclei (white asterisks) appear to belong to a single cell 
as they appear not to be separated by cell membranes. They adjoin the bone 
layer (bo) deposited outside the notochordal sheath (ns). Scale bars: 50 µm in 
C’; 20 µm in E; 15 µm in F; 2 µm in G. Images F and G were provided by P.E. 






3.2.3 Bisphosphonate treatment stimulates bone recovery in medaka 
I next tested whether BP treatment also affects de novo bone remineralization. 
For this, BP treatments were started three days after osteoclasts had been 
induced by transgenic RANKL expression. Similar to the previous experiment, 
RANKL:HSE:CFP transgenic larvae were subjected to heat-shock at 9 dpf, 
except that the heat-shock was extended to 2 hours. Under these conditions, 
ectopic osteoclasts are efficiently induced and more than 90% of the larvae 
exhibit a complete loss of mineralized neural arches at 12 dpf when compared 
with non-heat-shocked controls. BPs were added to larvae with strong 
mineralization defects at 12 dpf, as analyzed by ALC staining. Larvae were 
subjected to a second heat-shock at 14 dpf to induce severe lesions in the centra. 
The second heat-shock was performed to enhance the effect of RANKL 
induction, and thereby, make the effect of the BP treatment more obvious. BP 
treatment was done from 12 to 16 dpf (i.e. 3 days after osteoclast induction) in 
order to detect any effects on bone recovery (Fig. 39). De novo mineralization 
was analyzed by successively staining larvae with calcein at 16 dpf. This allows 
previously existing mineralized (stained with ALC, red) matrix to be 
distinguished from de novo mineralized matrix (stained with calcein, green). 
Accordingly, in non-heat-shocked control embryos without BP treatment, 
newly mineralized matrix could be detected at the tips of the extending neural 
arches and around the notochordal sheath (Fig. 39A-C”). For +RANKL non-
BP-treated control larvae, repair of lesions in the centra region can be observed, 
but only 14.3% of heat-shocked embryos developed neural arches (Fig. 39D-
D”). By contrast, with BP treatment, 68.4% larvae after Etidronate (Fig. 39E-
E”, G) and 62.5% after alendronate (Fig. 39F-F”, G) treatment showed partially 
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recovered neural arches at 16 dpf. Compared with arches in -RANKL non-BP-
treated control larvae (Fig. 39C”), the arches in BP-treated larvae were 
composed exclusively from de novo mineralized matrix as evident by uniform 
calcein staining in absence of any ALC label (Fig. 39E”,F”). These findings 





Figure 39: Etidronate and alendronate accelerate bone recovery after 
blocking bone resorption in RANKL:HSE:CFP larvae. (A,B) Normal 
development of centra and arches from 12 dpf (ALC stained) to 16 dpf (calcein 
stained). (C-C’’) Confocal stack of area boxed in (A,B), showing de novo 
mineralization at the tip of neural arches (arrowheads; calcein stained; C”) and 
around the notochordal sheath. (D, E, F) ALC-stained bone matrix at 12 dpf, 
three days after RANKL induction. Note lesions in the neural arches and centra 
(arrows). A second heat-shock was carried out at 14 dpf. (D’, E’, F’) At 16 dpf, 
the same larvae were stained with calcein to visualize newly formed mineralized 
bone matrix without (D-D”) and with etidronate (E-E”) or alendronate (F-F”) 
treatment. At this stage, lesions in centra are repaired (D-F), neural arches are 
remineralized only after BP treatment (arrowheads; E”,F”), but not without BP 
treatment (D”). (G) Statistical analysis showing the percentage of larvae with 
neural arches at 16 dpf, after RANKL induction (blue), and after RANKL 
induction and etidronate (red) or alendronate (green) treatment. ** P < 0.01; 
Scale bars, 50 µm.  
 
In severe cases, +RANKL non-BP-treated control larvae showed newly 
mineralized matrix only at the edges of the lesions induced in centra (Fig. 40A-
A”). By contrast, larvae after etidronate and alendronate treatment showed an 
almost complete de novo remineralization of cavities in the centra (Fig. 40B”-
C”). This suggests that after blocking osteoclast activity in medaka by BPs, 
coexisting osteoblasts efficiently remineralize damaged bone matrix resulting 




Figure 40: Etidronate and alendronate accelerate bone recovery in 
RANKL:HSE:CFP larvae. (A-C) ALC-stained bone matrix at 12 dpf, three 
days after heat-shock-induced RANKL expression. A second heat-shock was 
done at 14 dpf. The mineralized matrix was successively stained with Calcein 
at 16 dpf in the same larvae without (A’) and with BP treatment (B’, C’). Note 
significantly reduced mineralization in vertebral centra at 12 dpf (arrows; A-C). 
In the absence of BPs, re-mineralization occurred only around the edges of 
lesions in centra (arrowheads; A”). In contrast, centra lesions were almost 
completely re-mineralized four days after addition of etidronate (arrowheads; 
B”) or alendronate (arrowheads; C”). Scale bars, 50 µm. 
 
3.2.4 Bisphosphonate treatment affects osteoblast distribution 
Osteoblast-osteoclast coupling implies a tightly coordinated interaction 
between both cell types in order to maintain appropriate cell numbers and bone 
homeostasis. In human osteoporosis patients, long-term BP treatment reduces 
bone formation by osteoblasts, but the underlying cellular mechanisms remain 
unclear (reviewed by Charles and Aliprantis, 2014). Therefore, I tested whether 
osteoblast-osteoclast coupling is affected by BP treatment in medaka. 
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Specifically, it was analyzed whether the behaviour of osteoblasts expressing 
osterix (osx) is altered when larvae are treated with BPs. For this, 
RANKL:HSE:CFP/ctsk:nlGFP/osx:mCherry triple transgenic medaka larvae 
were subjected to two successive rounds of heat-shock at 9 and 14 dpf to 
enhance the effect of Rankl induction. The formation and distribution of osx-
expressing osteoblasts with and without BP treatment was assessed. In controls, 
neither heat-shock alone (without RANKL) nor BP treatment alone affected 
distribution of osx:mCherry-positive osteoblasts (Fig. 41).  
 
Figure 41: Heat shock or BP treatment alone does not affect osteoblast 
distribution in osx:mCherry larvae. (A) osx:mCherry-expressing osteoblasts 
at neural arches and vertebral centra in larvae without heat shock and BP 
treatment. (B) osx:mCherry cells after heat shock, without both RANKL 
induction and BPs treatment. (C-D) osx:mCherry cells after six day Etidronate 
(C) or Alendronate (D) treatment. Scale bars, 50 µm. 
 
Significant differences in the distribution of osx-positive osteoblasts were 
observed between larvae without (Fig. 42A-C) and with ectopic osteoclast 
formation (Fig. 42D-D”) at 12 dpf (see also Renn et al., 2013). The number of 
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osx-positive cells was strongly reduced along the neural arches, and instead, 
osx-positive cells accumulated in the centra (Fig. 42D’) along with the presence 
of active osteoclasts (Fig. 42D”). At 16 dpf, osteoblasts were completely absent 
from the neural arches in RANKL-induced larvae without BP treatment and 
were only found in the centra (Fig. 42E’-E”). By contrast, in larvae treated with 
BPs from 12 to 16 dpf, osteoblasts were present along the neural arches and 
were less prominent in the centra (Fig. 42F’,G’). Intriguingly, osteoclasts were 
abundant in these embryos with RANKL expression (Fig. 42F,G). Together, 
these results suggest that RANKL-induced, active osteoclasts drive osteoblasts 
to lesion sites inside the centra. In the presence of BPs, however, many 




Figure 42: Effect of BP treatment on osteoblast distribution. (A-C) 
Expression of osx:mCherry in osteoblasts without RANKL induction. (C-C”) 
Confocal stack of area boxed in (A-B), showing absence of ctsk:nlGFP-
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expressing osteoclasts in vertebral bodies at 12 dpf (C). osx:mCherry-positive 
osteoblasts are positioned along neural arches and the edges of centra 
(arrowhead; C’). (D-D’’) Position of osx:mCherry positive osteoblasts after 
ectopic osteoclast induction. Confocal stack showing ctsk:nlGFP cells in 
vertebral bodies of RANKL-induced larvae (arrowhead; D). Note reduction of 
osx:mCherry-positive osteoblasts around arches and increased presence in 
centra (arrowheads; D’). A second heat-shock was performed at 14 dpf. 
Osteoblast-osteoclast behaviour was observed at 16 dpf (E-G”), with RANKL 
induction and no BP treatment (E-E”), and with both RANKL induction and 
etidronate (F-F”) or alendronate (G-G”) treatment. The number of osteoclasts is 
reduced at 16 dpf (E,F,G) when compared with 12 dpf (D). Note the reduced 
numbers of osx:mCherry-positive cells around neural arches but increased 
numbers in the centra (arrowheads; E’) without BP treatment. By contrast, more 
osx:mCherry-positive cells are positioned along neural arches (arrowheads; 
F’,G’) after etidronate (F-F”) or alendronate (G-G”) treatment from 12 to 16 dpf. 
This coincides with reduced numbers of osx:mCherry-positive cells in centra. 
Scale bars, 50 µm. 
 
3.2.5 Bisphosphonate treatment shows an anti-inflammatory effects in 
medaka 
Pre-clinical evidence shows an anti-tumor effect of N-BPs. For example, 
zoledronic acid and ibandronate, are used as adjuvants in cancer treatment, 
including breast cancer, prostate cancer and myeloma (reviewed by Clezardin, 
2012; reviewed by Mathew and Brufsky, 2014). I found that RANKL induction 
resulted in an upregulation of tumor necrosis factor (TNF)-α expression, thus 
suggesting the initiation of an inflammatory response (Fig. 43). Interestingly, 
this response was attenuated in the presence of BPs (Fig. 43), raising the 
possibility that BPs modulate inflammatory reactions during increased bone 





Figure 43: BP treatment reduces RANKL-induced TNF-α expression. TNF-
α, a common maker for systemic inflammation, is up-regulated at 11 dpf, two 
days after RANKL induction. After two days of Etidronate or Alendronate 
treatment, TNF-α levels are down-regulated. Bottom: Fold regulation values 
compared between groups without BP treatment with (red) and without (blue) 
RANKL induction, and groups with RANKL induction without BP (red) and 
with either Etidronate (green) or Alendronate (purple) treatment. β-actin 
loading control was used for normalization. Significance values are for 
comparison to +RANKL (**P<0.01). 
 
In conclusion, my studies showed a successful recapitulation of the anti-
resorptive effects of BPs in the medaka osteoporosis model. My findings 
provide strong evidences to support transgenic medaka lines as suitable in vivo 
models for characterizing bone modulating compounds. In general, the project 
provided unique and novel insight into the cell interactions taking place during 






4. DISCUSSION  
The function of Osx during skeletal formation in mammals has been well 
studied (Nakashima et al., 2002). However, its function in non-mammalian 
vertebrates is still unclear. Here, I report for the first time that osx has a similar 
key regulatory function during skeletogenesis in the teleost fish medaka. 
Medaka osx mutants failed to develop mature osteoblasts, resulting in defects 
on both intramembranous and perichondral ossification, leading to embryonic 
lethality, similar as in Osx null mice. 
 
4.1 Bone defects in osx_tv1 and osx_tv1&2 medaka mutants 
As previously reported, there are two different osx isoforms in medaka: osx_tv1 
and osx_tv2 (Renn and Winkler, 2014). Morpholino (MO) knock-down of 
osx_tv1 and/or osx_tv2 caused bone defects or delays in ossification. To analyze 
the long-term effects of osx deficiency, stable mutant lines were established. 
osx_tv1 mutants showed strong defects in intramembranous bone formation, 
while the mineralization of perichondral bone was not severely affected. 
Knocking-out both osx_tv1 and osx_tv2 resulted in more pronounced bone 
defects, shown as completely absent intramembranous bone and a lack of 
perichondral ossification (Fig. 44). While osx_tv2 mRNA showed upregulation 
in osx_tv1 mutants (Fig. 24), its expression level was undetectable in osx_tv1&2 
mutants (Fig. 28). Both RT-PCR and in situ hybridization analyses showed a 
slight reduction of osx mRNA levels in osx_tv1 mutants (Figs. 14 and 17). On 
the other hand, its levels were significantly reduced in osx_tv1&2 mutants (Fig. 
28). As osx_tv2 is upregulated when osx_tv1 is disrupted, I propose that this 
isoform plays a compensatory role, and stimulates and maintains the level of 
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the pre-dominantly expressed osx_tv1. Therefore, with a functional osx_tv2 
isoform in osx_tv1 mutants, parts of the intramembranous bone and majority of 
the perichondral bone could still form. However, when both isoforms were 
knocked-out in osx_tv1&2 mutants, the compensating function of osx_tv2 was 
lost, leading to much more severe bone defects, including complete absence of 
intramembranous bone and stronger defects on perichondral ossification.  
 
Figure 44: Schematic representation of bone and cartilage elements in the 
cranial skeleton of medaka larvae at 15-20 dpf. Intramembranous bone 
elements in wildtype (left) and mutants (center and right) are shown in red, 
including branchiostegal rays (bs), parasphenoid (ps), operculum (op) and 
cleithrum (cl). Parts of mineralized perichondral bone elements are shown in 
yellow, including basihyal (bh), palatoquadrate (pq) and ceratohyal (ch). 
Cartilage elements are shown in blue, including Meckel’s cartilage (m), non-
mineralized bh, pq, ch1-5 and hyosmplectic (hs). Other types of bone elements 
are shown in orange, including teeth, otolith (ot), pharyngeal teeth (pt), occipital 
arches (oa), basilar plate (bp) and notochord (nc). 
 
4.2 Osx mutants in different teleost species 
It was recently reported that osx mutants in common carp and zebrafish exhibit 
only mild bone deformations at late developmental stages, and are viable until 
adulthood (Zhong et al., 2016; Kague et al. 2016). Compared with Osx null mice 
that show severe bone defects causing embryonic lethality (Nakashima et al., 
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2002), embryonic and larval bone formation was not blocked in carp and 
zebrafish thus raising doubts of a highly conserved role of osx during vertebrate 
osteogenesis.  
Importantly, the phenotypes in the medaka osx knock-out model analyzed in 
this study are strikingly different from those reported in carp and zebrafish. 
While both carp and zebrafish showed bone deformities they still developed into 
adult stages. In contrast, knocking-out osx in medaka leads to early embryonic 
lethality in homozygous mutants and vertebral malformations in heterozygous 
carriers. Hence, my results demonstrate a significant degree of functional 
conservation between medaka and mammals, as the observed defects in medaka 
osx mutants resemble those of Osx null mice (Nakashima et al., 2002). The fact 
that osx-deficient carp and zebrafish show relatively normal initial bone 
patterning and formation suggests that compensatory mechanisms could be in 
place in these species, which are likely to be absent in medaka. 
 
4.3 The role of osx during intramembranous and chondral bone formation 
During intramembranous bone formation, osteoblasts directly differentiate from 
mesenchymal progenitors and Osx is required during this process in mammals 
as well as in medaka. Comparable with the situation in mouse Osx mutants 
(Nakashima et al., 2002), also medaka osx mutants also lacked properly formed 
intramembranous structures and were not viable. This suggests that in mammals 
as well as medaka, Osx is the master regulator for the formation of 
intramembranous bone. Unexpectedly, also osteoblast progenitors are affected 
in osx medaka mutants (Figs. 17,28). These findings suggest that medaka osx 
has a so far unknown role in osteoblast progenitor specification. Alternatively, 
107	
	
it is possible that formation of osteoblast progenitors depends on the presence 
of mature osteoblasts and/or mineralized bone. This is strikingly different from 
the situation in osx null mice, where Runx2 expression was found to be normal 
(Nakashima et al. 2002). 
During chondral bone formation, mesenchymal progenitors differentiate into 
both chondrocytes and perichondral cells. In mammals, chondrocyte 
hypertrophy triggers the initiation of perichondral osteoblast differentiation 
through activation of Indian Hedgehog (Ihh) signalling (reviewed by Long, 
2012). Deficiency of Ihh in mice resulted in a complete absence of osteoblasts 
in endochondral bone while the formation of intramembranous osteoblasts 
remained normal (St-Jacques and Hammerschmidt, 1999; Long et al., 2004). 
This shows that Ihh signalling is dispensable for intramembranous bone 
formation, but is required for perichondral osteoblast formation in mammals 
(St-Jacques and Hammerschmidt, 1999; Long et al., 2004). On the other hand, 
a chondrocyte-specific conditional knock-out of Osx in mice resulted in 
impaired but not absent endochondral bone (Oh et al., 2012), indicating that Osx 
might not play an essential role in perichondral osteoblasts formation and 
mineralization of chondral bone in mammals.  
The milder defects on perichondral ossification observed in osx_tv1 mutants 
seems to show a similar dispensable role of osx during medaka perichondral 
bone formation as in mammals. However, the complete lack of mineralized 
perichondral bones in osx_tv1&2 mutants indicated that the milder defects in 
osx_tv1 mutants were likely due to a compensatory role of osx_tv2. Therefore, 
different as in mammals, osx in medaka could be essential not only during 
intramembranous, but also perichondral ossification.  
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4.4 The plasticity of the osteoblast lineage 
Recent discoveries in mice suggest a remarkable plasticity of the osteoblast 
lineage. For example, osteoblasts can be derived from fully differentiated 
hypertrophic chondrocytes (Yang et al., 2014; Zhou et al., 2014; Park et al., 
2015). In zebrafish, it was shown that there are two subtypes of osx-expressing 
osteoblasts in perichondral bone: one population is located outside the cartilage 
matrix and the other derived from chondrocytes (Hammond and Schulte-Merker, 
2009).  
In perichondral bone, two populations of col10a1-expressing cells were 
observed in medaka: stacking chondrocytes located in the center of perichondral 
bone and elongated perichondral cells surrounding the cartilage matrix (Fig. 
45A). col10a1:nlGFP-positive chondrocytes actively changed their morphology 
over time in wildtype (Fig. 45A red arrows) and developed into hypertrophic -
like chondrocytes, which closely interacted with the outer layer containing 
perichondral cells (Fig. 45A white arrow). The finding that there was a 
dramatically reduced number of perichondral osteoblasts in osx mutants (Fig. 
15 and Fig. 27) strongly suggests that osx is required for the differentiation of 
perichondral osteoblasts in medaka.  
Based on this observation and findings in zebrafish (Hammond and Schulte-
Merker, 2009), I propose two possible models for the origin of perichondral 
osteoblasts (Fig. 45). In Model 1, I hypothesized that perichondral osteoblasts 
in medaka possibly originate from transdifferentiated chondrocytes (Fig. 45B). 
Since Ihh regulates chondrocyte hypertrophy in mammals, which initiates the 
differentiation of perichondral osteoblasts (reviewed by Long, 2012), a Ihh 
signal might also be involved during the development of regularly stacked 
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mature chondrocytes into “hypertrophic chondrocytes” in medaka. osx, on the 
other hand, might be required for the transdifferentiation of chondrocyte-
derived perichondral cells and their differentiation into perichondral osteoblasts. 
However, I cannot exclude the possibility that some of the mesenchymal 
progenitors can directly differentiate into perichondral cells. Therefore, in 
Model 2, I hypothesized that mesenchymally-derived perichondral cells can 
further differentiate into perichondral osteoblasts, a process for which osx is 
required (Fig. 45C). Taking into consideration the complexity of the bone 
regulating system, it is also possible that both origins of perichondral osteoblasts 
exist and are dependent on each other.  
 
Figure 45: Two models for perichondral osteoblast formation and a 
proposed role for osx. A. Close interaction between perichondral osteoblasts 
(white arrow) and chondrocytes in 12 dpf col10a1:nlGFP larvae. Strong 
morphology changes in chondrocytes (red arrows) in wildtype. B. Model 1: 
Perichondral osteoblasts transdifferentiate from chondrocytes. While ihh 
stimulates the formation of “hypertrophic chondrocytes”, osx is essential for the 
maturation of chondrocyte-derived perichondral osteoblasts. C. Model 2: 
Perichondral osteoblasts differentiate from mensenchymally-derived 
perichondral cells. osx is required for the maturation of perichondral osteoblasts. 





4.5 Hormone regulation and skeletogenesis in medaka 
In medaka osx_tv1 mutants, heterozygous larvae showed only mild defects in 
osteoblast distribution (Fig. 21). However, the fact that only DMY+ positive 
heterozygous larvae but no heterozygous adult fish carrying a Y chromosome 
were detected, suggests the possibility that DMY+ positive heterozygous larvae 
gradually developed bone defects at later stages and were not viable till sexual 
maturation. Consistent with this, the majority of DMY+ heterozygous osx_tv1&2 
mutant larvae showed severe defects in osx:mCherry cell distribution (Fig. 29), 
indicating that knocking-out both isoforms revealed a more pronounced effect 
of osx deficiency on male gender without the compensation from osx_tv2. 
Estrogen contributes to bone formation by stimulating osteoblast activity and 
lifespan (Kousteni et al., 2001). I propose that the lower levels of estrogen in 
osx heterozygous male mutants could be the reason for the severe defects 
observed in osteoblast distribution. In female heterozygous carriers, on the other 
hand, the level of estrogen reduces at later stages. Therefore, a kyphosis-like 
spinal curvature phenotype only became apparent at around 6 months. Since no 
heterozygous phenotype was reported in Osx knock-out mice, this sex steroid-
dependent phenotype observed in medaka could indicate a further difference 
between mice and fish. Interestingly, however, it resembles aspects of the 
situation in humans where hormone regulation of bone homeostasis is firmly 
established.  
Osteocalcin (osc) is a bone-derived hormone with a well-known role in 
regulating energy metabolism and glucose homeostasis (reviewed by Kanazawa, 
2015). Recent studies have also shown its effect on testosterone production (Lee 
et al., 2007; Oury et al., 2011; Yoshikawa et al., 2011). A strong disturbance in 
111	
	
the testosterone/estradiol ratio was observed in osc-/- male mice (Oury et al., 
2011).While a severe decrease in testis weight and levels of circulating 
testosterone were observed in osc-/- male mice, osc-/- female mice did not show 
any estrogen deficiency or abnormality of ovaries. This shows that the role of 
osc on testosterone biosynthesis is male specific (Oury et al., 2011). Similarly, 
the deficiency in osc secretion because of the lack of mature osteoblasts in 
medaka osx mutants might be the reason for the lower embryonic fertility rate 
observed when crossing osx heterozygous carriers.  
 
4.6 Anti-resorptive effects of Bisphosphonates in the medaka osteoporosis 
model 
Apart from bone defects, medaka osx mutants also revealed gender-specific 
differences in heterozygous carriers, suggesting close interactions between sex 
hormones and bone homeostasis. In postmenopausal women, low levels of 
estrogen results in disequilibrium in the numbers and activity of different bone 
cells, leading to osteoporosis. Our lab previously established a RANKL-induced 
osteoporosis medaka model with ectopically forming osteoclasts (To et al., 
2012). To in vivo characterize drugs used for osteoporosis treatment, I took 
advantage of this model to test the effects of BPs on osteoclast formation and 
activity. My results show that a treatment with BP can prevent bone loss caused 
by ectopic osteoclasts in transgenic medaka, and can stimulate bone recovery 
by blocking the bone-resorptive function of osteoclasts. 
In preclinical models and human patients, alendronate was described to be 
significantly more potent than etidronate (Iwamoto et al., 2005; Masarachia et 
al., 1996). In the present medaka study, however, both BPs appeared to have 
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similar efficacy in blocking osteoclast activity and stimulating bone recovery, 
in fact, with a higher effective dose of alendronate compared with etidronate. 
The reason for this difference remains unknown but possibly reflects 
biochemical differences of the affected pathways in larval compared with adult 
osteoclasts. Alternatively, it cannot be excluded that BPs bind different targets 
in teleosts compared with humans or that common targets are poorly conserved, 
which would explain the different efficacies of etidronate and alendronate in 
medaka and mammals.    
 
4.7 Morphological changes in BP-treated osteoclasts of medaka 
Bone resorption requires a sealed extracellular microenvironment and tight 
contact between osteoclasts and the mineralized matrix in order to generate 
resorption lacunae and allow proper osteoclast function. Using live confocal 
imaging, osteoclasts were observed in the vicinity of mineralized neural arches 
and vertebral bodies after BP treatment. However, these BP-treated osteoclasts 
were not able to resorb mineralized matrix. This suggests that these osteoclasts 
were probably not capable of generating sealed lacunae required for resorption. 
Future ultra-histological analyses will show the morphological defects induced 
in BP-treated medaka osteoclasts.  
After long-term treatment with etidronate or alendronate, changes in osteoclast 
morphology were described in human osteoporosis patients of different ages 
and sexes. Multinucleated osteoclasts became non-functional and underwent 
cell fusion, leading to “giant” osteoclasts with a two- to threefold increase in the 
number of nuclei (Jobke et al., 2014; Weinstein et al., 2009). Similar 
observations were made in the medaka osteoporosis model, where osteoclasts 
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after BP treatment showed reduced resorptive activity but extended lifespan and 
appeared to aggregate and even fuse into multinucleated cells. With the 
advantage of conducting in vivo live imaging in transparent fish larvae, a lineage 
tracing technique could be used in future experiments to understand the 
mechanism of formation of these “giant” osteoclasts with prolonged lifespan.  
BPs block osteoclast activity in medaka and stimulate the formation of 
multinucleated osteoclasts with increased size faithfully recapitulate aspects 
found in human osteoporosis patients. This therefore makes the transgenic 
medaka described here an efficient and valuable in vivo model for future drug 
screening to identify novel antiresorptive and bone-anabolic compounds. 
 
4.8 The effect of bisphosphonate treatment on osteoclast induction 
In my studies, the BP treatment showed effects on osteoclastogenesis. It remains 
to be shown whether this effect on osteoclasts could be due to a reduction in cell 
numbers or a possible delay in morphological maturation. However, this 
observation raised the possibility that osteoclast maturation depends on a proper 
interaction of osteoclast precursors with mineralized matrix, which could be 
impaired by matrix-bound BPs. In human BP research, the focus has been 
placed mainly on the effect of BPs on the inhibition of osteoclast resorption and 
survival. Much less attention has been paid to understand the effects of BP on 
early osteoclast differentiation and maturation. Here, my in vivo observations 
suggest that these early differentiation stages deserve further investigation, 




4.9 In vivo analysis of osteoblast-osteoclast coupling in transgenic medaka 
lines 
In the past decades, traditional histological analysis and bone biopsies were used 
for testing bone quality (Patsch et al., 2011). However, in recent years, advanced 
techniques such as in vivo high resolution peripheral quantitative computed 
tomography (HR-pQCT) and magnetic resonance imaging (MRI) systems serve 
as precise, non-destructive and non-invasive methods to measure bone 
competence and quality (Van Lenthe and Müller, 2008; Krug et al., 2011; Bae 
et al., 2012). In addition, multimodality imaging technologies, such as whole 
body 3D micro-computerized tomography (CT) can be used in quantifications 
of bone parameters (Snoeks et al., 2012). These novel procedures can help to 
accurately monitor and predict the pathophysiology of bone diseases. However, 
live imaging at a subcellular resolution is still not possible in humans or 
mammalian models. The availability of transgenic medaka lines expressing 
multiple fluorescent reporters allows simultaneous visualization of different cell 
types in experimental conditions such as increased bone resorption or BP 
treatment. This is especially useful to characterize osteoblast-osteoclast 
coupling in an in vivo context. Interestingly, the distribution of osx-positive 
osteoblasts was altered after BP treatment and these osteoblasts contributed to 
an efficient bone repair. This suggests that osteoclast signaling to maintain 
osteoblast numbers and distribution is affected by the presence of BPs, at least 




Figure 46: Model of dynamic osteoclast and osteoblast behaviour under 
different conditions. (A-C) Model of dynamic osteoclast behaviour in vertebral 
bodies without RANKL and BP treatment (A), with RANKL but without BP 
treatment (B), and with both RANKL and BP treatment (C). The change in 
osteoclast morphology after BP treatment (less extensions, smaller size) and the 
reduction of mineralized matrix in neural arches and centra after RANKL 
induction is indicated. (D-F) Model of osteoblast-osteoclast coupling in the 
absence of RANKL and BP treatment (D), with RANKL but without BP 
treatment (E), and with both RANKL and BP treatment (F). Width of arrows 
indicate hypothesized extent of cross talk between both cell types. 
 
4.10 Anabolic effects of BPs in medaka osteoporosis model  
Our most striking observation was that BP treatment in medaka stimulated de 
novo mineralization of neural arches and vertebral bodies. This suggests the 
presence of active osteoblasts in the vertebral column that are able to repair bone 
lesions as soon as osteoclast activity is blocked by BPs. Whether this reflects 
the enormous regenerative potential of teleost fish or can also be found in 
defective mammalian bone remains to be elucidated in future experiments. 
In mammals, BPs suppress bone formation and act as potent mineralization 
inhibitors (reviewed by Charles and Aliprantis, 2014). Surprisingly, in our 
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studies, accelerated bone recovery and rapid remineralization of bone matrix 
were observed after BP treatment in medaka, which would suggest anabolic 
effects of BPs in this model. At present, the reason why BPs in medaka allow 
efficient remineralization of bone lesions is elusive. Future studies using live 
imaging in transparent medaka larvae in different mineralization conditions 




5. OUTLOOK AND FUTURE EXPERIMENTS 
5.1 Cell lineage analysis to study the role of osx in controlling osteoblast 
plasticity  
The close interaction between col10a1-expressing chondrocytes and 
perichondral osteoblasts opens the possibility that plasticity exists in the 
osteoblast lineage in medaka and that osx is involved in the transdifferentiation 
of chondrocyte-derived perichondral osteoblasts. To directly answer this 
question, the Cre-loxP based genetic lineage tracing technique can be employed 
in future experiments (Centanin et al., 2014). A tamoxifen-inducible, col10a1-
specific Cre driver transgenic line needs to be established to mark all col10a1-
expressing premature osteoblasts and mature chondrocytes. When this col10a1-
specific Cre driver line is crossed with a line that ubiquitously expresses 
fluorescent loxP flanked reporters, a subset of col10a1-expressing chondrocytes 
can be labelled before the formation of perichondral osteoblasts, and tracked to 
determine if these cells differentiate into to perichondral osteoblasts. This could 
provide strong evidence to reveal osteoblast plasticity and whether 
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transdifferentiation occurs during bone formation. Furthermore, by comparing 
the phenotype observed from controls and larvae with osx deficiency, the role 
of osx during this process of perichondral bone formation can be better 
characterized.  
 
5.2 Hormonal regulation of bone homeostasis in medaka  
The majority of medaka osx_tv1&2 heterozygous male carriers showed stronger 
defects in osteoblast distribution and revealed a possible steroid-dependent 
phenotype in medaka. To test whether this is caused by lower levels of estrogen 
during male larvae development, external estrogen treatment could be 
conducted during the time window before or after the onset of bone defects in 
male DMY+ heterzygous carriers. Alternatively, a treatment with aromatase 
inhibitors in female DMY- heterzygous carriers could lead to lower levels of 
estrogen and bone defects, possibly similar to those observed in male 
heterozygous carriers. A rescue in male larvae and a higher lethality rate in 
female larvae could evidence for a link between sex steroids and osteogenesis 
in medaka.  
 
5.3 Combination of drugs tested in a medaka osteoporosis model 
To in vivo characterize drug mechanism and to establish an animal model for 
compound testing, the anti-resorptive effects of BPs were tested in medaka 
osteoporotic larvae. Other than testing single compounds in a transgenic 
background, fish also offer simple approaches to test combinations of various 
drugs to test for possible synergy or interference of compounds, which could be 
used to mimic the condition of patients taking more than one drug (Barrett et 
118	
	
al., 2006). Furthermore, the use of a combination of different reporter lines for 
example in the context of a particular mutant background, provides ample 
opportunities to study the behaviour of bone cells during different stages of bone 
degeneration and repair, or in the presence of a bone modulating drug.  
 
5.4 Long-term BP treatment and bone anabolic effects in medaka 
Future studies could also show whether the osteogenic activity of osteoblasts is 
affected after long-term BP treatment. We have previously shown that RANKL-
induced osteoclastogenesis and subsequent resorption of the mineralized matrix 
triggers a remineralization process that involves recruitment of osteoblast 
progenitors to the lesion sites (Renn et al., 2013). It will be interesting to test in 
detail in future experiments whether this osteoblast progenitor recruitment is 
affected by BP treatment, which would have major implications for 
antiresorptive therapies in human osteoporosis patients. 
 
5.5 Adult medaka fish as osteoporosis animal model 
Osteoporosis is a disease that mostly affects elderly humans. Therefore, an ideal 
in vivo model for osteoporosis drug screening should involve adult fish. So far, 
however, the technique of live imaging described in this report is limited to 
embryonic and larval stages. Presently available confocal imaging does not 
allow live imaging of genetically labeled bone cells in adult fish due to 
limitations in penetration depth. With the recent development of light sheet 
fluorescence microscopy (LSFM) that allows imaging deep into living tissue 
(Hockendorf et al., 2012), together with the availability of less pigmented ‘see 
through’ medaka strains (Wakamatsu et al., 2001), it is conceivable that this 
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limitation will soon be overcome and live imaging of bone cells in adult medaka 
fish after drug screening will be possible. Alternatively, with technical advances 
in micro-CT measurements, bone density and composition of adult fish can now 
be quantified and analyzed (reviewed by Bruneel and Witten, 2015; Mackay et 
al., 2013).  
Osteoporosis is a disorder primarily affecting postmenopausal women 
(reviewed by Charles and Aliprantis, 2014). It would therefore be interesting to 
test the effect of BPs on older medaka fish of both sexes, in which osteoclasts 
have been activated during adult stages. Different from zebrafish, medaka has 
heteromorphic sex chromosomes, therefore allowing a sex-specific analysis 
during larval and adult stages (Nanda et al., 2002; Anderson et al., 2004). 
Furthermore, bone defects have been reported in adult medaka in a gender sex-
specific manner (Shanthanagouda et al., 2014). Therefore, the medaka model is 
well suited to study the biology behind age- and gender-specific bone 




In conclusion, the first part of my study described severe bone defects in medaka 
with a deficiency in the osx gene, thus suggesting a key role for this zinc-finger 
transcription factor in skeletogenesis also in non-mammalian vertebrates. 
Taking the advantage of in vivo imaging using transgenic reporter lines, 
osteoblast-osteoclast coupling and heterozygous phenotypes were analyzed, 
which provides novel insight into the role of osx during osteogenesis and 
complements previous studies in mice. Thus, medaka osx mutants could serve 
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as an attractive animal model for human diseases, including osteogenesis 
imperfecta (Lapunzina et al. 2010). The medaka osteoporosis model, on the 
other hand, could contribute to an in vivo approach to test and quantify the 
anabolic and anti-resorptive effects of novel bone modulating compounds, as 























Appendix 1: Genotyping by RFLP: 258 bp fragments are detected in mutants 




















Appendix 2: index of material and company  
Company Name of Material 
AppliChem Glycerin 
Bio Rad beta-Mercaptoethanol 
Fermentas RevertAid first strand cDNA kit 
Gadot Ethanol 
IDT Osx_tv1&2 Crispr gRNA  
J.T. Baker Methanol 
Life Technologies T7 mMessage mMachine Kit 
Life Technologies Ambion MEGA shortscript T7 kit  
Merk NaCl 
Merk KCl 
Merk  MgSO4 
Merk  Ca(NO3)2 




Promega GoTaq Polymerase  
Promega Wizard SV Gel and PCR clean-up system 
Qiagen RNEasy Mini kit 
Roche T4 ligase 
SCRS Tween 20 
Sigma Alendronate  
Sigma Etidronate 
Sigma alizarin-3-methyliminodiacetic acid, Alizarin 
Complexone (ALC) 
Sigma Calcein 
Sigma ethyl 3-aminobenzoate methanesulfonate 
(Tricaine) 
Sigma Dimethylsuphoxide (DMSO) 
Sigma Formamide 
Takara 2x PrimerStar enzyme  
Thermo Fisher Scientific HpaII 
Thermo Fisher Scientific DraI 
Thermo Fisher Scientific Poly (A) Tailing Kit  
1st Base 20X SST 
1st Base Agarose 






Ablain, J. and Zon, L.I., 2013. Of fish and men: using zebrafish to fight human diseases. Trends 
in cell biology, 23(12), pp.584-586. 
 
Abu, E.O., Horner, A., Kusec, V., Triffitt, J.T. and Compston, J.E., 1997. The localization of 
androgen receptors in human bone. The Journal of Clinical Endocrinology & 
Metabolism, 82(10), pp.3493-3497. 
 
Adachi, J.D., Bensen, W.G., Bianchi, F., Cividino, A., Pillersdorf, S., Sebaldt, R.J., Tugwell, P., 
Gordon, M., Steele, M., Webber, C. and Goldsmith, C.H., 1996. Vitamin D and calcium in the 
prevention of corticosteroid induced osteoporosis: a 3 year followup. The Journal of 
rheumatology, 23(6), pp.995-1000.  
 
Adinoff, A.D. and Hollister, J.R., 1983. Steroid-induced fractures and bone loss in patients with 
asthma. New England Journal of Medicine, 309(5), pp.265-268. 
 
Aida, T., 1921. On the inheritance of color in a fresh-water fish, Aplocheilus latipes Temmick 
and Schlegel, with special reference to sex-linked inheritance. Genetics, 6(6), p.554.  
 
Almeida, M., 2012. Aging mechanisms in bone. BoneKEy reports, 1(7). 
 
Almeida, M. and O’Brien, C.A., 2013. Basic biology of skeletal aging: role of stress response 
pathways. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 
p.glt079. 
 
Alt, B., Reibe, S., Feitosa, N.M., Elsalini, O.A., Wendl, T. and Rohr, K.B., 2006. Analysis of 
origin and growth of the thyroid gland in zebrafish.Developmental dynamics, 235(7), pp.1872-
1883. 
 
Anderson, G.L., Limacher, M., Assaf, A.R., Bassford, T., Beresford, S.A., Black, H., Bonds, 
D., Brunner, R., Brzyski, R., Caan, B. and Chlebowski, R., 2004. Women’s Health Initiative 
Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with 
hysterectomy: the Women’s Health Initiative randomized controlled trial. Jama, 291(14), 
pp.1701-1712. 
 
Ansai, S. and Kinoshita, M., 2014. Targeted mutagenesis using CRISPR/Cas system in 
medaka. Biology open, 3(5), pp.362-371. 
 
Apschner, A., Schulte-Merker, S. and Witten, P.E., 2011. Not all bones are created equal-using 
zebrafish and other teleost species in osteogenesis research. Methods Cell Biol, 105, pp.239-
255. 
 
Arratia, G., Schultze, H.P. and Casciotta, J., 2001. Vertebral column and associated elements in 
dipnoans and comparison with other fishes: development and homology. Journal of 
Morphology, 250(2), pp.101-172. 
 
Asharani, P.V., Keupp, K., Semler, O., Wang, W., Li, Y., Thiele, H., Yigit, G., Pohl, E., Becker, 
J., Frommolt, P. and Sonntag, C., 2012. Attenuated BMP1 function compromises osteogenesis, 
leading to bone fragility in humans and zebrafish. The American Journal of Human Genetics, 
90(4), pp.661-674. 
  
Aspenberg, P., Genant, H.K., Johansson, T., Nino, A.J., See, K., Krohn, K., García-Hernández, 
P.A., Recknor, C.P., Einhorn, T.A., Dalsky, G.P. and Mitlak, B.H., 2010. Teriparatide for 
acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 
postmenopausal women with distal radial fractures. Journal of Bone and Mineral 
Research,25(2), pp.404-414. 
 




Bae, W.C., Chen, P.C., Chung, C.B., Masuda, K., D'Lima, D. and Du, J., 2012. Quantitative 
ultrashort echo time (UTE) MRI of human cortical bone: correlation with porosity and 
biomechanical properties. Journal of Bone and Mineral Research, 27(4), pp.848-857. 
 
Barasch, A., Cunha-Cruz, J., Curro, F.A., Hujoel, P., Sung, A.H., Vena, D., Voinea-Griffin, 
A.E., Beadnell, S., Craig, R.G., DeRouen, T. and Desaranayake, A., 2011. Risk factors for 
osteonecrosis of the jaws a case-control study from the CONDOR Dental PBRN. Journal of 
dental research,90(4), pp.439-444. 
 
Barbot, N., Calmettes, C., Schuffenecker, I., Saint-Andre, J.P., Franc, B., Rohmer, V., Jallet, P. 
and Bigorgne, J.C., 1994. Pentagastrin stimulation test and early diagnosis of medullary thyroid 
carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening 
in hereditary medullary thyroid carcinoma. The Journal of Clinical Endocrinology & 
Metabolism, 78(1), pp.114-120.  
 
Baron, R., Neff, L., Louvard, D. and Courtoy, P.J., 1985. Cell-mediated extracellular 
acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization 
of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. The Journal of cell 
biology, 101(6), pp.2210-2222. 
 
Baron, R. and Kneissel, M., 2013. WNT signaling in bone homeostasis and disease: from human 
mutations to treatments. Nature medicine, 19(2), pp.179-192. 
 
Barrett, R., Chappell, C., Quick, M. and Fleming, A., 2006. A rapid, high content, in vivo model 
of glucocorticoid-induced osteoporosis. Biotechnology journal, 1(6), pp.651-655. 
 
Baek, W.Y., de Crombrugghe, B. and Kim, J.E., 2010. Postnatally induced inactivation of 
Osterix in osteoblasts results in the reduction of bone formation and maintenance. Bone, 46(4), 
pp.920-928. 
 
Bellido, T. and Plotkin, L.I., 2011. Novel actions of bisphosphonates in bone: preservation of 
osteoblast and osteocyte viability. Bone, 49(1), pp.50-55. 
 
Bellido, T., Saini, V. and Pajevic, P.D., 2013. Effects of PTH on osteocyte function. Bone, 54(2), 
pp.250-257. 
 
Ben-awadh, A.N., Delgado-Calle, J., Tu, X., Kuhlenschmidt, K., Allen, M.R., Plotkin, L.I. and 
Bellido, T., 2014. Parathyroid hormone receptor signaling induces bone resorption in the adult 
skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology, 155(8), 
pp.2797-2809. 
 
Benford, H.L., McGowan, N.W.A., Helfrich, M.H., Nuttall, M.E. and Rogers, M.J., 2001. 
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in 
vitro. Bone, 28(5), pp.465-473. 
 
Bi, W., Deng, J.M., Zhang, Z., Behringer, R.R. and de Crombrugghe, B., 1999. Sox9 is required 
for cartilage formation. Nature genetics, 22(1), pp.85-89. 
 
Bianco, P., 2008. Bone cells, osteoprogenitors, and hematopoiesis. IBMS BoneKEy, 5(8), 
pp.269-274. 
 
Bischoff-Ferrari, H.A., Dawson-Hughes, B., Willett, W.C., Staehelin, H.B., Bazemore, M.G., 
Zee, R.Y. and Wong, J.B., 2004. Effect of vitamin D on falls: a meta-analysis. Jama, 291(16), 
pp.1999-2006. 
 
Black, D.M., Greenspan, S.L., Ensrud, K.E., Palermo, L., McGowan, J.A., Lang, T.F., Garnero, 
P., Bouxsein, M.L., Bilezikian, J.P. and Rosen, C.J., 2003. The effects of parathyroid hormone 
and alendronate alone or in combination in postmenopausal osteoporosis. New England Journal 




Bonewald, L.F., 2011. The amazing osteocyte. Journal of Bone and Mineral Research, 26(2), 
pp.229-238. 
  
Bonnick, S., De Villiers, T., Odio, A., Palacios, S., Chapurlat, R., DaSilva, C., Scott, B.B., Le 
Bailly De Tilleghem, C., Leung, A.T. and Gurner, D., 2013. Effects of odanacatib on BMD and 
safety in the treatment of osteoporosis in postmenopausal women previously treated with 
alendronate: a randomized placebo-controlled trial. The Journal of Clinical Endocrinology & 
Metabolism, 98(12), pp.4727-4735. 
 
Bose, S., Vahabzadeh, S. and Bandyopadhyay, A., 2013. Bone tissue engineering using 3D 
printing. Materials Today, 16(12), pp.496-504. 
 
Boyle, W.J., Simonet, W.S. and Lacey, D.L., 2003. Osteoclast differentiation and 
activation. Nature, 423(6937), pp.337-342. 
 
Boyden, L.M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M.A., Wu, D., Insogna, K. 
and Lifton, R.P., 2002. High bone density due to a mutation in LDL-receptor–related protein 
5. New England Journal of Medicine, 346(20), pp.1513-1521. 
 
Bruneel, B. and Witten, P.E., 2015. Power and challenges of using zebrafish as a model for 
skeletal tissue imaging. Connective tissue research, 56(2), pp.161-173. 
 
Burr, D.B., Martin, R.B., Schaffler, M.B. and Radin, E.L., 1985. Bone remodeling in response 
to in vivo fatigue microdamage. Journal of biomechanics, 18(3), pp.189-200. 
 
Calvi, L.M., Adams, G.B., Weibrecht, K.W., Weber, J.M., Olson, D.P., Knight, M.C., Martin, 
R.P., Schipani, E., Divieti, P., Bringhurst, F.R. and Milner, L.A., 2003. Osteoblastic cells 
regulate the haematopoietic stem cell niche. Nature, 425(6960), pp.841-846. 
  
Canario, A.V., Rotllant, J., Fuentes, J., Guerreiro, P.M., Teodosio, H.R., Power, D.M. and Clark, 
M.S., 2006. Novel bioactive parathyroid hormone and related peptides in teleost fish. FEBS 
letters, 580(1), pp.291-299. 
 
Centanin, L., Ander, J.J., Hoeckendorf, B., Lust, K., Kellner, T., Kraemer, I., Urbany, C., Hasel, 
E., Harris, W.A., Simons, B.D. and Wittbrodt, J., 2014. Exclusive multipotency and preferential 
asymmetric divisions in post-embryonic neural stem cells of the fish 
retina. Development, 141(18), pp.3472-3482.  
 
Centrella, M., Casinghino, S., Kim, J., Pham, T., Rosen, V., Wozney, J. and McCarthy, T.L., 
1995. Independent changes in type I and type II receptors for transforming growth factor beta 
induced by bone morphogenetic protein 2 parallel expression of the osteoblast 
phenotype. Molecular and cellular biology, 15(6), pp.3273-3281. 
 
Chambers, T.J. and Magnus, C.J., 1982. Calcitonin alters behaviour of isolated osteoclasts. The 
Journal of pathology, 136(1), pp.27-39.  
 
Charles, J.F. and Aliprantis, A.O., 2014. Osteoclasts: more than ‘bone eaters’.Trends in 
molecular medicine, 20(8), pp.449-459. 
 
Chatani, M., Takano, Y. and Kudo, A., 2011. Osteoclasts in bone modeling, as revealed by in 
vivo imaging, are essential for organogenesis in fish.Developmental biology, 360(1), pp.96-109. 
 
Chesnut, C. and Rosen, C.J., 2001. Perspective: Reconsidering the effects of antiresorptive 
therapies in reducing osteoporotic fracture. Journal of bone and mineral research, 16(12), 
pp.2163-2172. 
 
Choi, J.Y., Pratap, J., Javed, A., Zaidi, S.K., Xing, L., Balint, E., Dalamangas, S., Boyce, B., 
Van Wijnen, A.J., Lian, J.B. and Stein, J.L., 2001. Subnuclear targeting of Runx/Cbfa/AML 
factors is essential for tissue-specific differentiation during embryonic 




Choi, S.Y., An, C.H., Kim, S.Y. and Kwon, T.G., 2013. Bone turnover and inflammatory 
markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis 
patients. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 25(2), pp.123-
128. 
 
Clarke, B.L. and Khosla, S., 2009. Androgens and bone. Steroids, 74(3), pp.296-305. 
 
Clezardin, P., 2012. Potential anticancer properties of bisphosphonates: insights from 
preclinical studies. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal 
Chemistry-Anti-Cancer Agents), 12(2), pp.102-113. 
 
Cohen, D. and Adachi, J.D., 2004. The treatment of glucocorticoid-induced osteoporosis. The 
Journal of steroid biochemistry and molecular biology,88(4), pp.337-349. 
 
Cohen, A., Stein, E.M., Recker, R.R., Lappe, J.M., Dempster, D.W., Zhou, H., Cremers, S., 
McMahon, D.J., Nickolas, T.L., Müller, R. and Zwahlen, A., 2013. Teriparatide for idiopathic 
osteoporosis in premenopausal women: a pilot study. The Journal of Clinical Endocrinology & 
Metabolism, 98(5), pp.1971-1981. 
 
Compston, J., 2012. The use of combination therapy in the treatment of postmenopausal 
osteoporosis. Endocrine, 41(1), pp.11-18. 
 
De Azevedo, T.P., Witten, P.E., Huysseune, A., Bensimon-Brito, A., Winkler, C., To, T.T. and 
Palmeirim, I., 2012. Interrelationship and modularity of notochord and somites: a comparative 
view on zebrafish and chicken vertebral body development. Journal of Applied 
Ichthyology, 28(3), pp.316-319. 
 
DeLaurier, A., Eames, B.F., Blanco-Sánchez, B., Peng, G., He, X., Swartz, M.E., Ullmann, B., 
Westerfield, M. and Kimmel, C.B., 2010. Zebrafish sp7: EGFP: a transgenic for studying otic 
vesicle formation, skeletogenesis, and bone regeneration. Genesis, 48(8), pp.505-511.  
 
De Sarro, A. and Minutoli, L., 2012. Use of Bisphosphonates in Osteoporosis. 
In Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach (pp. 49-57). 
Springer Milan. 
 
Dominguez, L.J., Di Bella, G., Belvedere, M. and Barbagallo, M., 2011. Physiology of the aging 
bone and mechanisms of action of bisphosphonates.Biogerontology, 12(5), pp.397-408. 
 
Du, S.J., Frenkel, V., Kindschi, G. and Zohar, Y., 2001. Visualizing normal and defective bone 
development in zebrafish embryos using the fluorescent chromophore calcein. Developmental 
biology, 238(2), pp.239-246. 
 
Duque, G. and Rivas, D., 2007. Alendronate has an anabolic effect on bone through the 
differentiation of mesenchymal stem cells. Journal of Bone and Mineral Research, 22(10), 
pp.1603-1611. 
 
Ebetino, F.H., Hogan, A.M.L., Sun, S., Tsoumpra, M.K., Duan, X., Triffitt, J.T., Kwaasi, A.A., 
Dunford, J.E., Barnett, B.L., Oppermann, U. and Lundy, M.W., 2011. The relationship between 
the chemistry and biological activity of the bisphosphonates. Bone, 49(1), pp.20-33. 
 
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W.J., Lacey, D.L. and Riggs, B.L., 2003. 
Role of RANK ligand in mediating increased bone resorption in early postmenopausal 
women. Journal of Clinical Investigation, 111(8), p.1221. 
 
Elsalini, O.A. and Rohr, K.B., 2003. Phenylthiourea disrupts thyroid function in developing 
zebrafish. Development genes and evolution, 212(12), pp.593-598. 
 
Eriksen, E.F., 2010. Cellular mechanisms of bone remodeling. Reviews in Endocrine and 




Falahati-Nini, A., Riggs, B.L., Atkinson, E.J., O’Fallon, W.M., Eastell, R. and Khosla, S., 2000. 
Relative contributions of testosterone and estrogen in regulating bone resorption and formation 
in normal elderly men. Journal of Clinical Investigation, 106(12), p.1553. 
 
Feldstein, A.C., Black, D., Perrin, N., Rosales, A.G., Friess, D., Boardman, D., Dell, R., Santora, 
A., Chandler, J.M., Rix, M.M. and Orwoll, E., 2012. Incidence and demography of femur 
fractures with and without atypical features. Journal of Bone and Mineral Research, 27(5), 
pp.977-986. 
 
Fleisch, H., 1986. Bisphosphonates--history and experimental basis. Bone,8, pp.S23-8. 
 
Fleming, A., Keynes, R. and Tannahill, D., 2004. A central role for the notochord in vertebral 
patterning. Development, 131(4), pp.873-880. 
 
Fleming, A., Sato, M. and Goldsmith, P., 2005. High-throughput in vivo screening for bone 
anabolic compounds with zebrafish. Journal of biomolecular screening, 10(8), pp.823-831. 
 
Fleming, A., Kishida, M.G., Kimmel, C.B. and Keynes, R.J., 2015. Building the backbone: the 
development and evolution of vertebral patterning.Development, 142(10), pp.1733-1744.  
 
Forlino, A., Cabral, W.A., Barnes, A.M. and Marini, J.C., 2011. New perspectives on 
osteogenesis imperfecta. Nature Reviews Endocrinology, 7(9), pp.540-557. 
 
Foster, B.L., Nociti Jr, F.H. and Somerman, M.J., 2013. The rachitic tooth. Endocrine reviews, 
35(1), pp.1-34. 
 
Franceschi, R.T. and Xiao, G., 2003. Regulation of the osteoblast-specific transcription factor, 
Runx2: Responsiveness to multiple signal transduction pathways. Journal of cellular 
biochemistry, 88(3), pp.446-454. 
 
Fu, L.J., Tang, T.T., Hao, Y.Q. and Dai, K.R., 2013. Long-term effects of alendronate on 
fracture healing and bone remodeling of femoral shaft in ovariectomized rats. Acta 
Pharmacologica Sinica, 34(3), pp.387-392.  
 
Fuentes, J., Figueiredo, J., Power, D.M. and Canário, A.V., 2006. Parathyroid hormone-related 
protein regulates intestinal calcium transport in sea bream (Sparus auratus). American Journal 
of Physiology-Regulatory, Integrative and Comparative Physiology, 291(5), pp.R1499-R1506. 
 
Furutani-Seiki, M., Sasado, T., Morinaga, C., Suwa, H., Niwa, K., Yoda, H., Deguchi, T., Hirose, 
Y., Yasuoka, A., Henrich, T. and Watanabe, T., 2004. A systematic genome-wide screen for 
mutations affecting organogenesis in Medaka, Oryzias latipes. Mechanisms of 
development, 121(7), pp.647-658. 
 
Glass, D.A. and Karsenty, G., 2006. Molecular bases of the regulation of bone remodeling by 
the canonical Wnt signaling pathway. Current topics in developmental biology, 73, pp.43-84. 
 
Grotmol, S., Kryvi, H., Nordvik, K. and Totland, G.K., 2003. Notochord segmentation may lay 
down the pathway for the development of the vertebral bodies in the Atlantic salmon. Anatomy 
and embryology, 207(4-5), pp.263-272. 
 
Guerreiro, P.M., Fuentes, J., Canario, A.V. and Power, D.M., 2002. Calcium balance in sea 
bream (Sparus aurata): the effect of oestradiol-17beta.Journal of endocrinology, 173(2), 
pp.377-385. 
 
Haffter, P., Granato, M., Brand, M., Mullins, M.C., Hammerschmidt, M., Kane, D.A., Odenthal, 
J., Van Eeden, F.J., Jiang, Y.J., Heisenberg, C.P. and Kelsh, R.N., 1996. The identification of 
genes with unique and essential functions in the development of the zebrafish, Danio 




Hammond, C.L. and Moro, E., 2012. Using transgenic reporters to visualize bone and cartilage 
signaling during development in vivo. Frontiers in endocrinology, 3. 
 
Hammond, C.L. and Schulte-Merker, S., 2009. Two populations of endochondral osteoblasts 
with differential sensitivity to Hedgehog signalling.Development, 136(23), pp.3991-4000. 
 
Han, Z.H., Palnitkar, S., Rao, D.S., Nelson, D. and Parfitt, A.M., 1997. Effects of ethnicity and 
age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms 
of bone loss. Journal of Bone and Mineral Research, 12(4), pp.498-508. 
 
Harada, S.I. and Rodan, G.A., 2003. Control of osteoblast function and regulation of bone 
mass. Nature, 423(6937), pp.349-355. 
 
Hattori, R.S., Gould, R.J., Fujioka, T., Saito, T., Kurita, J., Strüssmann, C.A., Yokota, M. and 
Watanabe, S., 2007. Temperature-dependent sex determination in Hd-rR medaka Oryzias 
latipes: gender sensitivity, thermal threshold, critical period, and DMRT1 expression 
profile. Sexual Development, 1(2), pp.138-146.  
 
Hayes, W.C. and Bouxsein, M.L., 1991. Biomechanics of cortical and trabecular bone: 
implications for assessment of fracture risk. Basic orthopaedic biomechanics, 2, pp.69-111. 
 
Henriksen, K., Tanko, L.B., Qvist, P., Delmas, P.D., Christiansen, C. and Karsdal, M.A., 2007. 
Assessment of osteoclast number and function: application in the development of new and 
improved treatment modalities for bone diseases. Osteoporosis international, 18(5), pp.681-685. 
 
Henriksen, K., Neutzsky-Wulff, A.V., Bonewald, L.F. and Karsdal, M.A., 2009. Local 
communication on and within bone controls bone remodeling. Bone, 44(6), pp.1026-1033. 
 
Henry, H.L., 2011. Regulation of vitamin D metabolism. Best practice & research Clinical 
endocrinology & metabolism, 25(4), pp.531-541. 
 
Hilton, M.J., Tu, X., Cook, J., Hu, H. and Long, F., 2005. Ihh controls cartilage development 
by antagonizing Gli3, but requires additional effectors to regulate osteoblast and vascular 
development. Development, 132(19), pp.4339-4351.  
 
Hofbauer, L.C., Khosla, S., Dunstan, C.R., Lacey, D.L., Spelsberg, T.C. and Riggs, B.L., 1999. 
Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human 
Osteoblastic Cells*. Endocrinology,140(9), pp.4367-4370.  
 
Hojo, H., Ohba, S., He, X., Lai, L.P. and McMahon, A.P., 2016. Sp7/Osterix Is Restricted to 
Bone-Forming Vertebrates where It Acts as a Dlx Co-factor in Osteoblast 
Specification. Developmental cell, 37(3), pp.238-253.  
 
Holick, M.F., 2007. Vitamin D deficiency. New England Journal of Medicine, 357(3), pp.266-
281. 
 
HOLTROP, M.E., COX, K.A., CLARK, M.B., HOLICK, M.F. and ANAST, C.S., 1981. 1, 25-
Dihydroxycholecalciferol Stimulates Osteoclasts in Rat Bones in the Absence of Parathyroid 
Hormone*. Endocrinology, 108(6), pp.2293-2301.  
 
Howe, K., Clark, M.D., Torroja, C.F., Torrance, J., Berthelot, C., Muffato, M., Collins, J.E., 
Humphray, S., McLaren, K., Matthews, L. and McLaren, S., 2013. The zebrafish reference 
genome sequence and its relationship to the human genome. Nature, 496(7446), pp.498-503. 
 
Huang, Q.Y., Recker, R.R. and Deng, H.W., 2003. Searching for osteoporosis genes in the post-
genome era: progress and challenges. Osteoporosis international, 14(9), pp.701-715. 
 
Huber, D.M., Bendixen, A.C., Pathrose, P., Srivastava, S., Dienger, K.M., Shevde, N.K. and 
Pike, J.W., 2001. Androgens suppress osteoclast formation induced by RANKL and 




Huitema, L.F., Renn, J., Logister, I., Gray, J.K., Waltz, S.E., Flik, G. and Schulte-Merker, S., 
2012. Macrophage-stimulating protein and calcium homeostasis in zebrafish. The FASEB 
Journal, 26(10), pp.4092-4101.  
 
Hwang, W.Y., Fu, Y., Reyon, D., Maeder, M.L., Tsai, S.Q., Sander, J.D., Peterson, R.T., Yeh, 
J.J. and Joung, J.K., 2013. Efficient genome editing in zebrafish using a CRISPR-Cas 
system. Nature biotechnology, 31(3), pp.227-229. 
 
Imai, Y., Bonewald, L.F., Kondoh, S. and Kato, S., 2011. Estrogen receptor alpha expression 
in osteocytes is necessary to maintain normal bone mineral density and reduce bone loss due to 
unloading. J Bone Miner Res,26(Suppl 1). 
 
Inohaya, K., Takano, Y. and Kudo, A., 2007. The teleost intervertebral region acts as a growth 
center of the centrum: in vivo visualization of osteoblasts and their progenitors in transgenic 
fish. Developmental Dynamics, 236(11), pp.3031-3046. 
 
Ishii, M., Egen, J.G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y., Vacher, J., Proia, R.L. 
and Germain, R.N., 2009. Sphingosine-1-phosphate mobilizes osteoclast precursors and 
regulates bone homeostasis. Nature,458(7237), pp.524-528. 
 
Ishii, M., Kikuta, J., Shimazu, Y., Meier-Schellersheim, M. and Germain, R.N., 2010. 
Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling 
in vivo. The Journal of experimental medicine, 207(13), pp.2793-2798. 
 
Ito, S., Suzuki, N., Kato, S., Takahashi, T. and Takagi, M., 2007. Glucocorticoids induce the 
differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, 
but fail to induce terminal osteoblast differentiation. Bone, 40(1), pp.84-92. 
 
Iwamatsu, T., 2004. Stages of normal development in the medaka Oryzias latipes. Mechanisms 
of development, 121(7), pp.605-618. 
 
Iwamoto, J., Takeda, T., Sato, Y. and Uzawa, M., 2005. Comparison of effect of treatment with 
etidronate and alendronate on lumbar bone mineral density in elderly women with 
osteoporosis. Yonsei medical journal, 46(6), pp.750-758.  
 
Jee, W.S. and Yao, W., 2001. Overview: animal models of osteopenia and osteoporosis. J 
Musculoskelet Neuronal Interact, 1(3), pp.193-207. 
 
Jilka, R.L., 2007. Molecular and cellular mechanisms of the anabolic effect of intermittent 
PTH. Bone, 40(6), pp.1434-1446.  
 
Jilka, R.L., O'Brien, C.A., Bartell, S.M., Weinstein, R.S. and Manolagas, S.C., 2010. 
Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent 
and-independent mechanisms. Journal of Bone and Mineral Research, 25(11), pp.2427-2437. 
 
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A. and Charpentier, E., 2012. A 
programmable dual-RNA–guided DNA endonuclease in adaptive bacterial 
immunity. Science, 337(6096), pp.816-821. 
 
Jobke, B., 2009. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Eng 
J Med, 360, pp.1676-1676.  
 
Jobke, B., Milovanovic, P., Amling, M. and Busse, B., 2014. Bisphosphonate-osteoclasts: 
changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing 
bisphosphonate treatment in osteoporosis patients. Bone, 59, pp.37-43. 
 
Kanazawa, I., 2015. Osteocalcin as a hormone regulating glucose metabolism. World journal 




Kanis, J.A., 2000. Primer on the metabolic bone diseases and disorders of mineral 
metabolism. Clinical Endocrinology, 52(4), pp.526-526. 
 
Kanis, J.A., Burlet, N., Cooper, C., Delmas, P.D., Reginster, J.Y., Borgstrom, F. and Rizzoli, 
R., 2008. European guidance for the diagnosis and management of osteoporosis in 
postmenopausal women. Osteoporosis international, 19(4), pp.399-428. 
 
Karsenty, G., Kronenberg, H.M. and Settembre, C., 2009. Genetic control of bone 
formation. Annual Review of Cell and Developmental, 25, pp.629-648.  
 
Kasper, G., Mao, L., Geissler, S., Draycheva, A., Trippens, J., Kühnisch, J., Tschirschmann, M., 
Kaspar, K., Perka, C., Duda, G.N. and Klose, J., 2009. Insights into mesenchymal stem cell 
aging: involvement of antioxidant defense and actin cytoskeleton. Stem cells, 27(6), pp.1288-
1297.  
 
Kasperk, C.H., Wakley, G.K., Hierl, T. and Ziegler, R., 1997. Gonadal and adrenal androgens 
are potent regulators of human bone cell metabolism in vitro. Journal of Bone and Mineral 
Research, 12(3), pp.464-471.  
 
Kassem, M. and Marie, P.J., 2011. Senescence-associated intrinsic mechanisms of osteoblast 
dysfunctions. Aging cell, 10(2), pp.191-197. 
 
Kasturi, G.C., Cifu, D.X. and Adler, R.A., 2009. A review of osteoporosis: part I. Impact, 
pathophysiology, diagnosis and unique role of the physiatrist. PM&R,1(3), pp.254-260. 
 
Kague, E., Roy, P., Asselin, G., Hu, G., Stanley, A., Albertson, C., Simonet, J. and Fisher, S., 
2016. Osterix/sp7 limits cranial bone initiation sites and is required for formation of 
sutures. Developmental Biology. 
 
Kavanagh, K.L., Guo, K., Dunford, J.E., Wu, X., Knapp, S., Ebetino, F.H., Rogers, M.J., Russell, 
R.G.G. and Oppermann, U., 2006. The molecular mechanism of nitrogen-containing 
bisphosphonates as antiosteoporosis drugs. Proceedings of the National Academy of 
Sciences, 103(20), pp.7829-7834. 
 
Keaveny, T.M., Hoffmann, P.F., Singh, M., Palermo, L., Bilezikian, J.P., Greenspan, S.L. and 
Black, D.M., 2008. Femoral bone strength and its relation to cortical and trabecular changes 
after treatment with PTH, alendronate, and their combination as assessed by finite element 
analysis of quantitative CT scans. Journal of Bone and Mineral Research, 23(12), pp.1974-
1982. 
 
Kennedy, C.C., Papaioannou, A. and Adachi, J.D., 2006. Glucocorticoid-induced osteoporosis. 
 
Khan, A.A., Sandor, G.K., Dore, E., Morrison, A.D., Alsahli, M., Amin, F., Peters, E., Hanley, 
D.A., Chaudry, S.R., Lentle, B. and Dempster, D.W., 2009. Bisphosphonate associated 
osteonecrosis of the jaw. The Journal of Rheumatology, 36(3), pp.478-490. 
 
Khosla, S., 2001. Minireview: The opg/rankl/rank system. Endocrinology,142(12), pp.5050-
5055. 
 
Khosla, S., Atkinson, E.J., Dunstan, C.R., O'Fallon, W.M. and Riggs, B.L., 2001, September. 
Estrogen and testosterone have opposite effects on circulating OPG levels following induction 
of hypogonadism and aromatase inhibition in normal elderly men: Potential mechanism for 
differential effects of estrogen versus testosterone on bone resorption. In JOURNAL OF BONE 
AND MINERAL RESEARCH (Vol. 16, pp. S146-S146). 2025 M ST, NW, STE 800, 
WASHINGTON, DC 20036-3309 USA: AMER SOC BONE & MINERAL RES.  
 
Khosla, S., Melton, L.J. and Riggs, B.L., 2011. The unitary model for estrogen deficiency and 
the pathogenesis of osteoporosis: is a revision needed?. Journal of Bone and Mineral 




Kimura, H., Kwan, K.M., Zhang, Z., Deng, J.M., Darnay, B.G., Behringer, R.R., Nakamura, T., 
de Crombrugghe, B. and Akiyama, H., 2008. Cthrc1 is a positive regulator of osteoblastic bone 
formation. PLoS One, 3(9), p.e3174. 
 
Komori, T., Nomura, S., Yamaguchi, A., Sasaka, K., Deguchi, K., Shimizu, Y., Bronson, R.T., 
Gao, Y.-H., Inada, M., Kitamura, Y., Yoshiki, S. and Kishimoto, T., 1997. Targeted disruption 
of Cbfa1 results in a complete lack of bone formation owning to maturational arrest of 
osteoblasts. Cell, 89, pp.755-64.  
 
Koga, T., Matsui, Y., Asagiri, M., Kodama, T., de Crombrugghe, B., Nakashima, K. and 
Takayanagi, H., 2005. NFAT and Osterix cooperatively regulate bone formation. Nature 
medicine, 11(8), pp.880-885.  
 
Komori, T., 2015. Animal models for osteoporosis. European journal of pharmacology, 759, 
pp.287-294. 
 
Kousteni, S., Bellido, T., Plotkin, L.I., O'Brien, C.A., Bodenner, D.L., Han, L., Han, K., 
DiGregorio, G.B., Katzenellenbogen, J.A., Katzenellenbogen, B.S. and Roberson, P.K., 2001. 
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: 
dissociation from transcriptional activity. Cell, 104(5), pp.719-730. 
 
Krug, R., Larson, P.E.Z., Wang, C., Burghardt, A.J., Kelley, D.A., Link, T.M., Zhang, X., 
Vigneron, D.B. and Majumdar, S., 2011. Ultrashort echo time MRI of cortical bone at 7 tesla 
field strength: a feasibility study. Journal of Magnetic Resonance Imaging, 34(3), pp.691-695. 
 
Lacey, D.L., Boyle, W.J., Simonet, W.S., Kostenuik, P.J., Dougall, W.C., Sullivan, J.K., San 
Martin, J. and Dansey, R., 2012. Bench to bedside: elucidation of the OPG–RANK–RANKL 
pathway and the development of denosumab. Nature reviews Drug discovery, 11(5), pp.401-
419. 
 
Laizé, V., Gavaia, P.J. and Cancela, M.L., 2014. Fish: a suitable system to model human bone 
disorders and discover drugs with osteogenic or osteotoxic activities. Drug Discovery Today: 
Disease Models. 
 
Lapunzina, P., Aglan, M., Temtamy, S., Caparrós-Martín, J.A., Valencia, M., Letón, R., 
Martínez-Glez, V., Elhossini, R., Amr, K., Vilaboa, N. and Ruiz-Perez, V.L., 2010. 
Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis 
imperfecta. The American Journal of Human Genetics, 87(1), pp.110-114.  
 
Lean, J.M., Mackay, A.G., Chow, J.W. and Chambers, T.J., 1996. Osteocytic expression of 
mRNA for c-fos and IGF-I: an immediate early gene response to an osteogenic 
stimulus. American Journal of Physiology-Endocrinology And Metabolism, 270(6), pp.E937-
E945. 
 
Lee, K.S., Kim, H.J., Li, Q.L., Chi, X.Z., Ueta, C., Komori, T., Wozney, J.M., Kim, E.G., Choi, 
J.Y., Ryoo, H.M. and Bae, S.C., 2000. Runx2 is a common target of transforming growth factor 
β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces 
osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line 
C2C12. Molecular and cellular biology, 20(23), pp.8783-8792. 
 
Lee, N.K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J.D., Confavreux, C., Dacquin, R., Mee, P.J., 
McKee, M.D., Jung, D.Y. and Zhang, Z., 2007. Endocrine regulation of energy metabolism by 
the skeleton. Cell, 130(3), pp.456-469. 
 
Lehenkari, P.P., Kellinsalmi, M., Näpänkangas, J.P., Ylitalo, K.V., Mönkkönen, J., Rogers, M.J., 
Azhayev, A., Väänänen, H.K. and Hassinen, I.E., 2002. Further insight into mechanism of 
action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, 




Iida, Y., Hibiya, K., Inohaya, K. and Kudo, A., 2014. Eda/Edar signaling guides fin ray 
formation with preceding osteoblast differentiation, as revealed by analyses of the medaka all-
fin less mutant afl. Developmental Dynamics,243(6), pp.765-777. 
 
Little, R.D., Folz, C., Manning, S.P., Swain, P.M., Zhao, S.C., Eustace, B., Lappe, M.M., 
Spitzer, L., Zweier, S., Braunschweiger, K. and Benchekroun, Y., 2002. A mutation in the LDL 
receptor–related protein 5 gene results in the autosomal dominant high–bone-mass trait. The 
American Journal of Human Genetics, 70(1), pp.11-19. 
 
Liu, Y., Porta, A., Peng, X., Gengaro, K., Cunningham, E.B., Li, H., Dominguez, L.A., Bellido, 
T. and Christakos, S., 2004. Prevention of Glucocorticoid-Induced Apoptosis in Osteocytes and 
Osteoblasts by Calbindin-D28k. Journal of Bone and Mineral Research, 19(3), pp.479-490. 
 
Long, F., 2012. Building strong bones: molecular regulation of the osteoblast lineage. Nature 
reviews Molecular cell biology, 13(1), pp.27-38. 
 
Long, F., Chung, U.I., Ohba, S., McMahon, J., Kronenberg, H.M. and McMahon, A.P., 2004. 
Ihh signaling is directly required for the osteoblast lineage in the endochondral 
skeleton. Development, 131(6), pp.1309-1318. 
 
Lotinun, S., Kiviranta, R., Matsubara, T., Alzate, J.A., Neff, L., Lüth, A., Koskivirta, I., Kleuser, 
B., Vacher, J., Vuorio, E. and Horne, W.C., 2013. Osteoclast-specific cathepsin K deletion 
stimulates S1P-dependent bone formation. The Journal of clinical investigation, 123(2), p.666. 
 
Luckman, S.P., Hughes, D.E., Coxon, F.P., Russell, R.G.G. and Rogers, M.J., 1998. Nitrogen-
containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational 
prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral 
Research, 13(4), pp.581-589. 
 
Ma, D. and Liu, F., 2016. Genome Editing and Its Applications in Model Organisms. Genomics, 
Proteomics & Bioinformatics. 
 
Määttä, J.A., Büki, K.G., Ivaska, K.K., Nieminen-Pihala, V., Elo, T.D., Kähkönen, T., Poutanen, 
M., Härkönen, P. and Väänänen, K., 2013. Inactivation of the androgen receptor in bone-
forming cells leads to trabecular bone loss in adult female mice. BoneKEy reports, 2. 
 
MacGowan, J.R., Pringle, J., Morris, V.H. and Stamp, T.C.B., 2000. Gross vertebral collapse 
associated with long-term disodium etidronate treatment for pelvic Paget’s disease. Skeletal 
radiology, 29(5), pp.279-282.  
 
Mackay, E.W., Apschner, A. and Schulte-Merker, S., 2013. A bone to pick with 
zebrafish. BoneKEy reports, 2. 
 
Mackay, E.W., Apschner, A. and Schulte-Merker, S., 2015. Vitamin K reduces 
hypermineralisation in zebrafish models of PXE and GACI. Development,142(6), pp.1095-
1101. 
 
MacRae, C.A. and Peterson, R.T., 2015. Zebrafish as tools for drug discovery.Nature Reviews 
Drug Discovery, 14(10), pp.721-731. 
 
Maeda, S., Hayashi, M., Komiya, S., Imamura, T. and Miyazono, K., 2004. Endogenous TGF-
β signaling suppresses maturation of osteoblastic mesenchymal cells. The EMBO journal, 23(3), 
pp.552-563. 
 
Manabe, T., Mori, S., Mashiba, T., Kaji, Y., Iwata, K., Komatsubara, S. and Yamamoto, T., 
2012. Effect of dosing interval duration of intermittent ibandronate treatment on the healing 





Manolagas, S.C., 2000. Birth and death of bone cells: basic regulatory mechanisms and 
implications for the pathogenesis and treatment of osteoporosis 1. Endocrine reviews, 21(2), 
pp.115-137. 
 
Manolagas, S.C., O'Brien, C.A. and Almeida, M., 2013. The role of estrogen and androgen 
receptors in bone health and disease. Nature Reviews Endocrinology, 9(12), pp.699-712. 
 
Mauck, K.F. and Clarke, B.L., 2006, May. Diagnosis, screening, prevention, and treatment of 
osteoporosis. In Mayo Clinic Proceedings (Vol. 81, No. 5, pp. 662-672). Elsevier. 
 
Martin-Millan, M., Almeida, M., Ambrogini, E., Han, L., Zhao, H., Weinstein, R.S., Jilka, R.L., 
O'Brien, C.A. and Manolagas, S.C., 2010. The estrogen receptor-α in osteoclasts mediates the 
protective effects of estrogens on cancellous but not cortical bone. Molecular 
endocrinology, 24(2), pp.323-334.  
 
Martínez-Glez, V., Valencia, M., Caparrós-Martín, J.A., Aglan, M., Temtamy, S., Tenorio, J., 
Pulido, V., Lindert, U., Rohrbach, M., Eyre, D. and Giunta, C., 2012. Identification of a 
mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive 
osteogenesis imperfecta. Human mutation, 33(2), pp.343-350. 
 
Masarachia, P., Weinreb, M., Balena, R. and Rodan, G.A., 1996. Comparison of the distribution 
of 3 H-alendronate and 3 H-etidronate in rat and mouse bones. Bone, 19(3), pp.281-290.  
 
Mathew, A. and Brufsky, A., 2014. Bisphosphonates in breast cancer.International Journal of 
Cancer. 
 
Matsubara, T., Kida, K., Yamaguchi, A., Hata, K., Ichida, F., Meguro, H., Aburatani, H., 
Nishimura, R. and Yoneda, T., 2008. BMP2 regulates Osterix through Msx2 and Runx2 during 
osteoblast differentiation. Journal of Biological Chemistry, 283(43), pp.29119-29125. 
 
Matsuda, M., Nagahama, Y., Shinomiya, A., Sato, T., Matsuda, C., Kobayashi, T., Morrey, C.E., 
Shibata, N., Asakawa, S., Shimizu, N. and Hori, H., 2002. DMY is a Y-specific DM-domain 
gene required for male development in the medaka fish. Nature, 417(6888), pp.559-563.  
 
Matsuoka, K., Park, K.A., Ito, M., Ikeda, K. and Takeshita, S., 2014. Osteoclast-Derived 
Complement Component 3a Stimulates Osteoblast Differentiation. Journal of Bone and 
Mineral Research, 29(7), pp.1522-1530. 
 
Mazziotti, G., Angeli, A., Bilezikian, J.P., Canalis, E. and Giustina, A., 2006. Glucocorticoid-
induced osteoporosis: an update. Trends in Endocrinology & Metabolism, 17(4), pp.144-149. 
 
Mosekilde, L., 2008. Primary hyperparathyroidism and the skeleton. Clinical 
endocrinology, 69(1), pp.1-19. 
 
Mukherjee, D., Sen, U., Bhattacharyya, S.P. and Mukherjee, D., 2004. The effects of calcitonin 
on plasma calcium levels and bone metabolism in the fresh water teleost Channa 
punctatus. Comparative Biochemistry and Physiology Part A: Molecular & Integrative 
Physiology, 138(4), pp.417-426. 
 
Mundy, G.R. and Guise, T.A., 1999. Hormonal control of calcium homeostasis. Clinical 
chemistry, 45(8), pp.1347-1352. 
 
Murshed, M., Harmey, D., Millán, J.L., McKee, M.D. and Karsenty, G., 2005. Unique 
coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of 
ECM mineralization to bone. Genes & development, 19(9), pp.1093-1104. 
 
Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, 
Y., Krust, A., Yamamoto, Y. and Nishina, H., 2007. Estrogen prevents bone loss via estrogen 




Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R. and de 
Crombrugghe, B., 2002. The novel zinc finger-containing transcription factor osterix is required 
for osteoblast differentiation and bone formation. Cell, 108(1), pp.17-29.  
 
Nanda, I., Kondo, M., Hornung, U., Asakawa, S., Winkler, C., Shimizu, A., Shan, Z., Haaf, T., 
Shimizu, N., Shima, A. and Schmid, M., 2002. A duplicated copy of DMRT1 in the sex-
determining region of the Y chromosome of the medaka, Oryzias latipes. Proceedings of the 
National Academy of Sciences, 99(18), pp.11778-11783. 
 
Norman, A.W., Okamura, W.H., Bishop, J.E. and Henry, H.L., 2002. Update on biological 
actions of 1α, 25 (OH) 2-vitamin D 3 (rapid effects) and 24R, 25 (OH) 2-vitamin D 3. Molecular 
and cellular endocrinology, 197(1), pp.1-13. 
 
O’Brien, C.A., Jia, D., Plotkin, L.I., Bellido, T., Powers, C.C., Stewart, S.A., Manolagas, S.C. 
and Weinstein, R.S., 2004. Glucocorticoids act directly on osteoblasts and osteocytes to induce 
their apoptosis and reduce bone formation and strength. Endocrinology, 145(4), pp.1835-1841. 
 
Odvina, C.V., Zerwekh, J.E., Rao, D.S., Maalouf, N., Gottschalk, F.A. and Pak, C.Y., 2005. 
Severely suppressed bone turnover: a potential complication of alendronate therapy. The 
Journal of Clinical Endocrinology & Metabolism, 90(3), pp.1294-1301.  
 
Ogura, K., Iimura, T., Makino, Y., Sugie-Oya, A., Takakura, A., Takao-Kawabata, R., Ishizuya, 
T., Moriyama, K. and Yamaguchi, A., 2016. Short-term intermittent administration of 
parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical 
bone. Bone Reports. 
 
Oh, J.H., Park, S.Y., de Crombrugghe, B. and Kim, J.E., 2012. Chondrocyte-specific ablation 
of Osterix leads to impaired endochondral ossification. Biochemical and biophysical research 
communications, 418(4), pp.634-640.  
 
Ohba, S., Yano, F. and Chung, U.I., 2009. Tissue engineering of bone and cartilage. IBMS 
BoneKEy, 6(11), pp.405-419. 
 
Ohnaka, K., Tanabe, M., Kawate, H., Nawata, H. and Takayanagi, R., 2005. Glucocorticoid 
suppresses the canonical Wnt signal in cultured human osteoblasts. Biochemical and 
biophysical research communications, 329(1), pp.177-181. 
 
Opperman, L.A., 2000. Cranial sutures as intramembranous bone growth sites. Developmental 
dynamics, 219(4), pp.472-485.  
 
Ota, S. and Kawahara, A., 2014. Zebrafish: a model vertebrate suitable for the analysis of human 
genetic disorders. Congenital anomalies, 54(1), pp.8-11. 
 
Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W., 
Beddington, R.S., Mundlos, S., Olsen, B.R. and Selby, P.B., 1997. Cbfa1, a candidate gene for 
cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone 
development. Cell, 89(5), pp.765-771. 
 
Ott, S.M., 2011. What is the optimal duration of bisphosphonate therapy?.Cleveland Clinic 
journal of medicine, 78(9), pp.619-630. 
 
Oury, F., Sumara, G., Sumara, O., Ferron, M., Chang, H., Smith, C.E., Hermo, L., Suarez, S., 
Roth, B.L., Ducy, P. and Karsenty, G., 2011. Endocrine regulation of male fertility by the 
skeleton. Cell, 144(5), pp.796-809. 
 
Parfitt, A.M., 2002. Targeted and nontargeted bone remodeling: relationship to basic 
multicellular unit origination and progression. Bone, 30(1), pp.5-7. 
 
Park, J., Gebhardt, M., Golovchenko, S., Perez-Branguli, F., Hattori, T., Hartmann, C., Zhou, 
X., Stock, M., Schneider, H. and von der Mark, K., 2015. Dual pathways to endochondral 
135	
	
osteoblasts: a novel chondrocyte-derived osteoprogenitor cell identified in hypertrophic 
cartilage. Biology open,4(5), pp.608-621.  
 
Patntirapong, S., Singhatanadgit, W. and Arphavasin, S., 2014. Alendronate-induced atypical 
bone fracture: evidence that the drug inhibits osteogenesis.Journal of clinical pharmacy and 
therapeutics, 39(4), pp.349-353. 
 
Pazianas, M., Miller, P., Blumentals, W.A., Bernal, M. and Kothawala, P., 2007. A review of 
the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral 
bisphosphonates: prevalence, risk factors, and clinical characteristics. Clinical 
therapeutics, 29(8), pp.1548-1558. 
 
Pederson, L., Ruan, M., Westendorf, J.J., Khosla, S. and Oursler, M.J., 2008. Regulation of 
bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-
phosphate. Proceedings of the National Academy of Sciences, 105(52), pp.20764-20769. 
 
Peichl, P., Holzer, L.A., Maier, R. and Holzer, G., 2011. Parathyroid hormone 1-84 accelerates 
fracture-healing in pubic bones of elderly osteoporotic women.The Journal of Bone & Joint 
Surgery, 93(17), pp.1583-1587. 
 
Peruzzi, B. and Teti, A., 2012. The physiology and pathophysiology of the osteoclast. Clinical 
Reviews in Bone and Mineral Metabolism, 10(2), pp.71-97. 
 
Pettifor, J.M. and Prentice, A., 2011. The role of vitamin D in paediatric bone health. Best 
Practice & Research Clinical Endocrinology & Metabolism, 25(4), pp.573-584. 
 
Plotkin, L.I., Weinstein, R.S., Parfitt, A.M., Roberson, P.K., Manolagas, S.C. and Bellido, T., 
1999. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and 
calcitonin. Journal of Clinical Investigation, 104(10), p.1363. 
 
Plotkin, L.I., Lezcano, V., Thostenson, J., Weinstein, R.S., Manolagas, S.C. and Bellido, T., 
2008. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes 
and osteoblasts in vivo. Journal of Bone and Mineral Research, 23(11), pp.1712-1721. 
 
Plotkin, L.I., Bivi, N. and Bellido, T., 2011. A bisphosphonate that does not affect osteoclasts 
prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by 
glucocorticoids in mice. Bone, 49(1), pp.122-127. 
 
Poole, Kenneth ES, and Jonathan Reeve. "Parathyroid hormone—a bone anabolic and catabolic 
agent." Current opinion in pharmacology 5, no. 6 (2005): 612-617. 
  
Raisz, L.G., 1999. Physiology and pathophysiology of bone remodeling. Clinical chemistry, 
45(8), pp.1353-1358. 
 
Reid, I.R., 1997. Glucocorticoid osteoporosis--mechanisms and management. European 
Journal of Endocrinology, 137(3), pp.209-217. 
 
Renn, J., Winkler, C., Schartl, M., Fischer, R. and Goerlich, R., 2006. Zebrafish and medaka as 
models for bone research including implications regarding space-related 
issues. Protoplasma, 229(2-4), pp.209-214. 
 
Renn, J. and Winkler, C., 2009. Osterix-mCherry transgenic medaka for in vivo imaging of 
bone formation. Developmental Dynamics, 238(1), pp.241-248. 
 
-. 2014. Osterix/Sp7 regulates biomineralization of otoliths and bone in medaka (Oryzias 
latipes). Matrix Biology, 34, pp.193-204. 
 
Renn, J., Büttner, A., To, T.T., Chan, S.J.H. and Winkler, C., 2013. A col10a1: nlGFP transgenic 
line displays putative osteoblast precursors at the medaka notochordal sheath prior to 




Rhee, Y., Allen, M.R., Condon, K., Lezcano, V., Ronda, A.C., Galli, C., Olivos, N., Passeri, G., 
O'Brien, C.A., Bivi, N. and Plotkin, L.I., 2011. PTH receptor signaling in osteocytes governs 
periosteal bone formation and intracortical remodeling. Journal of Bone and Mineral Research, 
26(5), pp.1035-1046. 
 
Riggs, B.L., Khosla, S. and Melton, L.J., 1998. A unitary model for involutional osteoporosis: 
estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and 
contributes to bone loss in aging men. Journal of bone and mineral research, 13(5), pp.763-
773. 
 
Riggs, B.L., Khosla, S. and Melton III, L.J., 2002. Sex steroids and the construction and 
conservation of the adult skeleton. Endocrine reviews,23(3), pp.279-302.  
 
Robinson, L.J., Yaroslavskiy, B.B., Griswold, R.D., Zadorozny, E.V., Guo, L., Tourkova, I.L. 
and Blair, H.C., 2009. Estrogen inhibits RANKL-stimulated osteoclastic differentiation of 
human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-α 
with BCAR1 and Traf6.Experimental cell research, 315(7), pp.1287-1301. 
 
Rogers, M.J., Gordon, S., Benford, H.L., Coxon, F.P., Luckman, S.P., Monkkonen, J. and Frith, 
J.C., 2000. Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 88(S12), 
pp.2961-2978. 
 
Rogers, M.J., Crockett, J.C., Coxon, F.P. and Mönkkönen, J., 2011. Biochemical and molecular 
mechanisms of action of bisphosphonates. Bone,49(1), pp.34-41. 
 
Rondeau, J.M., Bitsch, F., Bourgier, E., Geiser, M., Hemmig, R., Kroemer, M., Lehmann, S., 
Ramage, P., Rieffel, S., Strauss, A. and Green, J.R., 2006. Structural basis for the exceptional 
in vivo efficacy of bisphosphonate drugs. ChemMedChem, 1(2), pp.267-273. 
 
Rubin, M.R., Cosman, F., Cosman, F., Lindsay, R., Lindsay, R., Bilezikian, J.P. and Bilezikian, 
J.P., 2002. The anabolic effects of parathyroid hormone.Osteoporosis international, 13(4), 
pp.267-277.  
 
Russell, R.G.G. and Rogers, M.J., 1999. Bisphosphonates: from the laboratory to the clinic and 
back again. Bone, 25(1), pp.97-106. 
 
Ryu, J., Kim, H.J., Chang, E.J., Huang, H., Banno, Y. and Kim, H.H., 2006. Sphingosine 1-
phosphate as a regulator of osteoclast differentiation and osteoclast–osteoblast coupling. The 
EMBO journal, 25(24), pp.5840-5851. 
 
Salmon, C.R., Tomazela, D.M., Ruiz, K.G.S., Foster, B.L., Leme, A.F.P., Sallum, E.A., 
Somerman, M.J. and Nociti, F.H., 2013. Proteomic analysis of human dental cementum and 
alveolar bone. Journal of proteomics, 91, pp.544-555. 
 
Savaridas, T., Wallace, R.J., Salter, D.M. and Simpson, A.H.R.W., 2013. Do bisphosphonates 
inhibit direct fracture healing? A laboratory investigation using an animal model. Bone & Joint 
Journal, 95(9), pp.1263-1268. 
 
Sawakami, K., Robling, A.G., Ai, M., Pitner, N.D., Liu, D., Warden, S.J., Li, J., Maye, P., Rowe, 
D.W., Duncan, R.L. and Warman, M.L., 2006. The Wnt co-receptor LRP5 is essential for 
skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone 
treatment. Journal of Biological Chemistry, 281(33), pp.23698-23711. 
 
Scaffidi, P. and Misteli, T., 2008. Lamin A-dependent misregulation of adult stem cells 
associated with accelerated ageing. Nature cell biology, 10(4), pp.452-459. 
 
Schafer, A.L., Sellmeyer, D.E., Schwartz, A.V., Rosen, C.J., Vittinghoff, E., Palermo, L., 
Bilezikian, J.P., Shoback, D.M. and Black, D.M., 2011. Change in undercarboxylated 
osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid 
137	
	
hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH 
study). The Journal of Clinical Endocrinology & Metabolism, 96(12), pp.E1982-E1989. 
 
Schaffler, M. B., and R. J. Majeska. "Role of the osteocyte in mechanotransduction and skeletal 
fragility." In Proceedings of the NIAMS–ASBMR scientific meeting, Bone quality: what is it and 
can we measure it, pp. 2-3. 
 
Schilling, T.F. and Kimmel, C.B., 1994. Segment and cell type lineage restrictions during 
pharyngeal arch development in the zebrafish embryo.Development, 120(3), pp.483-494. 
 
Seeman, E., 2003. Periosteal bone formation--a neglected determinant of bone strength. The 
New England journal of medicine, 349(4), p.320. 
 
Seeman, E. and Delmas, P.D., 2006. Bone quality—the material and structural basis of bone 
strength and fragility. New England Journal of Medicine, 354(21), pp.2250-2261. 
 
Shanthanagouda, A.H., Guo, B.S., Ye, R.R., Chao, L., Chiang, M.W., Singaram, G., Cheung, 
N.K., Zhang, G. and Au, D.W., 2014. Japanese Medaka: A Non-Mammalian Vertebrate Model 
for Studying Sex and Age-Related Bone Metabolism In. PloS one, 9(2), p.e88165. 
 
Sharif, P.S., Abdollahi, M. and Larijani, B., 2011. Current, new and future treatments of 
osteoporosis. Rheumatology international, 31(3), pp.289-300. 
 
Sheng, M.H.C., Zhou, X.D., Bonewald, L.F., Baylink, D.J. and Lau, K.H.W., 2013. Disruption 
of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in 
mice. Bone, 52(1), pp.133-144. 
 
Shevde, N.K., Bendixen, A.C., Dienger, K.M. and Pike, J.W., 2000. Estrogens suppress RANK 
ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving 
c-Jun repression.Proceedings of the National Academy of Sciences, 97(14), pp.7829-7834. 
 
Sims, N.A. and Martin, T.J., 2014. Coupling the activities of bone formation and resorption: a 
multitude of signals within the basic multicellular unit.BoneKEy reports, 3. 
 
Sivagurunathan, S., Muir, M.M., Brennan, T.C., Seale, J.P. and Mason, R.S., 2005. Influence 
of glucocorticoids on human osteoclast generation and activity. Journal of bone and mineral 
research, 20(3), pp.390-398. 
 
Snoeks, T.J., Baiker, M., Kaijzel, E.L., Lelieveldt, B.P. and Löwik, C.W., 2012. CT-based 
handling and analysis of preclinical multimodality imaging data of bone metastases. BoneKEy 
reports, 1(5). 
 
Spoorendonk, K.M., Peterson-Maduro, J., Renn, J., Trowe, T., Kranenbarg, S., Winkler, C. and 
Schulte-Merker, S., 2008. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in 
the axial skeleton. Development,135(22), pp.3765-3774.  
 
Srivastava, S., Toraldo, G., Weitzmann, M.N., Cenci, S., Ross, F.P. and Pacifici, R., 2001. 
Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand 
(RANKL)-induced JNK activation. Journal of Biological Chemistry, 276(12), pp.8836-8840. 
 
Stemmer, M., Thumberger, T., del Sol Keyer, M., Wittbrodt, J. and Mateo, J.L., 2015. CCTop: 
An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. 
 
St-Jacques, B., Hammerschmidt, M. and McMahon, A.P., 1999. Indian hedgehog signaling 
regulates proliferation and differentiation of chondrocytes and is essential for bone 
formation. Genes & development, 13(16), pp.2072-2086. 
 
Swanson, C., Lorentzon, M., Conaway, H.H. and Lerner, U.H., 2006. Glucocorticoid regulation 
of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) 
138	
	
ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial 
bones. Endocrinology, 147(7), pp.3613-3622. 
 
Swarthout, J.T., D'Alonzo, R.C., Selvamurugan, N. and Partridge, N.C., 2002. Parathyroid 
hormone-dependent signaling pathways regulating genes in bone cells. Gene, 282(1), pp.1-17. 
 
Tabane, K. and Vorobiof, D.A., 2011. Bone targeted therapies in early breast cancer. Current 
treatment options in oncology, 12(4), pp.412-423. 
 
TAKAHASHI, N., YAMANA, H., YOSHIKI, S., ROODMAN, G.D., MUNDY, G.R., JONES, 
S.J., BOYDE, A. and SUDA, T., 1988. Osteoclast-Like Cell Formation and its Regulation by 
Osteotropic Hormones in Mouse Bone Marrow Cultures*. Endocrinology, 122(4), pp.1373-
1382.  
 
Takeshita, S., Fumoto, T., Matsuoka, K., Park, K.A., Aburatani, H., Kato, S., Ito, M. and Ikeda, 
K., 2013. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. The 
Journal of clinical investigation, 123(9), p.3914. 
 
Teti, A., 2013. Mechanisms of osteoclast-dependent bone formation.BoneKEy reports, 2. 
 
Thudium, C.S., Moscatelli, I., Flores, C., Thomsen, J.S., Brüel, A., Gudmann, N.S., Hauge, 
E.M., Karsdal, M.A., Richter, J. and Henriksen, K., 2014. A comparison of osteoclast-rich and 
osteoclast-poor osteopetrosis in adult mice sheds light on the role of the osteoclast in coupling 
bone resorption and bone formation. Calcified tissue international, 95(1), pp.83-93. 
 
To, T.T., Witten, P.E., Renn, J., Bhattacharya, D., Huysseune, A. and Winkler, C., 2012. Rankl-
induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model. 
Development, 139(1), pp.141-150. 
 
To, T.T., Witten, P.E., Huysseune, A. and Winkler, C., 2015. An adult osteopetrosis model in 
medaka reveals the importance of osteoclast function for bone remodeling in teleost fish. 
Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 178, pp.68-
75. 
 
Tomkinson, A., Gevers, E.F., Wit, J.M., Reeve, J. and Noble, B.S., 1998. The role of estrogen 
in the control of rat osteocyte apoptosis. Journal of Bone and Mineral Research, 13(8), pp.1243-
1250. 
 
US Department of Health and Human Services, 2004. Bone health and osteoporosis: a report of 
the Surgeon General. 
 
Van Eeden, F.J., Granato, M., Schach, U., Brand, M., Furutani-Seiki, M., Haffter, P., 
Hammerschmidt, M., Heisenberg, C.P., Jiang, Y.J., Kane, D.A. and Kelsh, R.N., 1996. Genetic 
analysis of fin formation in the zebrafish, Danio rerio. Development, 123(1), pp.255-262.  
 
Van Lenthe, G.H. and Müller, R., 2008. CT-based visualization and quantification of bone 
microstructure in vivo. IBMS BoneKEy, 5(11), pp.410-425. 
 
Von Knoch, F., Jaquiery, C., Kowalsky, M., Schaeren, S., Alabre, C., Martin, I., Rubash, H.E. 
and Shanbhag, A.S., 2005. Effects of bisphosphonates on proliferation and osteoblast 
differentiation of human bone marrow stromal cells.Biomaterials, 26(34), pp.6941-6949. 
 
Wagner, T.U., Renn, J., Riemensperger, T., Volff, J.N., Köster, R.W., Goerlich, R., Schartl, M. 
and Winkler, C., 2003. The teleost fish medaka (Oryzias latipes) as genetic model to study 
gravity dependent bone homeostasis in vivo. Advances in Space Research, 32(8), pp.1459-1465.  
 
Wang, F.S., Lin, C.L., Chen, Y.J., Wang, C.J., Yang, K.D., Huang, Y.T., Sun, Y.C. and Huang, 
H.C., 2005. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of 




Weber, J.M., Forsythe, S.R., Christianson, C.A., Frisch, B.J., Gigliotti, B.J., Jordan, C.T., 
Milner, L.A., Guzman, M.L. and Calvi, L.M., 2006. Parathyroid hormone stimulates expression 
of the Notch ligand Jagged1 in osteoblastic cells. Bone, 39(3), pp.485-493. 
  
Weinstein, R.S., Jilka, R.L., Parfitt, A.M. and Manolagas, S.C., 1998. Inhibition of 
osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. 
Potential mechanisms of their deleterious effects on bone. Journal of Clinical 
Investigation, 102(2), p.274. 
 
Weinstein, R.S., Jia, D., Powers, C.C., Stewart, S.A., Jilka, R.L., Parfitt, A.M. and Manolagas, 
S.C., 2004. The skeletal effects of glucocorticoid excess override those of orchidectomy in 
mice. Endocrinology, 145(4), pp.1980-1987.  
 
Weinstein, R.S., Roberson, P.K. and Manolagas, S.C., 2009. Giant osteoclast formation and 
long-term oral bisphosphonate therapy. New England Journal of Medicine, 360(1), pp.53-62.  
 
Weinstein, R.S., 2011. Glucocorticoid-induced bone disease. New England Journal of 
Medicine, 365(1), pp.62-70. 
 
Wiren, K.M., Zhang, X., Chang, C., Keenan, E. and Orwoll, E.S., 1997. Transcriptional Up-
Regulation of the Human Androgen Receptor by Androgen in Bone Cells 
1. Endocrinology, 138(6), pp.2291-2300. 
 
Wittbrodt, J., Shima, A. and Schartl, M., 2002. Medaka—a model organism from the far 
East. Nature Reviews Genetics, 3(1), pp.53-64.  
 
Witten, P.E., Hansen, A. and Hall, B.K., 2001. Features of mono-and multinucleated bone 
resorbing cells of the zebrafish Danio rerio and their contribution to skeletal development, 
remodeling, and growth. Journal of Morphology, 250(3), pp.197-207. 
 
Witten, P.E. and Huysseune, A., 2009. A comparative view on mechanisms and functions of 
skeletal remodelling in teleost fish, with special emphasis on osteoclasts and their 
function. Biological reviews, 84(2), pp.315-346.  
 
Witten, P.E., Huysseune, A. and Hall, B.K., 2010. A practical approach for the identification of 
the many cartilaginous tissues in teleost fish. Journal of Applied Ichthyology, 26(2), pp.257-262. 
 
Yang, L., Tsang, K.Y., Tang, H.C., Chan, D. and Cheah, K.S., 2014. Hypertrophic chondrocytes 
can become osteoblasts and osteocytes in endochondral bone formation. Proceedings of the 
National Academy of Sciences, 111(33), pp.12097-12102. 
 
Yoshida, C.A., Komori, H., Maruyama, Z., Miyazaki, T., Kawasaki, K., Furuichi, T., Fukuyama, 
R., Mori, M., Yamana, K., Nakamura, K. and Liu, W., 2012. SP7 inhibits osteoblast 
differentiation at a late stage in mice.PLoS One, 7(3), p.e32364. 
 
Yoshikawa, Y., Kode, A., Xu, L., Mosialou, I., Silva, B.C., Ferron, M., Clemens, T.L., 
Economides, A.N. and Kousteni, S., 2011. Genetic evidence points to an osteocalcin-
independent influence of osteoblasts on energy metabolism. Journal of Bone and Mineral 
Research, 26(9), pp.2012-2025. 
 
Zebaze, R.M., Ghasem-Zadeh, A., Bohte, A., Iuliano-Burns, S., Mirams, M., Price, R.I., Mackie, 
E.J. and Seeman, E., 2010. Intracortical remodelling and porosity in the distal radius and post-
mortem femurs of women: a cross-sectional study. The Lancet, 375(9727), pp.1729-1736. 
 
Zhong, Z., Niu, P., Wang, M., Huang, G., Xu, S., Sun, Y., Xu, X., Hou, Y., Sun, X., Yan, Y. 
and Wang, H., 2016. Targeted disruption of sp7 and myostatin with CRISPR-Cas9 results in 
severe bone defects and more muscular cells in common carp. Scientific reports, 6. 
 
Zhou, X., Zhang, Z., Feng, J.Q., Dusevich, V.M., Sinha, K., Zhang, H., Darnay, B.G. and de 
Crombrugghe, B., 2010. Multiple functions of Osterix are required for bone growth and 
140	
	
homeostasis in postnatal mice. Proceedings of the National Academy of Sciences, 107(29), 
pp.12919-12924. 
 
Zhou, X., von der Mark, K., Henry, S., Norton, W., Adams, H. and de Crombrugghe, B., 2014. 
Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, 
postnatal growth and fracture healing in mice. PLoS Genet, 10(12), p.e1004820. 
 
